10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

xQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended September 30, 2013

oTransition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From                    to                     .

Commission File Number:  001 – 34465 and 001 – 31441

SELECT MEDICAL HOLDINGS CORPORATION

SELECT MEDICAL CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware	20-1764048
Delaware	23-2872718
(State or other jurisdiction of incorporation or organization)	(I.R.S. employer identification number)

4714 Gettysburg Road, P.O. Box 2034, Mechanicsburg, Pennsylvania 17055

(Address of principal executive offices and zip code)

(717) 972-1100

(Registrants’ telephone number, including area code)

Indicate by check mark whether the Registrant, Select Medical Holdings Corporation (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x  NO o

Indicate by check mark whether the Registrant, Select Medical Corporation (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES o  NO x

Indicate by check mark whether the Registrants have submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrants were required to submit and post such files).  YES x  NO o

Indicate by check mark whether the Registrants are large accelerated filers, accelerated filers, non-accelerated filers, or smaller reporting companies.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  o  Accelerated filer  x  Non-accelerated filer  o

Smaller reporting company  o

Indicate by check mark whether the Registrants are shell companies (as defined in Rule 12b-2 of the Exchange Act).  YES o  NO x

As of October 15, 2013, Select Medical Holdings Corporation had outstanding 139,546,090 shares of common stock.

This Form 10-Q is a combined quarterly report being filed separately by two Registrants: Select Medical Holdings Corporation and Select Medical Corporation.  Unless the context indicates otherwise, any reference in this report to “Holdings” refers to Select Medical Holdings Corporation and any reference to “Select” refers to Select Medical Corporation, the wholly-owned operating subsidiary of Holdings.  References to the “Company,” “we,” “us,” and “our” refer collectively to Select Medical Holdings Corporation and Select Medical Corporation.

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3
ITEM 1.	CONSOLIDATED FINANCIAL STATEMENTS
	Consolidated balance sheets	3
	Consolidated statements of operations	4
	Consolidated statements of changes in equity and income	6
	Consolidated statements of cash flows	7
	Notes to consolidated financial statements	8
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	27
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	53
ITEM 4.	CONTROLS AND PROCEDURES	54
PART II	OTHER INFORMATION	54
ITEM 1.	LEGAL PROCEEDINGS	54
ITEM 1A.	RISK FACTORS	56
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	56
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	56
ITEM 4.	MINE SAFETY DISCLOSURES	56
ITEM 5.	OTHER INFORMATION	56
ITEM 6.	EXHIBITS	56
SIGNATURES		57

2

PART I FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

	Select Medical Holdings Corporation				Select Medical Corporation
	December 31,		September 30,		December 31,		September 30,
	2012		2013		2012		2013
ASSETS
Current Assets:
Cash and cash equivalents	$	40,144	$	9,293	$	40,144	$	9,293
Accounts receivable, net of allowance for doubtful accounts of $41,854 and $41,255 at 2012 and 2013, respectively	359,929		423,334		359,929		423,334
Current deferred tax asset	17,877		15,372		17,877		15,372
Prepaid income taxes	3,895		4,044		3,895		4,044
Other current assets	31,818		39,968		31,818		39,968
Total Current Assets	453,663		492,011		453,663		492,011
Property and equipment, net	501,552		499,531		501,552		499,531
Goodwill	1,640,534		1,641,836		1,640,534		1,641,836
Other identifiable intangibles	71,745		71,831		71,745		71,831
Other assets	93,867		137,215		92,819		137,215
Total Assets	$	2,761,361	$	2,842,424	$	2,760,313	$	2,842,424
LIABILITIES AND EQUITY
Current Liabilities:
Bank overdrafts	$	17,836	$	7,435	$	17,836	$	7,435
Current portion of long-term debt and notes payable	11,646		13,966		11,646		13,966
Accounts payable	89,547		96,360		89,547		96,360
Accrued payroll	88,586		81,303		88,586		81,303
Accrued vacation	55,714		57,328		55,714		57,328
Accrued interest	22,016		22,005		18,759		22,005
Accrued other	102,040		102,925		107,280		102,925
Due to third party payors	1,078		3,968		1,078		3,968
Total Current Liabilities	388,463		385,290		390,446		385,290
Long-term debt, net of current portion	1,458,597		1,474,915		1,291,297		1,474,915
Non-current deferred tax liability	89,510		90,859		89,510		90,859
Other non-current liabilities	68,502		80,077		68,502		80,077
Total Liabilities	2,005,072		2,031,141		1,839,755		2,031,141
Redeemable non-controlling interests	10,811		11,623		10,811		11,623
Stockholders’ Equity:
Common stock of Holdings, $0.001 par value, 700,000,000 shares authorized, 140,589,256 shares and 139,546,090 shares issued and outstanding at 2012 and 2013, respectively	141		140		—		—
Common stock of Select, $0.01 par value, 100 shares issued and outstanding	—		—		0		0
Capital in excess of par	473,697		472,080		859,839		866,423
Retained earnings (accumulated deficit)	243,210		296,196		21,478		(98,007		)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	717,048		768,416		881,317		768,416
Non-controlling interest	28,430		31,244		28,430		31,244
Total Equity	745,478		799,660		909,747		799,660
Total Liabilities and Equity	$	2,761,361	$	2,842,424	$	2,760,313	$	2,842,424

The accompanying notes are an integral part of these consolidated financial statements.

3

Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Three Months Ended September 30,						For the Three Months Ended September 30,
	2012			2013			2012			2013
Net operating revenues	$	713,669		$	722,845		$	713,669		$	722,845
Costs and expenses:
Cost of services	598,984			617,281			598,984			617,281
General and administrative	17,130			17,740			17,130			17,740
Bad debt expense	11,199			9,262			11,199			9,262
Depreciation and amortization	15,537			16,163			15,537			16,163
Total costs and expenses	642,850			660,446			642,850			660,446
Income from operations	70,819			62,399			70,819			62,399
Other income and expense:
Loss on early retirement of debt	(6,064		)	—			(6,064		)	—
Equity in earnings (losses) of unconsolidated subsidiaries	1,167			(179		)	1,167			(179		)
Interest expense	(24,575		)	(21,252		)	(21,740		)	(21,252		)
Income before income taxes	41,347			40,968			44,182			40,968
Income tax expense	16,189			15,761			17,181			15,761
Net income	25,158			25,207			27,001			25,207
Less: Net income attributable to non-controlling interests	1,048			1,935			1,048			1,935
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	24,110		$	23,272		$	25,953		$	23,272
Income per common share:
Basic	$	0.17		$	0.17
Diluted	$	0.17		$	0.17

The accompanying notes are an integral part of these consolidated financial statements.

4

Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,
	2012			2013			2012			2013
Net operating revenues	$	2,207,883		$	2,229,473		$	2,207,883		$	2,229,473
Costs and expenses:
Cost of services	1,823,272			1,867,915			1,823,272			1,867,915
General and administrative	49,908			53,065			49,908			53,065
Bad debt expense	31,603			27,429			31,603			27,429
Depreciation and amortization	47,164			47,872			47,164			47,872
Total costs and expenses	1,951,947			1,996,281			1,951,947			1,996,281
Income from operations	255,936			233,192			255,936			233,192
Other income and expense:
Loss on early retirement of debt	(6,064		)	(18,747		)	(6,064		)	(17,788		)
Equity in earnings of unconsolidated subsidiaries	6,384			1,447			6,384			1,447
Interest expense	(72,295		)	(66,614		)	(63,947		)	(64,204		)
Income before income taxes	183,961			149,278			192,309			152,647
Income tax expense	71,415			57,391			74,337			58,570
Net income	112,546			91,887			117,972			94,077
Less: Net income attributable to non-controlling interests	3,722			6,417			3,722			6,417
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	108,824		$	85,470		$	114,250		$	87,660
Income per common share:
Basic	$	0.77		$	0.61
Diluted	$	0.77		$	0.61

The accompanying notes are an integral part of these consolidated financial statements.

5

Consolidated Statements of Changes in Equity and Income

(unaudited)

(in thousands)

						Select Medical Holdings Corporation Stockholders
	Comprehensive Income		Total			Common Stock Issued		Common Stock Par Value			Capital in Excess of Par			Retained Earnings			Non-controlling Interests
Balance at December 31, 2012			$	745,478		140,589		$	141		$	473,697		$	243,210		$	28,430
Net income	$	89,588	89,588											85,470			4,118
Net income - attributable to redeemable non-controlling interests	2,299
Total comprehensive income	$	91,887
Dividends paid to common stockholders			(27,929		)									(27,929		)
Issuance and vesting of restricted stock			4,695			72		0			4,695
Stock option expense			708								708
Repurchase of common shares			(10,946		)	(1,115	)	(1		)	(7,020		)	(3,925		)
Acquisitions of non-controlling interests			261														261
Distributions to non-controlling interests			(1,565		)												(1,565		)
Redeemable non-controlling interests redemption value adjustment			(630		)									(630		)
Balance at September 30, 2013			$	799,660		139,546		$	140		$	472,080		$	296,196		$	31,244

						Select Medical Corporation Stockholders
	Comprehensive Income		Total			Common Stock Issued	Common Stock Par Value		Capital in Excess of Par		Retained Earnings (accumulated deficit)			Non-controlling Interests
Balance at December 31, 2012			$	909,747		0	$	0	$	859,839	$	21,478		$	28,430
Net income	$	91,778	91,778								87,660			4,118
Net income - attributable to redeemable non-controlling interests	2,299
Total comprehensive income	$	94,077
Federal tax benefit of losses contributed by Holdings			1,181						1,181
Net change in dividends payable to Holdings			5,239								5,239
Dividends declared and paid to Holdings			(211,754		)						(211,754		)
Contribution related to restricted stock awards and stock option issuances by Holdings			5,403						5,403
Acquisitions of non-controlling interests			261											261
Distributions to non-controlling intersts			(1,565		)									(1,565		)
Redeemable non-controlling interests redemption value adjustment			(630		)						(630		)
Balance at September 30, 2013			$	799,660		0	$	0	$	866,423	$	(98,007	)	$	31,244

The accompanying notes are an integral part of these consolidated financial statements.

6

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,
	2012			2013			2012			2013
Operating activities
Net income	$	112,546		$	91,887		$	117,972		$	94,077
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	47,164			47,872			47,164			47,872
Provision for bad debts	31,603			27,429			31,603			27,429
Equity in earnings of unconsolidated subsidiaries	(6,384		)	(1,447		)	(6,384		)	(1,447		)
Loss on early retirement of debt	6,064			18,747			6,064			17,788
Gain from disposal or sale of assets	(3,484		)	(93		)	(3,484		)	(93		)
Non-cash stock compensation expense	3,990			5,403			3,990			5,403
Amortization of debt discount and issuance costs	5,494			6,507			5,215			6,418
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable	(10,507		)	(89,237		)	(10,507		)	(89,237		)
Other current assets	(1,849		)	(7,642		)	(1,849		)	(7,642		)
Other assets	1,270			(3,211		)	1,270			(3,211		)
Accounts payable	(4,098		)	6,798			(4,098		)	6,798
Due to third-party payors	360			2,890			360			2,890
Accrued expenses	348			4,788			2,956			8,046
Income and deferred taxes	11,559			4,414			14,481			5,593
Net cash provided by operating activities	194,076			115,105			204,753			120,684
Investing activities
Purchases of property and equipment	(45,188		)	(45,331		)	(45,188		)	(45,331		)
Proceeds from sale of assets	16,511			518			16,511			518
Investment in businesses, net of distributions	(9,899		)	(32,430		)	(9,899		)	(32,430		)
Acquisition of businesses, net of cash acquired	(1,547		)	(848		)	(1,547		)	(848		)
Net cash used in investing activities	(40,123		)	(78,091		)	(40,123		)	(78,091		)
Financing activities
Borrowings on revolving credit facility	365,000			580,000			365,000			580,000
Payments on revolving credit facility	(405,000		)	(645,000		)	(405,000		)	(645,000		)
Borrowings on credit facility term loans, net of discount	266,750			298,500			266,750			298,500
Payments on credit facility term loans	(7,063		)	(594,668		)	(7,063		)	(594,668		)
Issuance of 6.375% senior notes	—			600,000			—			600,000
Repurchase of senior floating rate notes	—			(167,300		)	—			—
Repurchase of 7 5/8% senior subordinated notes	(278,495		)	(70,000		)	(278,495		)	(70,000		)
Borrowings of other debt	5,835			9,238			5,835			9,238
Principal payments on other debt	(7,417		)	(7,467		)	(7,417		)	(7,467		)
Debt issuance costs	(4,236		)	(18,820		)	(4,236		)	(18,820		)
Dividends paid to common stockholders	—			(27,929		)	—			—
Dividends paid to Holdings	—			—			(57,467		)	(211,754		)
Repurchase of common stock	(46,790		)	(10,946		)	—			—
Proceeds from issuance of common stock	1,104			—			—			—
Equity investment by Holdings	—			—			1,104			—
Repayment of bank overdrafts	(3,011		)	(10,401		)	(3,011		)	(10,401		)
Distributions to non-controlling interests	(2,997		)	(3,072		)	(2,997		)	(3,072		)
Net cash used in financing activities	(116,320		)	(67,865		)	(126,997		)	(73,444		)
Net increase (decrease) in cash and cash equivalents	37,633			(30,851		)	37,633			(30,851		)
Cash and cash equivalents at beginning of period	12,043			40,144			12,043			40,144
Cash and cash equivalents at end of period	$	49,676		$	9,293		$	49,676		$	9,293
Supplemental Cash Flow Information
Cash paid for interest	$	68,122		$	60,439		$	57,448		$	54,860
Cash paid for taxes	$	59,850		$	52,977		$	59,850		$	52,977

The accompanying notes are an integral part of these consolidated financial statements.

7

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.Basis of Presentation

The unaudited consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) and Select Medical Corporation (“Select”) as of September 30, 2013 and for the three and nine month periods ended September 30, 2012 and 2013 have been prepared in accordance with generally accepted accounting principles (“GAAP”).  In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.  All significant intercompany transactions and balances have been eliminated.  The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2013.  Holdings and Select and their subsidiaries are collectively referred to as the “Company.” The consolidated financial statements of Holdings include the accounts of its wholly-owned subsidiary Select. Holdings conducts substantially all of its business through Select and its subsidiaries.

Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted consistent with the rules and regulations of the Securities and Exchange Commission (the “SEC”), although the Company believes the disclosure is adequate to make the information presented not misleading.   The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2012 contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2013.

2.Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

3.  Intangible Assets

The gross carrying amounts of the Company’s indefinite-lived intangible assets consist of the following:

	December 31, 2012		September 30, 2013
	(in thousands)
Goodwill	$	1,640,534	$	1,641,836
Trademarks	57,709		57,709
Certificates of need	11,914		12,039
Accreditations	2,122		2,083
Total	$	1,712,279	$	1,713,667

8

The Company’s accreditations and trademarks have renewal terms. The costs to renew these intangibles are expensed as incurred. At September 30, 2013, the accreditations and trademarks have a weighted average time until next renewal of approximately 1.5 years and 6.7 years, respectively.

The changes in the carrying amount of goodwill for the Company’s reportable segments for the nine months ended September 30, 2013 are as follows:

	Specialty Hospitals		Outpatient Rehabilitation			Total
	(in thousands)
Balance as of December 31, 2012	$	1,333,220	$	307,314		$	1,640,534
Goodwill acquired during the period	1,395		40			1,435
Purchase price adjustment	—		(133		)	(133		)
Balance as of September 30, 2013	$	1,334,615	$	307,221		$	1,641,836

4.  Indebtedness

The components of long-term debt and notes payable are as follows:

	Select Medical Holdings Corporation
	December 31, 2012		September 30, 2013
	(in thousands)
7 5/8% senior subordinated notes	$	70,000	$	—
6.375% senior notes	—		600,000
Senior secured credit facilities:
Revolving loan	130,000		65,000
Term loans (1)	1,096,641		809,438
Senior floating rate notes	167,300		—
Other	6,302		14,443
Total debt	1,470,243		1,488,881
Less: current maturities	11,646		13,966
Total long-term debt	$	1,458,597	$	1,474,915

	Select Medical Corporation
	December 31, 2012		September 30, 2013
	(in thousands)
7 5/8% senior subordinated notes	$	70,000	$	—
6.375% senior notes	—		600,000
Senior secured credit facilities:
Revolving loan	130,000		65,000
Term loans (1)	1,096,641		809,438
Other	6,302		14,443
Total debt	1,302,943		1,488,881
Less: current maturities	11,646		13,966
Total long-term debt	$	1,291,297	$	1,474,915

9

(1)Presented net of unamortized discounts of $14.2 million and $6.8 million at December 31, 2012 and September 30, 2013, respectively.

On February 20, 2013, Select entered into a credit extension amendment to its senior secured credit facilities providing for a $300.0 million additional term loan tranche, (the “series B term loan”) to Select.  Select used the borrowings under the series B term loan to redeem all of its outstanding 7 5/8% senior subordinated notes due 2015 on March 22, 2013, to finance Holdings’ redemption of all of its senior floating rate notes due 2015 on March 22, 2013 and to repay a portion of the balance outstanding under Select’s revolving credit facility.  The Company recognized a loss on early retirement of debt of $1.5 million during the three months ended March 31, 2013 for unamortized debt issuance costs, of which approximately $0.5 million was associated with Select’s 7 5/8% senior subordinated notes due 2015 and approximately $1.0 million was associated with Holdings’ senior floating rate notes due 2015.

Borrowings under the series B term loan bear interest at a rate equal to Adjusted LIBO plus 3.25%, or Alternate Base Rate plus 2.25%.  The series B term loan amortizes in equal quarterly installments on the last day of each March, June, September and December in aggregate annual amounts equal to $3.0 million.  The balance of the series B term loan is payable on February 20, 2016.

At the time of issuing the series B term loan, Select had additional term loan tranches outstanding including an $850.0 million term loan tranche issued on June 1, 2011 (the “original term loan”) and a $275.0 million incremental term loan tranche issued August 13, 2012 (the “series A term loan”). Both the original term loan and series A term loan tranches were issued at a discount and amortized in equal quarterly installments on the last day of each March, June, September and December. The balance of both the original term loan and series A term loan was payable on June 1, 2018.

On May 28, 2013, Select issued and sold $600.0 million aggregate principal amount of its 6.375% senior notes due 2021.  On May 28, 2013, Select used the proceeds of the senior notes to pay a portion of the amounts then outstanding on the original term loan and the series A term loan, and to pay related fees and expenses.  Select recognized a loss on early retirement of debt of $17.3 million in the three months ended June 30, 2013 in connection with the repayment of a portion of its term loans and amendment of the existing senior secured credit facility, which included the write-off of unamortized debt issuance costs.

Interest on the senior notes accrues at the rate of 6.375% per annum and is payable semi-annually in cash in arrears on June 1 and December 1 of each year, commencing on December 1, 2013.  The senior notes are Select’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.  The senior notes are unconditionally guaranteed by all of Select’s wholly-owned subsidiaries.  The senior notes are guaranteed, jointly and severally, by Select’s direct or indirect existing and future domestic restricted subsidiaries other than certain non-guarantor subsidiaries.

Select may redeem some or all of the senior notes prior to June 1, 2016 by paying a “make-whole” premium.  Select may redeem some or all of the senior notes on or after June 1, 2016 at specified redemption prices.  In addition, prior to June 1, 2016, Select may redeem up to 35% of the senior notes with the net proceeds of certain equity offerings at a price of 106.375% plus accrued and unpaid interest, if any. Select is obligated to offer to repurchase the senior notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events.  These restrictions and prohibitions are subject to certain qualifications and exceptions.

10

The Indenture relating to the senior notes contains covenants that, among other things, limit Select’s ability and the ability of certain of its subsidiaries to (i) grant liens on its assets, (ii) make dividend payments, other distributions or other restricted payments, (iii) incur restrictions on the ability of Select’s restricted subsidiaries to pay dividends or make other payments, (iv) enter into sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of substantially all of their assets, (vi) incur additional indebtedness, (vii) make investments, (viii) sell assets, including capital stock of subsidiaries, (ix) use the proceeds from sales of assets, including capital stock of restricted subsidiaries, and (x) enter into transactions with affiliates.  In addition, the Indenture requires, among other things, Select to provide financial and current reports to holders of the senior notes or file such reports electronically with the U.S. Securities and Exchange Commission (the “SEC”).  These covenants are subject to a number of exceptions, limitations and qualifications set forth in the Indenture.

On June 3, 2013, Select amended its existing senior secured credit facilities in order to:

·extend the maturity date on $293.3 million of its $300.0 million revolving credit facility from June 1, 2016 to March 1, 2018;

·convert the remaining original term loan and series A term loan to a series C term loan and lower the interest rate payable on the series C term loan from Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%, to Adjusted LIBO plus 3.00%, or Alternate Base Rate plus 2.00%, and amend the provision of the series C term loan from providing that Adjusted LIBO will at no time be less than 1.75% to providing that Adjusted LIBO will at no time be less than 1.00%; and

·amend the restrictive covenants governing the senior secured credit facilities in order to allow for unlimited restricted payments so long as there is no event of default under the senior secured credit facilities and the total pro forma ratio of total indebtedness to Consolidated EBITDA (as defined in our senior secured credit facilities) is less than or equal to 2.75 to 1.00.

Maturities of Long-Term Debt and Notes Payable

Maturities of the Company’s long-term debt for the period from October 1, 2013 through December 31, 2013 and the years after 2013 are approximately as follows and are presented net of the discounts on the senior secured credit facility term loans (in thousands):

October 1, 2013 – December 31, 2013	$	4,869
2014	11,497
2015	10,086
2016	296,134
2017	4,075
2018 and beyond	1,162,220

5.  Fair Value

Financial instruments include cash and cash equivalents, notes payable and long-term debt.  The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

The carrying value of Select’s senior secured credit facility was $1,226.6 million and $874.4 million at December 31, 2012 and September 30, 2013, respectively.  The fair value of Select’s senior secured credit facility was $1,216.2 million and $867.9 million at December 31, 2012 and September 30, 2013, respectively.  The fair value of Select’s senior secured credit facility was based on quoted market prices for this debt in the syndicated loan market.

11

The carrying value of Select’s 6.375% senior notes was $600.0 million at September 30, 2013.  The fair value of Select’s 6.375% senior notes was $570.0 million at September 30, 2013.  The fair value of this debt was based on quoted market prices.

The Company considers the inputs in the valuation process of its senior secured credit facility and 6.375% senior notes to be Level 2 in the fair value hierarchy.  Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly which includes quoted prices for identical assets or liabilities in markets that are not active.

6.  Segment Information

The Company’s reportable segments consist of (i) specialty hospitals and (ii) outpatient rehabilitation. Other activities include the Company’s corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The outpatient rehabilitation reportable segment has two operating segments: outpatient rehabilitation clinics and contract therapy. These operating segments are aggregated for reporting purposes as they have common economic characteristics and provide a similar service to a similar patient base. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries and other income (expense).

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select with the exception of total assets:

	Three Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	531,409	$	182,246	$	14		$	713,669
Adjusted EBITDA	83,659		20,354		(16,266		)	87,747
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	12,281		3,073		1,900			17,254

	Three Months Ended September 30, 2013
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	532,610	$	190,223	$	12		$	722,845
Adjusted EBITDA	75,280		21,619		(16,471		)	80,428
Total assets:
Select Medical Corporation	2,232,756		445,729		163,939			2,842,424
Select Medical Holdings Corporation	2,232,756		445,729		163,939			2,842,424
Capital expenditures	14,157		2,802		410			17,369

12

	Nine Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	1,641,577	$	566,195	$	111		$	2,207,883
Adjusted EBITDA	285,779		68,669		(47,358		)	307,090
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	31,963		9,786		3,439			45,188

	Nine Months Ended September 30, 2013
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	1,649,747	$	579,404	$	322		$	2,229,473
Adjusted EBITDA	265,020		70,506		(49,059		)	286,467
Total assets:
Select Medical Corporation	2,232,756		445,729		163,939			2,842,424
Select Medical Holdings Corporation	2,232,756		445,729		163,939			2,842,424
Capital expenditures	35,257		8,646		1,428			45,331

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2012
	Specialty Hospitals				Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$		83,659		$	20,354		$	(16,266	)
Depreciation and amortization	(11,553			)	(3,152		)	(832		)
Stock compensation expense	—				—			(1,391		)
Income (loss) from operations	$	72,106			$	17,202		$	(18,489	)	$	70,819		$	70,819
Loss on early retirement of debt											(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries											1,167			1,167
Interest expense											(24,575		)	(21,740		)
Income before income taxes											$	41,347		$	44,182

13

	Three Months Ended September 30, 2013
	Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$	75,280		$	21,619		$	(16,471	)
Depreciation and amortization	(12,267		)	(2,979		)	(917		)
Stock compensation expense	—			—			(1,866		)
Income (loss) from operations	$	63,013		$	18,640		$	(19,254	)	$	62,399		$	62,399
Equity in losses of unconsolidated subsidiaries										(179		)	(179		)
Interest expense										(21,252		)	(21,252		)
Income before income taxes										$	40,968		$	40,968

		Nine Months Ended September 30, 2012
		Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
		(in thousands)
Adjusted EBITDA		$	285,779		$	68,669		$	(47,358	)
Depreciation and amortization			(34,875	)		(10,034	)		(2,255	)
Stock compensation expense		—			—			(3,990		)
Income (loss) from operations	$		250,904		$	58,635		$	(53,603	)	$	255,936		$	255,936
Loss on early retirement of debt											(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries											6,384			6,384
Interest expense											(72,295		)	(63,947		)
Income before income taxes											$	183,961		$	192,309

14

	Nine Months Ended September 30, 2013
	Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$	265,020		$	70,506		$	(49,059	)
Depreciation and amortization	(36,061		)	(8,949		)	(2,862		)
Stock compensation expense	—			—			(5,403		)
Income (loss) from operations	$	228,959		$	61,557		$	(57,324	)	$	233,192		$	233,192
Equity in earnings of unconsolidated subsidiaries										1,447			1,447
Loss on early retirement of debt										(18,747		)	(17,788		)
Interest expense										(66,614		)	(64,204		)
Income before income taxes										$	149,278		$	152,647

7.  Income per Common Share

The Company applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings. The following table sets forth for the periods indicated the calculation of income per common share in the Company’s consolidated statement of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted income per common share, respectively:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2012		2013		2012		2013
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	24,110	$	23,272	$	108,824	$	85,470
Less: Earnings allocated to unvested restricted stockholders	407		497		1,759		1,802
Net income available to common stockholders	$	23,703	$	22,775	$	107,065	$	83,668
Denominator:
Weighted average shares — basic	137,551		136,646		139,138		136,879
Effect of dilutive securities:
Stock options	337		147		266		161
Weighted average shares — diluted	137,888		136,793		139,404		137,040
Basic income per common share	$	0.17	$	0.17	$	0.77	$	0.61
Diluted income per common share	$	0.17	$	0.17	$	0.77	$	0.61

15

The following share amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2012	2013	2012	2013
	(in thousands)
Stock options	78	1,477	1,683	1,528

8. Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”) or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company’s specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

On January 8, 2013, a federal magistrate judge unsealed an Amended Complaint in United States of America and the State of Indiana, ex rel. Doe I, Doe II and Doe III v. Select Medical Corporation, Select Specialty Hospital-Evansville, Evansville Physician Investment Corporation, Dr. Richard Sloan and Dr. Jeffrey Selby. The Amended Complaint, which was served on the Company on February 15, 2013, is a civil action filed under seal on September 28, 2012 in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States and the state of Indiana under the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act. Although the Amended Complaint identifies

16

the relators by fictitious pseudonyms, on March 28, 2013, the relators filed a Notice identifying themselves as the former CEO at the Company’s long term acute care hospital in Evansville, Indiana (“SSH-Evansville”) and two former case managers at SSH-Evansville. The named defendants include the Company, SSH-Evansville, and two physicians who have practiced at SSH-Evansville. On March 26, 2013, the defendants, relators and the United States filed a joint motion seeking a stay of the proceedings, in which the United States notified the court that its investigation has not been completed and therefore it is not yet able to decide whether or not to intervene, and on March 29, 2013, the magistrate judge granted the motion and stayed all deadlines in the case for 90 days. On June 26, 2013, the United States filed a motion seeking to extend such stay of the proceedings for an additional 90 days, and, on August 12, 2013, the court granted the motion and stayed all deadlines in the case until October 1, 2013. On September 25, 2013, the United States filed a motion seeking to extend such stay for an additional 90 days.

The Amended Complaint alleges that the defendants manipulated the length of stay of patients at SSH-Evansville in order to maximize reimbursement under the Medicare prospective payment system applicable to long term acute care hospitals. It also alleges that the defendants manipulated the discharge of patients to other facilities and the timing of readmissions from those facilities in order to enable SSH-Evansville to receive two separate Medicare payments and causing the other facility to submit claims for unnecessary services. The Amended Complaint discusses the federal Stark Law and Anti-Kickback Statute and implies that the behavior of physicians referring to or providing services at SSH-Evansville was based on their financial interests. The Amended Complaint further alleges that Dr. Selby, a pulmonologist formerly on the medical staff of SSH-Evansville, performed unnecessary bronchoscopies at the hospital with the knowledge of the Company, and that Dr. Sloan, the Chief Medical Officer and an attending physician at SSH-Evansville, falsely coded the diagnoses of Medicare patients in order to increase SSH-Evansville’s reimbursement. Moreover, the Amended Complaint alleges that the practices at SSH-Evansville involved corporate policies of the Company used to maximize profit at all Select long term acute care hospitals. The Amended Complaint alleges that, through these acts, the defendants have violated the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act and are liable for unspecified treble damages and penalties.

As previously disclosed, beginning in April 2012, the Company and SSH-Evansville have received various subpoenas and demands for documents relating to SSH-Evansville, including a request for information and subpoenas from the Office of Inspector General of the U.S. Department of Health and Human Services and subpoenas from the Office of Attorney General for the State of Indiana, and the Evansville (Indiana) Police Department has executed a search warrant at SSH-Evansville. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

Construction Commitments

At September 30, 2013, the Company had outstanding commitments under construction contracts related to new construction, improvements and renovations at the Company’s long term acute care properties and inpatient rehabilitation facilities totaling approximately $15.3 million.

9.Subsequent Event

On October 30, 2013, Holdings’ board of directors declared a quarterly cash dividend of $0.10 per share. The dividend will be payable on or about November 22, 2013 to stockholders of record as of the close of business on November 12, 2013.

17

10.Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select’s 6.375% Senior Notes

Select’s 6.375% senior notes are fully and unconditionally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly-owned subsidiaries (the “Subsidiary Guarantors”) which is defined as a subsidiary where Select or a subsidiary of Select holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the “Non-Guarantor Subsidiaries”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2012 and September 30, 2013 and for the three and nine months ended September 30, 2012 and 2013.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

18

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2013

(unaudited)

	Select Medical  Corporation (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	5,052		$	2,996	$	1,245	$	—		$	9,293
Accounts receivable, net	—			360,805		62,529		—			423,334
Current deferred tax asset	8,038			2,945		4,389		—			15,372
Prepaid income taxes	4,044			—		—		—			4,044
Intercompany receivables	—			1,034,542		100,930		(1,135,472		)(a)	—
Other current assets	8,325			26,783		4,860		—			39,968
Total Current Assets	25,459			1,428,071		173,953		(1,135,472		)	492,011
Property and equipment, net	14,911			426,915		57,705		—			499,531
Investment in affiliates	3,024,968			80,282		—		(3,105,250		)(b) (c)	—
Goodwill	—			1,641,836		—		—			1,641,836
Other identifiable intangibles	—			71,831		—		—			71,831
Non-current deferred tax asset	8,097			—		—		(8,097		)(d)	—
Other assets	36,509			100,113		593		—			137,215
Total Assets	$	3,109,944		$	3,749,048	$	232,251	$	(4,248,819	)	$	2,842,424
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	7,435		$	—	$	—	$	—		$	7,435
Current portion of long-term debt and notes payable	9,467			1,918		2,581		—			13,966
Accounts payable	7,554			75,452		13,354		—			96,360
Intercompany payables	1,135,472			—		—		(1,135,472		)(a)	—
Accrued payroll	516			80,527		260		—			81,303
Accrued vacation	4,502			45,567		7,259		—			57,328
Accrued interest	20,783			1,222		—		—			22,005
Accrued other	52,028			41,525		9,372		—			102,925
Due to third party payors	—			733		3,235		—			3,968
Total Current Liabilities	1,237,757			246,944		36,061		(1,135,472		)	385,290
Long-term debt, net of current portion	1,048,053			367,232		59,630		—			1,474,915
Non-current deferred tax liability	—			89,222		9,734		(8,097		)(d)	90,859
Other non-current liabilities	55,718			23,028		1,331		—			80,077
Total Liabilities	2,341,528			726,426		106,756		(1,143,569		)	2,031,141
Redeemable non-controlling interest	—			—		11,623		—			11,623
Stockholder’s Equity:
Common stock	0			—		—		—			0
Capital in excess of par	866,423			—		—		—			866,423
Retained earnings (accumulated deficit)	(98,007		)	886,099		18,438		(904,537		)(c)	(98,007		)
Subsidiary investment	—			2,136,523		64,190		(2,200,713		)(b)	—
Total Select Medical Corporation Stockholder’s Equity	768,416			3,022,622		82,628		(3,105,250		)	768,416
Non-controlling interest	—			—		31,244		—			31,244
Total Equity	768,416			3,022,622		113,872		(3,105,250		)	799,660
Total Liabilities and Equity	$	3,109,944		$	3,749,048	$	232,251	$	(4,248,819	)	$	2,842,424

(a)  Elimination of intercompany.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

19

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	12		$	617,415		$	105,418		$	—		$	722,845
Costs and expenses:
Cost of services	608			526,198			90,475			—			617,281
General and administrative	17,696			44			—			—			17,740
Bad debt expense	—			7,563			1,699			—			9,262
Depreciation and amortization	917			12,831			2,415			—			16,163
Total costs and expenses	19,221			546,636			94,589			—			660,446
Income (loss) from operations	(19,209		)	70,779			10,829			—			62,399
Other income and expense:
Intercompany interest and royalty fees	(278		)	310			(32		)	—			—
Intercompany management fees	32,621			(27,386		)	(5,235		)	—			—
Equity in earnings (losses) of unconsolidated subsidiaries	—			(196		)	17			—			(179		)
Interest expense	(14,192		)	(6,031		)	(1,029		)	—			(21,252		)
Income (loss) from operations before income taxes	(1,058		)	37,476			4,550			—			40,968
Income tax expense	44			15,218			499			—			15,761
Equity in earnings of subsidiaries	24,374			1,952			—			(26,326		)(a)	—
Net income	23,272			24,210			4,051			(26,326		)	25,207
Less: Net income attributable to non-controlling interests	—			—			1,935			—			1,935
Net income attributable to Select Medical Corporation	$	23,272		$	24,210		$	2,116		$	(26,326	)	$	23,272

(a) Elimination of equity in earnings of subsidiaries.

20

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	322		$	1,913,597		$	315,554		$	—		$	2,229,473
Costs and expenses:
Cost of services	1,718			1,599,493			266,704			—			1,867,915
General and administrative	52,915			150			—			—			53,065
Bad debt expense	—			22,485			4,944			—			27,429
Depreciation and amortization	2,862			37,856			7,154			—			47,872
Total costs and expenses	57,495			1,659,984			278,802			—			1,996,281
Income (loss) from operations	(57,173		)	253,613			36,752			—			233,192
Other income and expense:
Intercompany interest and royalty fees	(1,033		)	1,051			(18		)	—			—
Intercompany management fees	114,597			(100,005		)	(14,592		)	—			—
Loss on early retirement of debt	(17,788		)	—			—			—			(17,788		)
Equity in earnings of unconsolidated subsidiaries	—			1,375			72			—			1,447
Interest expense	(44,345		)	(16,800		)	(3,059		)	—			(64,204		)
Income (loss) from operations before income taxes	(5,742		)	139,234			19,155			—			152,647
Income tax expense	1,956			55,900			714						58,570
Equity in earnings of subsidiaries	95,358			12,073			—			(107,431		)(a)	—
Net income	87,660			95,407			18,441			(107,431		)	94,077
Less: Net income attributable to non-controlling interests	—			—			6,417			—			6,417
Net income attributable to Select Medical Corporation	$	87,660		$	95,407		$	12,024		$	(107,431	)	$	87,660

(a) Elimination of equity in earnings of subsidiaries.

21

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	87,660		$	95,407		$	18,441		$	(107,431	)(a)	$	94,077
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,862			37,856			7,154			—			47,872
Provision for bad debts	—			22,485			4,944			—			27,429
Equity in earnings of unconsolidated subsidiaries	—			(1,375		)	(72		)	—			(1,447		)
Loss on early retirement of debt	17,788			—			—			—			17,788
Loss (gain) from disposal of assets	—			25			(118		)	—			(93		)
Non-cash stock compensation expense	5,403			—			—			—			5,403
Amortization of debt discount and issuance costs	6,418			—			—			—			6,418
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(95,358		)	(12,073		)	—			107,431		(a)	—
Accounts receivable	—			(75,295		)	(13,942		)	—			(89,237		)
Other current assets	(2,725		)	(6,620		)	1,703			—			(7,642		)
Other assets	(7,829		)	4,519			99			—			(3,211		)
Accounts payable	2,880			3,224			694			—			6,798
Due to third-party payors	—			2,378			512			—			2,890
Accrued expenses	(3,211		)	10,381			876			—			8,046
Income and deferred taxes	5,593			—			—			—			5,593
Net cash provided by operating activities	19,481			80,912			20,291			—			120,684
Investing activities
Purchases of property and equipment	(1,428		)	(39,101		)	(4,802		)	—			(45,331		)
Proceeds from sale of assets	—			62			456			—			518
Investment in businesses, net of distributions	—			(32,430		)	—			—			(32,430		)
Acquisition of businesses, net of cash acquired	—			(848		)	—			—			(848		)
Net cash used in investing activities	(1,428		)	(72,317		)	(4,346		)	—			(78,091		)
Financing activities
Borrowings on revolving credit facility	580,000			—			—			—			580,000
Payments on revolving credit facility	(645,000		)	—			—			—			(645,000		)
Borrowings on credit facility term loans, net of discount	298,500			—			—			—			298,500
Payments on credit facility term loans	(594,668		)	—			—			—			(594,668		)
Issuance of 6.375% senior notes	600,000			—			—			—			600,000
Repurchase of 7 5/8% senior subordinated notes	(70,000		)	—			—			—			(70,000		)
Borrowings of other debt	8,154			—			1,084			—			9,238
Principal payments on other debt	(5,971		)	(521		)	(975		)	—			(7,467		)
Debt issuance costs	(18,820		)	—			—			—			(18,820		)
Dividends paid to Holdings	(211,754		)	—			—			—			(211,754		)
Repayments of bank overdrafts	(10,401		)	—			—			—			(10,401		)
Intercompany	21,889			(8,812		)	(13,077		)	—			—
Distributions to non-controlling interests	—			—			(3,072		)	—			(3,072		)
Net cash used in financing activities	(48,071		)	(9,333		)	(16,040		)	—			(73,444		)
Net decrease in cash and cash equivalents	(30,018		)	(738		)	(95		)	—			(30,851		)
Cash and cash equivalents at beginning of period	35,070			3,734			1,340			—			40,144
Cash and cash equivalents at end of period	$	5,052		$	2,996		$	1,245		$	—		$	9,293

(a)  Elimination of equity in earnings of consolidated subsidiaries.

22

Select Medical Corporation

Consolidating Balance Sheet

December 31, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)		Subsidiary Guarantors		Non-Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	35,070	$	3,734	$	1,340	$	—		$	40,144
Accounts receivable, net	—		308,043		53,531		(1,645		)(a)	359,929
Current deferred tax asset	12,383		1,060		4,434		—			17,877
Prepaid income taxes	3,895		—		—		—			3,895
Intercompany receivables	—		1,021,479		102,694		(1,124,173		)(b)	—
Other current assets	5,600		19,655		6,563		—			31,818
Total Current Assets	56,948		1,353,971		168,562		(1,125,818		)	453,663
Property and equipment, net	16,344		425,677		59,531		—			501,552
Investment in affiliates	2,930,022		82,475		—		(3,012,497		)(c) (d)	—
Goodwill	—		1,640,534		—		—			1,640,534
Other identifiable intangibles	—		71,745		—		—			71,745
Non-current deferred tax asset	5,107		—		—		(5,107		)(e)	—
Other assets	28,680		63,447		692		—			92,819
Total Assets	$	3,037,101	$	3,637,849	$	228,785	$	(4,143,422	)	$	2,760,313
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	17,836	$	—	$	—	$	—		$	17,836
Current portion of long-term debt and notes payable	8,916		1,059		1,671		—			11,646
Accounts payable	4,674		72,213		12,660		—			89,547
Intercompany payables	1,124,173		—		—		(1,124,173		)(b)	—
Accrued payroll	186		88,096		304		—			88,586
Accrued vacation	4,249		44,508		6,957		—			55,714
Accrued interest	17,955		804		—		—			18,759
Accrued other	58,650		39,876		8,754		—			107,280
Due to third party payors	—		—		2,723		(1,645		)(a)	1,078
Total Current Liabilities	1,236,639		246,556		33,069		(1,125,818		)	390,446
Long-term debt, net of current portion	872,671		358,104		60,522		—			1,291,297
Non-current deferred tax liability	—		85,287		9,330		(5,107		)(e)	89,510
Other non-current liabilities	46,474		20,275		1,753		—			68,502
Total Liabilities	2,155,784		710,222		104,674		(1,130,925		)	1,839,755
Redeemable non-controlling interests	—		—		10,811		—			10,811
Stockholder’s Equity:
Common stock	0		—		—		—			0
Capital in excess of par	859,839		—		—		—			859,839
Retained earnings	21,478		790,692		21,197		(811,889		)(d)	21,478
Subsidiary investment	—		2,136,935		63,673		(2,200,608		)(c)	—
Total Select Medical Corporation Stockholder’s Equity	881,317		2,927,627		84,870		(3,012,497		)	881,317
Non-controlling interests	—		—		28,430		—			28,430
Total Equity	881,317		2,927,627		113,300		(3,012,497		)	909,747
Total Liabilities and Equity	$	3,037,101	$	3,637,849	$	228,785	$	(4,143,422	)	$	2,760,313

(a)  Reclass portion of due to third party payor to accounts receivable net in consolidation.

(b)  Elimination of intercompany.

(c)  Elimination of investments in consolidated subsidiaries.

(d)  Elimination of investments in consolidated subsidiaries’ earnings.

(e)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

23

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	14		$	616,610		$	97,045		$	—		$	713,669
Costs and expenses:
Cost of services	544			514,136			84,304			—			598,984
General and administrative	17,742			(612		)	—			—			17,130
Bad debt expense	—			9,525			1,674			—			11,199
Depreciation and amortization	832			12,372			2,333			—			15,537
Total costs and expenses	19,118			535,421			88,311			—			642,850
Income (loss) from operations	(19,104		)	81,189			8,734			—			70,819
Other income and expense:
Intercompany interest and royalty fees	(469		)	459			10			—			—
Intercompany management fees	34,811			(29,960		)	(4,851		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			1,146			21			—			1,167
Interest expense	(14,676		)	(6,010		)	(1,054		)	—			(21,740		)
Income (loss) from operations before income taxes	(5,502		)	46,824			2,860			—			44,182
Income tax expense (benefit)	(3,589		)	21,020			(250		)	—			17,181
Equity in earnings of subsidiaries	27,866			2,123			—			(29,989		)(a)	—
Net income	25,953			27,927			3,110			(29,989		)	27,001
Less: Net income attributable to non-controlling interests	—			—			1,048			—			1,048
Net income attributable to Select Medical Corporation	$	25,953		$	27,927		$	2,062		$	(29,989	)	$	25,953

(a) Elimination of equity in earnings of subsidiaries.

24

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	111		$	1,910,563		$	297,209		$	—		$	2,207,883
Costs and expenses:
Cost of services	1,554			1,567,080			254,638			—			1,823,272
General and administrative	51,197			(1,289		)	—			—			49,908
Bad debt expense	—			27,199			4,404			—			31,603
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Total costs and expenses	55,006			1,630,942			265,999			—			1,951,947
Income (loss) from operations	(54,895		)	279,621			31,210			—			255,936
Other income and expense:
Intercompany interest and royalty fees	(2,025		)	1,998			27			—			—
Intercompany management fees	91,940			(78,202		)	(13,738		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			6,340			44			—			6,384
Interest expense	(40,823		)	(19,920		)	(3,204		)	—			(63,947		)
Income (loss) from operations before income taxes	(11,867		)	189,837			14,339			—			192,309
Income tax expense (benefit)	(1,613		)	75,924			26			—			74,337
Equity in earnings of subsidiaries	124,504			11,234			—			(135,738		)(a)	—
Net income	114,250			125,147			14,313			(135,738		)	117,972
Less: Net income attributable to non-controlling interests	—			—			3,722			—			3,722
Net income attributable to Select Medical Corporation	$	114,250		$	125,147		$	10,591		$	(135,738	)	$	114,250

(a) Elimination of equity in earnings of subsidiaries.

25

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	114,250		$	125,147		$	14,313		$	(135,738	)(a)	$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Provision for bad debts	—			27,199			4,404			—			31,603
Equity in earnings of unconsolidated subsidiaries	—			(6,340		)	(44		)	—			(6,384		)
Loss on early retirement of debt	6,064			—			—			—			6,064
Loss (gain) from disposal of assets	—			(3,501		)	17			—			(3,484		)
Non-cash stock compensation expense	3,990			—			—			—			3,990
Amortization of debt discount and issuance costs	5,215			—			—			—			5,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(124,504		)	(11,234		)	—			135,738		(a)	—
Accounts receivable	—			7,296			(17,803		)	—			(10,507		)
Other current assets	1,182			(2,141		)	(890		)	—			(1,849		)
Other assets	(604		)	1,688			186			—			1,270
Accounts payable	418			(5,842		)	1,326			—			(4,098		)
Due to third-party payors	—			(10,928		)	11,288			—			360
Accrued expenses	3,870			(1,912		)	998			—			2,956
Income and deferred taxes	14,481			—			—			—			14,481
Net cash provided by operating activities	26,617			157,384			20,752			—			204,753
Investing activities
Purchases of property and equipment	(3,617		)	(31,978		)	(9,593		)	—			(45,188		)
Proceeds from sale of assets	—			16,511			—			—			16,511
Investment in business, net of distributions	—			(9,899		)	—			—			(9,899		)
Acquisition of businesses, net of cash acquired	—			(1,547		)	—			—			(1,547		)
Net cash used in investing activities	(3,617		)	(26,913		)	(9,593		)	—			(40,123		)
Financing activities
Borrowings on revolving credit facility	365,000			—			—			—			365,000
Payments on revolving credit facility	(405,000		)	—			—			—			(405,000		)
Borrowings on credit facility term loans, net of discount	266,750			—			—			—			266,750
Payments on credit facility term loans	(7,063		)	—			—			—			(7,063		)
Repurchase of 7 5/8% senior subordinated notes	(278,495		)	—			—			—			(278,495		)
Borrowings of other debt	5,557			—			278			—			5,835
Principal payments on other debt	(6,667		)	(322		)	(428		)	—			(7,417		)
Debt issuance costs	(4,236		)	—			—			—			(4,236		)
Dividends paid to Holdings	(57,467		)	—			—			—			(57,467		)
Equity investment by Holdings	1,104			—			—			—			1,104
Repayment of bank overdrafts	(3,011		)	—			—			—			(3,011		)
Intercompany	134,170			(126,614		)	(7,556		)	—			—
Distributions to non-controlling interests	—			—			(2,997		)	—			(2,997		)
Net cash provided by (used in) financing activities	10,642			(126,936		)	(10,703		)	—			(126,997		)
Net increase in cash and cash equivalents	33,642			3,535			456			—			37,633
Cash and cash equivalents at beginning of period	11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	45,069		$	3,535		$	1,072		$	—		$	49,676

(a)  Elimination of equity in earnings of consolidated subsidiaries.

26

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws.  Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

·changes in government reimbursement for our services due to the implementation of healthcare reform legislation, deficit reduction measures, and/or new payment policies may result in a reduction in net operating revenues, an increase in costs and a reduction in profitability;

·the failure of our specialty hospitals to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;

·the failure of our facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;

·a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

·acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;

·private third-party payors for our services may undertake future cost containment initiatives that limit our future net operating revenues and profitability;

·the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;

·shortages in qualified nurses or therapists could increase our operating costs significantly;

·competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;

·the loss of key members of our management team could significantly disrupt our operations;

·the effect of claims asserted against us could subject us to substantial uninsured liabilities; and

27

·other factors discussed from time to time in our filings with the Securities and Exchange Commission (the “SEC”), including factors discussed under the heading “Risk Factors” for the year ended December 31, 2012 contained in our annual report on Form 10-K filed with the SEC on February 26, 2013 and our quarterly report on Form 10-Q for the three months ended March 31, 2013, filed with the SEC on May 2, 2013.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

We believe that we are one of the largest operators of both specialty hospitals and outpatient rehabilitation clinics in the United States based on number of facilities.  As of September 30, 2013, we operated 108 long term acute care hospitals and 15 acute medical rehabilitation hospitals in 28 states, and 997 outpatient rehabilitation clinics in 32 states and the District of Columbia. We also provide medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools and work sites.  We began operations in 1997 under the leadership of our current management team.  As of September 30, 2013 we had operations in 44 states and the District of Columbia.

We manage our Company through two business segments, our specialty hospital segment and our outpatient rehabilitation segment.  We had net operating revenues of $2,229.5 million for the nine months ended September 30, 2013.  Of this total, we earned approximately 74% of our net operating revenues from our specialty hospitals and approximately 26% from our outpatient rehabilitation business.  Our specialty hospital segment consists of hospitals designed to serve the needs of long term stay acute patients and hospitals designed to serve patients that require intensive medical rehabilitation care.  Patients are typically admitted to our specialty hospitals from general acute care hospitals.  These patients have specialized needs, and serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders and cancer.  Our outpatient rehabilitation segment consists of clinics and contract services that provide physical, occupational and speech rehabilitation services.  Our outpatient rehabilitation patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living.

28

Significant 2013 Events

Refinancing Activities

On February 20, 2013, Select entered into a credit extension amendment to its senior secured credit facilities providing for a $300.0 million additional term loan tranche, (the “series B term loan”) to Select.  Select used the borrowings under the series B term loan to redeem all of its outstanding 7 5/8% senior subordinated notes due 2015 on March 22, 2013, to finance Holdings’ redemption of all of its senior floating rate notes due 2015 on March 22, 2013 and to repay a portion of the balance outstanding under Select’s revolving credit facility.  Holdings and Select recognized a loss on early retirement of debt of $1.5 million and $0.5 million, respectively, in the three months ended March 31, 2013 related to this refinancing.

On May 28, 2013, Select issued and sold $600.0 million aggregate principal amount of its 6.375% senior notes due 2021.  The senior notes are senior unsecured obligations of Select and are fully and unconditionally guaranteed by all of Select’s wholly-owned subsidiaries.  On May 28, 2013, Select used the proceeds of the senior notes to pay a portion of the amounts then outstanding on the original term loan and the series A term loan and to pay related fees and expenses.  Select recognized a loss on early retirement of debt of $17.3 million in the three months ended June 30, 2013 in connection with the repayment of a portion of its term loans and amendment of the existing senior secured credit facility, which included the write-off of unamortized debt issuance costs.

On June 3, 2013, Select amended its existing senior secured credit facilities in order to:

·extend the maturity date on $293.3 million of its $300.0 million revolving credit facility from June 1, 2016 to March 1, 2018;

·convert the remaining original term loan and series A term loan to a series C term loan and lower the interest rate payable on the series C term loan from Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%, to Adjusted LIBO plus 3.00%, or Alternate Base Rate plus 2.00%, and amend the provision of the series C term loan from providing that Adjusted LIBO will at no time be less than 1.75% to providing that Adjusted LIBO will at no time be less than 1.00%; and

·amend the restrictive covenants governing the senior secured credit facilities in order to allow for unlimited restricted payments so long as there is no event of default under the senior secured credit facilities and the total pro forma ratio of total indebtedness to Consolidated EBITDA (as defined in our senior secured credit facilities) is less than or equal to 2.75 to 1.00.

Stock Repurchase Program

Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $350.0 million worth of shares of its common stock.  The program will remain in effect until March 31, 2014, unless extended by the board of directors.  Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings is funding this program with cash on hand and borrowings under its revolving credit facility.  In the three months ended September 30, 2013, Holdings did not repurchase any common stock.  Holdings repurchased 1,115,691 shares at a cost of approximately $10.0 million, an average cost per share of $8.95, which includes transaction costs, during the nine months ended September 30, 2013.  Since the inception of the program through September 30, 2013, Holdings has repurchased 23,606,080 shares at a cost of approximately $173.6 million, or $7.36 per share, which includes transaction costs.

29

Budget Control Act of 2011

On April 1, 2013, a federally mandated 2% reduction to Medicare payments was implemented resulting in reductions to both our net operating revenues and income from operations in the three months ended September 30, 2013 of approximately $7.2 million, of which approximately $6.8 million was related to our specialty hospitals and $0.4 million was related to our outpatient rehabilitation segment.  In the nine months ended September 30, 2013, the Medicare payment reduction resulted in reductions to both our net operating revenues and income from operations of approximately $16.6 million, of which approximately $15.9 million was related to our specialty hospitals and $0.7 million was related to our outpatient rehabilitation segment.  See the section titled “Regulatory Changes” — “Budget Control Act of 2011” for a discussion of this regulatory change.

American Taxpayer Relief Act of 2012

On April 1, 2013, the multiple procedure payment reduction (“MPPR Reduction”) for therapy services was increased from 25% to 50% resulting in reductions to both our net operating revenues and income from operations of approximately $1.9 million and $3.6 million in the three and nine months ended September 30, 2013, respectively.  See the section titled “Multiple Procedure Payment Reduction” for a discussion of this regulatory change.

Summary Financial Results

Three Months Ended September 30, 2013

For the three months ended September 30, 2013, our net operating revenues increased 1.3% to $722.8 million compared to $713.7 million for the three months ended September 30, 2012.  This increase in net operating revenues resulted principally from increases that occurred within our outpatient rehabilitation segment.  We had income from operations for the three months ended September 30, 2013 of $62.4 million compared to $70.8 million for the three months ended September 30, 2012.  Our Adjusted EBITDA for the three months ended September 30, 2013 was $80.4 million, compared to $87.7 million for the three months ended September 30, 2012 and our Adjusted EBITDA margin was 11.1% for the three months ended September 30, 2013 compared to 12.3% for the three months ended September 30, 2012.  See the section titled “Results of Operations” for a reconciliation of net income to Adjusted EBITDA.  The decrease in our income from operations, Adjusted EBITDA and Adjusted EBITDA margin is principally due to the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction.

Net income attributable to Holdings was $23.3 million for the three months ended September 30, 2013 compared to $24.1 million for the three months ended September 30, 2012.  The decrease in net income resulted principally from a decline in our income from operations described above and losses from unconsolidated subsidiaries, offset in part by a reduction in loss on early retirement of debt and reductions in interest expense and our effective tax rate.

Nine Months Ended September 30, 2013

For the nine months ended September 30, 2013, our net operating revenues increased 1.0% to $2,229.5 million compared to $2,207.9 million for the nine months ended September 30, 2012.  We experienced increases in net operating revenues in both our specialty hospital and outpatient rehabilitation segments.  We had income from operations for the nine months ended September 30, 2013 of $233.2 million compared to $255.9 million for the nine months ended September 30, 2012.  Our Adjusted EBITDA for the nine months

30

ended September 30, 2013 was $286.5 million, compared to $307.1 million for the nine months ended September 30, 2012 and our Adjusted EBITDA margin was 12.8% for the nine months ended September 30, 2013 compared to 13.9% for the nine months ended September 30, 2012.  See the section titled “Results of Operations” for a reconciliation of net income to Adjusted EBITDA.  The decrease in our income from operations, Adjusted EBITDA and Adjusted EBITDA margin is principally due to the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction.

Net income attributable to Holdings was $85.5 million for the nine months ended September 30, 2013 compared to $108.8 million for the nine months ended September 30, 2012.  The decrease in Holdings’ net income resulted from a decline in our income from operations described above, a greater loss on early retirement of debt and a decrease in our equity in earnings of unconsolidated subsidiaries during the nine months ended September 30, 2013, offset in part by reductions in interest expense and our effective income tax rate.

Cash flow from operations provided $115.1 million of cash for the nine months ended September 30, 2013 for Holdings and $120.7 million of cash for the nine months ended September 30, 2013 for Select.  The difference in cash flow from operations between Holdings and Select primarily relates to interest payments on Holdings’ senior floating rate notes.

Regulatory Changes

In the past few years, there have been significant regulatory changes that have affected our net operating revenues and, in some cases, caused us to change our operating models and strategies.  The following is a discussion of recent regulatory changes that are affecting our results of operations in 2013 or may have an effect on our future results of operations.  Our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on February 26, 2013 contains a more detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations, and the information below should be read in connection with that more detailed discussion.

Budget Control Act of 2011

The Budget Control Act of 2011, enacted on August 2, 2011, increased the federal debt ceiling in connection with deficit reductions over the next ten years. The Budget Control Act of 2011 requires automatic reductions in federal spending by approximately $1.2 trillion split evenly between domestic and defense spending.  Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap, which are expected to reduce Medicare payments by more than $9.5 billion in fiscal year 2013 and $123 billion over the period of fiscal years 2013 to 2021.  On April 1, 2013, a 2% reduction to Medicare payments was implemented. For the period from April 1, 2013 to September 30, 2013, this reduction has reduced both our net operating revenues and income from operations by approximately $16.6 million.  We have estimated that this reduction will reduce our net operating revenues and income from operations by approximately $8.0 million to $9.0 million in the three months ended December 31, 2013.

31

Medicare Payment of Long Term Acute Care Hospital Services (“LTCH-PPS”)

Medicare Payment of Long Term Acute Care Hospitals during Fiscal Year 2013

On August 1, 2012, CMS published the final rule updating the policies and payment rates for LTCH-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013).  Two different standard federal rates apply during fiscal year 2013.  The standard federal rate for discharges on or after October 1, 2012 and through December 28, 2012 was set at $40,916 and the standard federal rate for discharges on or after December 29, 2012 for the remainder of fiscal year 2013 is $40,398 both of which are an increase from the fiscal year 2012 standard federal rate of $40,222. The update to the standard federal rate for fiscal year 2013 through December 28, 2012 included a market basket increase of 2.6%, less a productivity adjustment of 0.7% and less an additional reduction of 0.1% mandated by the Patient Protection and Affordable Care Act (“PPACA”). The standard federal rate for the period of December 29, 2012 through the remainder of fiscal 2013 is further reduced by a portion of the one-time budget neutrality adjustment of 1.266%, as discussed below.  The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2013 of $15,408, which is a decrease from the fixed-loss amount in the 2012 fiscal year of $17,931.

Medicare Payment of Long Term Acute Care Hospitals during Fiscal Year 2014

On August 19, 2013, CMS published the final rule updating the policies and payment rates for LTCH-PPS for fiscal year 2014 (affecting discharges and cost reporting periods beginning on or after October 1, 2013 through September 30, 2014). The standard federal rate was set at $40,607, an increase from the standard federal rate applicable during the period from December 29, 2012 through September 30, 2013 of $40,398. The update to the standard federal rate for fiscal year 2014 includes a market basket increase of 2.5%, less a productivity adjustment of 0.5%, less a reduction of 0.3% mandated by the PPACA, and less a budget neutrality adjustment of 1.266%, as discussed below. The fixed-loss amount for high cost outlier cases was set at $13,314, which is a decrease from the fixed-loss amount in the 2013 fiscal year of $15,408.

Short Stay Outlier Policy

CMS established a different payment methodology for Medicare patients with a length of stay less than or equal to five-sixths of the geometric average length of stay for that particular MS-LTC-DRG, referred to as a short stay outlier, or “SSO.” The SSO rule was further revised adding a category referred to as a “very short stay outlier” for discharges occurring on or after December 29, 2012. For cases with a length of stay that is equal to or less than one standard deviation from the geometric average length of stay for the same MS-DRG under IPPS, referred to as the so-called “IPPS comparable threshold,” the rule lowers the LTCH payment to a rate based on the general acute care hospital IPPS per diem. SSO cases with covered lengths of stay that exceed the IPPS comparable threshold continue to be paid under the SSO payment policy.

25 Percent Rule

The 25 Percent Rule is a downward payment adjustment that applies to Medicare patients discharged from LTCHs who were admitted from a co-located hospital or a non-co-located hospital and caused the LTCH to exceed the applicable percentage thresholds for discharged Medicare patients.  The SCHIP Extension Act of 2007 as amended by the American Recovery and Reinvestment Act and the PPACA has limited the application of the 25 Percent Rule.  CMS adopted through regulations an additional one-year extension of relief from the full application of Medicare admission thresholds. As a result, full implementation of the Medicare admission thresholds did not go into effect until cost reporting periods beginning on or after October 1, 2013.  After the

32

expiration of the extension, our LTCHs will be subject to a downward payment adjustment for any Medicare patients who were admitted from a co-located or a non-co-located hospital and that exceed the applicable percentage threshold of all Medicare patients discharged from the LTCH during the cost reporting period.

In the preamble to the proposed update to the Medicare policies and payment rates for fiscal year 2014, CMS requested public comments on adoption of a payment adjustment based on whether a particular case qualifies as chronically critically ill/medically complex (“CCI/MC”). CMS is considering a change to the LTCH-PPS payment policies that would limit full LTCH-PPS payment to those patients meeting the definition of CCI/MC while they were in an IPPS hospital inpatient setting and subsequently directly admitted to an LTCH. Payment for non-CCI/MC patients would be made at an “IPPS comparable amount,” that is, an amount comparable to what would have been paid under the IPPS calculated as a per diem rate with total payments capped at the full IPPS MS-DRG payment rate. We cannot predict whether CMS will adopt the CCI/MC patient-level criteria in the future or, if adopted, how such criteria would affect the application of the 25 Percent Rule to our LTCHs.

One-Time Budget Neutrality Adjustment

The regulations governing LTCH-PPS authorizes CMS to make a one-time adjustment to the standard federal rate to correct any “significant difference between actual payments and estimated payments for the first year” of LTCH-PPS.  In the update to the Medicare policies and payment rates for fiscal year 2013, CMS adopted a one-time budget neutrality adjustment that results in a permanent negative adjustment of 3.75% to the LTCH base rate.  CMS is implementing the adjustment over a three-year period by applying a factor of 0.98734 to the standard federal rate in fiscal years 2013, 2014 and 2015, except that the adjustment did not apply to payments for discharges occurring on or after October 1, 2012 through December 28, 2012.

Medicare Market Basket Adjustments for Long Term Acute Care Hospitals

The PPACA instituted a market basket payment adjustment to LTCHs. In fiscal year 2014, the market basket update will be reduced by 0.3%.  Fiscal years 2015 and 2016 the market basket update will be reduced by 0.2%.  Finally, in fiscal years 2017-2019, the market basket update will be reduced by 0.75%.  The PPACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

Medicare Payment of Inpatient Rehabilitation Facility Services (“IRF-PPS”)

Medicare Payment of Inpatient Rehabilitation Facilities during Fiscal Year 2013

On July 30, 2012, CMS published the final rule updating policies and payment rates for IRF-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013).  The standard payment conversion factor for discharges for fiscal year 2013 is $14,343, which is an increase from the fiscal year 2012 standard payment conversion factor of $14,076.  The update to the standard payment conversion factor for fiscal year 2013 includes a market basket increase of 2.7%, less a productivity adjustment of 0.7%, less an additional reduction of 0.1% as mandated by the PPACA.  CMS decreased the outlier threshold amount for fiscal year 2013 to $10,466 from $10,713 established in the final rule for fiscal year 2012.

33

Medicare Payment of Inpatient Rehabilitation Facilities during Fiscal Year 2014

On August 6, 2013, CMS published the final rule updating policies and payment rates for IRF-PPS for fiscal year 2014 (affecting discharges and cost reporting periods beginning on or after October 1, 2013 through September 30, 2014).  The standard payment conversion factor for discharges for fiscal year 2014 is $14,846, which is an increase from the fiscal year 2013 standard payment conversion factor of $14,343.  The update to the standard payment conversion factor for fiscal year 2014 includes a market basket increase of 2.6%, less a productivity adjustment of 0.5%, less an additional reduction of 0.3% as mandated by the PPACA.  CMS decreased the outlier threshold amount for fiscal year 2014 to $9,272 from $10,466 established in the final rule for fiscal year 2013.

Classification Criteria for Inpatient Rehabilitation Facilities

In order to be excluded from the hospital inpatient PPS and be paid at the higher IRF-PPS rates, an inpatient hospital must demonstrate that at least 60 percent of its patients meet the criteria specified in the regulations, including the need for intensive inpatient rehabilitation services for one or more of the 13 listed conditions, representing a presumptive need for intensive inpatient rehabilitation. Compliance is demonstrated through either medical review or the “presumptive” method, in which a patient’s diagnosis codes are compared to a “presumptive compliance” list.

CMS has announced that it will remove a number of diagnosis codes from the presumptive compliance list.  According to CMS, these conditions do not demonstrate the need for intensive inpatient rehabilitation services in the absence of additional facts that would have to be pulled from a patient’s medical record.  As a result, beginning on or after October 1, 2014, a number of diagnosis codes previously on the presumptive compliance list will be removed, including diagnosis codes in the following categories: non specific diagnosis codes, arthritis diagnosis codes, unilateral upper extremity amputations diagnosis, some congenital anomalies diagnosis codes, other miscellaneous diagnosis codes.

Medicare Market Basket Adjustments for Inpatient Rehabilitation Facilities

The PPACA instituted a market basket payment adjustment for IRFs. For fiscal year 2014, the reduction is 0.3%.  For fiscal years 2015 and 2016, the reduction is 0.2%.  For fiscal years 2017 - 2019, the reduction is 0.75%.  The PPACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

Medicare Payment of Outpatient Rehabilitation Services

Medicare Physician Fee Schedule and Sustainable Growth Rate Update

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. The Medicare physician fee schedule rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula, contained in legislation. The SGR formula has resulted in automatic reductions in rates in every year since 2002; however, for each year through 2013 CMS or Congress has taken action to prevent the SGR formula reductions.  The American Taxpayer Relief Act of 2012 froze Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. On March 5, 2013, CMS estimated a 24.4% reduction in the Medicare physician fee schedule payment rates for calendar year 2014, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.  If the 24.4% reduction is averted by Congress, the projected impact of the proposed 2014 Medicare physician fee

34

schedule rule on outpatient physical therapy services would be a positive 1% in aggregate for calendar year 2014.  However, the amount of payment for each service would vary depending on CPT codes billed and the geographic practice cost indices adjustments among localities.

Therapy Caps

Beginning on January 1, 1999, the Balanced Budget Act of 1997 subjected certain outpatient therapy providers reimbursed under the Medicare physician fee schedule to annual limits for therapy expenses. Effective January 1, 2013, the annual limit on outpatient therapy services is $1,900 for combined physical and speech language pathology services and $1,900 for occupational therapy services. The per beneficiary caps were $1,880 for calendar year 2012.  It is anticipated that in calendar year 2014 the therapy cap will be the 2013 rate increased by the percentage increase in the Medicare Economic Index.  The Middle Class Tax Relief and Job Creation Act of 2012 extended the annual limits on therapy expenses to hospital outpatient departments for dates of service on or after October 1, 2012. The application of annual limits to hospital outpatient department settings will sunset on December 31, 2013 unless Congress takes further action to extend it.

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual limit for therapy expenses. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the therapy caps if the provision of therapy services was deemed to be medically necessary. Therapy cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The American Taxpayer Relief Act of 2012 extends the exceptions process for outpatient therapy caps through December 31, 2013. Unless Congress extends the exceptions process, the therapy caps will apply to all outpatient therapy services beginning January 1, 2014, except those services furnished and billed by outpatient hospital departments, as noted above.

The Middle Class Tax Relief and Job Creation Act of 2012 made several changes to the exceptions process to the annual limit for therapy expenses. For any claim above the annual limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record. Effective October 1, 2012, all claims exceeding $3,700 are subject to a manual medical review process. The $3,700 threshold is applied separately to the combined physical therapy/speech therapy cap and the occupational therapy cap. The American Taxpayer Relief Act of 2012 extends through December 31, 2013 the requirement that Medicare perform manual medical review of therapy services when an exception is requested for cases in which the beneficiary has reached a specified dollar aggregate threshold, including therapy services furnished in hospital outpatient departments. Effective October 1, 2012, all therapy claims, whether above or below the annual limit, must include the national provider identifier (NPI) of the physician responsible for certifying and periodically reviewing the plan of care.  As of January 1, 2013, CMS implemented a claims based data collection strategy that is designed to assist in reforming the Medicare payment system for outpatient therapy. Effective January 1, 2013, all therapy claims must include additional codes and modifiers providing information about the beneficiary’s functional status at the outset of the therapy episode of care, specified points during treatment, and at the time of discharge.  After July 1, 2013, claims submitted without the appropriate codes and modifiers will be returned unpaid.

35

Multiple Procedure Payment Reduction

CMS adopted a multiple procedure payment reduction for therapy services in the final update to the Medicare physician fee schedule for calendar year 2011. This multiple procedure payment reduction policy became effective January 1, 2011 and applies to all outpatient therapy services paid under Medicare Part B. Furthermore, the multiple procedure payment reduction policy applies across all therapy disciplines — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the therapy procedure or unit of service with the highest Relative Value Unit, and then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings.  The American Taxpayer Relief Act of 2012 increased the payment reduction in either setting to 50% effective April 1, 2013 for all outpatient therapy services. Our outpatient rehabilitation therapy services are primarily offered in institutional settings and, as such, were subject to the applicable 25% payment reduction in the practice expense component for the second and subsequent therapy services furnished by us to the same patient on the same day until April 1, 2013 when the payment reduction was increased to 50%.

36

Operating Statistics

The following tables set forth operating statistics for our specialty hospitals and our outpatient rehabilitation clinics for each of the periods presented. The data in the tables reflect the changes in the number of specialty hospitals and outpatient rehabilitation clinics we operate that resulted from acquisitions, start-up activities, closures and sales. The operating statistics reflect data for the period of time these operations were managed by us.

	Three Months Ended September 30,						Nine Months EndedSeptember 30,
	2012			2013			2012			2013
Specialty hospital data(1):
Number of hospitals owned - start of period	117			116			115			116
Number of hospitals acquired	—			—			1			1
Number of hospital start-ups	—			—			1			—
Number of hospitals closed/sold	—			(1		)	—			(2		)
Number of hospitals owned - end of period	117			115			117			115
Number of hospitals managed - end of period	6			8			6			8
Total number of hospitals (all) - end of period	123			123			123			123
Long term acute care hospitals	111			108			111			108
Rehabilitation hospitals	12			15			12			15
Available licensed beds (2)	5,174			5,172			5,174			5,172
Admissions (2)	13,477			13,778			41,404			41,740
Patient days (2)	328,871			336,120			1,007,908			1,017,157
Average length of stay (days) (2)	25			24			24			24
Net revenue per patient day (2)(3)	$	1,517		$	1,471		$	1,532		$	1,516
Occupancy rate (2)	69		%	71		%	71		%	72		%
Percent patient days - Medicare (2)	64		%	64		%	64		%	64		%
Outpatient rehabilitation data:
Number of clinics owned - start of period	852			872			850			867
Number of clinic acquired	3			1			3			1
Number of clinic start-ups	6			7			24			18
Number of clinics closed/sold	(3		)	(4		)	(19		)	(10		)
Number of clinics owned - end of period	858			876			858			876
Number of clinics managed - end of period	107			121			107			121
Total number of clinics (all) - end of period	965			997			965			997
Number of visits (2)	1,129,015			1,196,893			3,447,774			3,577,114
Net revenue per visit (2)(4)	$	103		$	103		$	103		$	104

(1)Specialty hospitals consist of long term acute care hospitals and inpatient rehabilitation facilities.

(2)Data excludes specialty hospitals and outpatient clinics managed by the Company.

(3)Net revenue per patient day is calculated by dividing specialty hospital direct patient service revenues by the total number of patient days.

(4)Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of visits. For purposes of this computation, outpatient rehabilitation direct patient service clinic revenue does not include contract services revenue.

37

Results of Operations

The following table outlines, for the periods indicated, selected operating data as a percentage of net operating revenues:

	Select Medical Holdings Corporation				Select Medical Corporation
	Three MonthsEnded September 30,				Three MonthsEnded September 30,
	2012		2013		2012		2013
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	83.9		85.4		83.9		85.4
General and administrative	2.4		2.5		2.4		2.5
Bad debt expense	1.6		1.3		1.6		1.3
Depreciation and amortization	2.2		2.2		2.2		2.2
Income from operations	9.9		8.6		9.9		8.6
Loss on early retirement of debt	(0.9	)	—		(0.9	)	—
Equity in earnings (losses) of unconsolidated subsidiaries	0.2		(0.0	)	0.2		(0.0	)
Interest expense	(3.3	)	(2.9	)	(3.0	)	(2.9	)
Income before income taxes	5.9		5.7		6.2		5.7
Income tax expense	2.3		2.2		2.4		2.2
Net income	3.6		3.5		3.8		3.5
Net income attributable to non-controlling interests	0.2		0.3		0.2		0.3
Net income attributable to Holdings and Select	3.4	%	3.2	%	3.6	%	3.2	%

	Select Medical Holdings Corporation				Select Medical Corporation
	Nine MonthsEnded September 30,				Nine MonthsEnded September 30,
	2012		2013		2012		2013
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	82.6		83.8		82.6		83.8
General and administrative	2.3		2.4		2.3		2.4
Bad debt expense	1.4		1.2		1.4		1.2
Depreciation and amortization	2.1		2.1		2.1		2.1
Income from operations	11.6		10.5		11.6		10.5
Loss on early retirement of debt	(0.3	)	(0.8	)	(0.3	)	(0.8	)
Equity in earnings of unconsolidated subsidiaries	0.3		0.0		0.3		0.0
Interest expense	(3.3	)	(3.0	)	(2.8	)	(2.9	)
Income before income taxes	8.3		6.7		8.8		6.8
Income tax expense	3.2		2.6		3.4		2.6
Net income	5.1		4.1		5.4		4.2
Net income attributable to non-controlling interests	0.2		0.3		0.2		0.3
Net income attributable to Holdings and Select	4.9	%	3.8	%	5.2	%	3.9	%

38

The following tables summarize selected financial data by business segment, for the periods indicated:

	Select Medical Holdings Corporation								Select Medical Corporation
	Three Months Ended September 30,								Three Months Ended September 30,
	2012			2013			% Change		2012			2013			% Change
	(in thousands)								(in thousands)
Net operating revenues:
Specialty hospitals	$	531,409		$	532,610		0.2	%	$	531,409		$	532,610		0.2	%
Outpatient rehabilitation	182,246			190,223			4.4		182,246			190,223			4.4
Other(2)	14			12			N/M		14			12			N/M
Total company	$	713,669		$	722,845		1.3	%	$	713,669		$	722,845		1.3	%
Income (loss) from operations:
Specialty hospitals	$	72,106		$	63,013		(12.6	)%	$	72,106		$	63,013		(12.6	)%
Outpatient rehabilitation	17,202			18,640			8.4		17,202			18,640			8.4
Other(2)	(18,489		)	(19,254		)	(4.1	)	(18,489		)	(19,254		)	(4.1	)
Total company	$	70,819		$	62,399		(11.9	)%	$	70,819		$	62,399		(11.9	)%
Adjusted EBITDA:(3)
Specialty hospitals	$	83,659		$	75,280		(10.0	)%	$	83,659		$	75,280		(10.0	)%
Outpatient rehabilitation	20,354			21,619			6.2		20,354			21,619			6.2
Other(2)	(16,266		)	(16,471		)	(1.3	)	(16,266		)	(16,471		)	(1.3	)
Total company	$	87,747		$	80,428		(8.3	)%	$	87,747		$	80,428		(8.3	)%
Adjusted EBITDA margin:(3)
Specialty hospitals	15.7		%	14.1		%			15.7		%	14.1		%
Outpatient rehabilitation	11.2			11.4					11.2			11.4
Other(2)	N/M			N/M					N/M			N/M
Total company	12.3		%	11.1		%			12.3		%	11.1		%
Total assets:
Specialty hospitals	$	2,165,248		$	2,232,756				$	2,165,248		$	2,232,756
Outpatient rehabilitation	431,310			445,729					431,310			445,729
Other(2)	185,250			163,939					184,120			163,939
Total company	$	2,781,808		$	2,842,424				$	2,780,678		$	2,842,424
Purchases of property and equipment:
Specialty hospitals	$	12,281		$	14,157				$	12,281		$	14,157
Outpatient rehabilitation	3,073			2,802					3,073			2,802
Other(2)	1,900			410					1,900			410
Total company	$	17,254		$	17,369				$	17,254		$	17,369

39

	Select Medical Holdings Corporation								Select Medical Corporation
	Nine Months Ended September 30,								Nine Months Ended September 30,
	2012			2013			% Change		2012			2013			% Change
	(in thousands)								(in thousands)
Net operating revenues:
Specialty hospitals	$	1,641,577		$	1,649,747		0.5	%	$	1,641,577		$	1,649,747		0.5	%
Outpatient rehabilitation	566,195			579,404			2.3		566,195			579,404			2.3
Other(2)	111			322			N/M		111			322			N/M
Total company	$	2,207,883		$	2,229,473		1.0	%	$	2,207,883		$	2,229,473		1.0	%
Income (loss) from operations:
Specialty hospitals	$	250,904		$	228,959		(8.7	)%	$	250,904		$	228,959		(8.7	)%
Outpatient rehabilitation	58,635			61,557			5.0		58,635			61,557			5.0
Other(2)	(53,603		)	(57,324		)	(6.9	)	(53,603		)	(57,324		)	(6.9	)
Total company	$	255,936		$	233,192		(8.9	)%	$	255,936		$	233,192		(8.9	)%
Adjusted EBITDA:(3)
Specialty hospitals	$	285,779		$	265,020		(7.3	)%	$	285,779		$	265,020		(7.3	)%
Outpatient rehabilitation	68,669			70,506			2.7		68,669			70,506			2.7
Other(2)	(47,358		)	(49,059		)	(3.6	)	(47,358		)	(49,059		)	(3.6	)
Total company	$	307,090		$	286,467		(6.7	)%	$	307,090		$	286,467		(6.7	)%
Adjusted EBITDA margin:(3)
Specialty hospitals	17.4		%	16.1		%			17.4		%	16.1		%
Outpatient rehabilitation	12.1			12.2					12.1			12.2
Other(2)	N/M			N/M					N/M			N/M
Total company	13.9		%	12.8		%			13.9		%	12.8		%
Total assets:
Specialty hospitals	$	2,165,248		$	2,232,756				$	2,165,248		$	2,232,756
Outpatient rehabilitation	431,310			445,729					431,310			445,729
Other(2)	185,250			163,939					184,120			163,939
Total company	$	2,781,808		$	2,842,424				$	2,780,678		$	2,842,424
Purchases of property and equipment:
Specialty hospitals	$	31,963		$	35,257				$	31,963		$	35,257
Outpatient rehabilitation	9,786			8,646					9,786			8,646
Other(2)	3,439			1,428					3,439			1,428
Total company	$	45,188		$	45,331				$	45,188		$	45,331

N/M — Not Meaningful.

(1)Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.

(2)Other includes our corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses.

40

(3)We define Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries, and other income (expense). We believe that the presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our operating units. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

Following is a reconciliation of net income to Adjusted EBITDA as utilized by us in reporting our segment performance:

	Select Medical Holdings Corporation					Select Medical Corporation
	Three Months Ended September 30,					Three Months Ended September 30,
	2012			2013		2012			2013
	(in thousands)					(in thousands)
Net income	$	25,158		$	25,207	$	27,001		$	25,207
Income tax expense	16,189			15,761		17,181			15,761
Interest expense	24,575			21,252		21,740			21,252
Loss on early retirement of debt	6,064			—		6,064			—
Equity in losses (earnings) of unconsolidated subsidiaries	(1,167		)	179		(1,167		)	179
Stock compensation expense:
Included in general and administrative	847			1,258		847			1,258
Included in cost of services	544			608		544			608
Depreciation and amortization	15,537			16,163		15,537			16,163
Adjusted EBITDA	$	87,747		$	80,428	$	87,747		$	80,428

	Select Medical Holdings Corporation						Select Medical Corporation
	Nine Months Ended September 30,						Nine Months Ended September 30,
	2012			2013			2012			2013
	(in thousands)						(in thousands)
Net income	$	112,546		$	91,887		$	117,972		$	94,077
Income tax expense	71,415			57,391			74,337			58,570
Interest expense	72,295			66,614			63,947			64,204
Loss on early retirement of debt	6,064			18,747			6,064			17,788
Equity in earnings of unconsolidated subsidiaries	(6,384		)	(1,447		)	(6,384		)	(1,447		)
Stock compensation expense:
Included in general and administrative	2,436			3,685			2,436			3,685
Included in cost of services	1,554			1,718			1,554			1,718
Depreciation and amortization	47,164			47,872			47,164			47,872
Adjusted EBITDA	$	307,090		$	286,467		$	307,090		$	286,467

41

Three Months Ended September 30, 2013 Compared to Three Months Ended September 30, 2012

In the following discussion, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, income from operations, loss on early retirement of debt, equity in earnings of unconsolidated subsidiaries and non-controlling interest which are the same for Holdings and Select.  In addition, we discuss separately for Holdings and Select, changes related to interest expense and income taxes.

Net Operating Revenues

Our net operating revenues increased by 1.3% to $722.8 million for the three months ended September 30, 2013 compared to $713.7 million for the three months ended September 30, 2012.

Specialty Hospitals.  Our specialty hospital net operating revenues increased by 0.2% to $532.6 million for the three months ended September 30, 2013 compared to $531.4 million for the three months ended September 30, 2012.  The growth in net operating revenue resulted from increases in our patient volume, almost all of which was offset by a 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and reductions in our non-Medicare net revenue per patient day.  The reductions in our Medicare net operating revenue due to the Budget Control Act of 2011 were $6.8 million for the three months ended September 30, 2013.  Our patient days increased 2.2% to 336,120 days for the three months ended September 30, 2013 as compared to the three months ended September 30, 2012.  Our occupancy percentage was 71% for the three months ended September 30, 2013 compared to 69% for the three months ended September 30, 2012.  Our average net revenue per patient day declined to $1,471 for the three months ended September 30, 2013 compared to $1,517 for the three months ended September 30, 2012, principally as a result of decreases resulting from a 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and reductions in our non-Medicare net revenue per patient day.

Outpatient Rehabilitation.  Our outpatient rehabilitation segment net operating revenues increased 4.4% to $190.2 million for the three months ended September 30, 2013 compared to $182.2 million for the three months ended September 30, 2012, more than offsetting reductions in net operating revenues of $0.4 million due to the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the $1.9 million reduction in revenues related to the MPPR Reduction.  The net operating revenues generated by our outpatient rehabilitation clinics for the three months ended September 30, 2013 increased 6.9% compared to the three months ended September 30, 2012.  The increase was primarily due to growth in the number of visits.  The number of visits in our owned outpatient rehabilitation clinics increased 6.0% for the three months ended September 30, 2013 to 1,196,893 visits compared to 1,129,015 visits for the three months ended September 30, 2012.  Net revenue per visit in our owned outpatient rehabilitation clinics was $103 for both the three months ended September 30, 2013 and 2012.  Our contract services business experienced a decrease in net operating revenues of $1.6 million compared to the three months ended September 30, 2012, which principally resulted from both regulatory changes that affected the annual limit for therapy services and reductions in the number of contracts under which services are provided.

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense and bad debt expense.  Our operating expenses increased by $17.0 million to $644.3 million for the three months ended September 30, 2013 compared to $627.3 million for the three months ended September 30, 2012 and resulted primarily from an increase in our cost of services.  As a percentage of our net operating revenues, our operating expenses were 89.2% for the three months ended September 30, 2013 compared to 87.9% for the three months ended September 30, 2012.  Our cost of services, a major component of which is labor expense, were $617.3

42

million for the three months ended September 30, 2013 compared to $599.0 million for the three months ended September 30, 2012.  The increase in our cost of services resulted principally from an increase in patient volumes.  As a percentage of our net operating revenues, our cost of services were 85.4% for the three months ended September 30, 2013 compared to 83.9% for the three months ended September 30, 2012.  The increase in our cost of services as a percentage of net operating revenues for the three months ended September 30, 2013 was principally from the loss of net operating revenues associated with the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction discussed above under “Net Operating Revenues,” with no relative offsetting reduction in costs.  Facility rent expense, which is a component of cost of services, was $32.2 million for the three months ended September 30, 2013 compared to $31.7 million for the three months ended September 30, 2012.  General and administrative expenses were 2.5% of net operating revenues or $17.7 million for the three months ended September 30, 2013 compared to 2.4% of net operating revenues or $17.1 million for the three months ended September 30, 2012.  Our bad debt expense was $9.3 million or 1.3% of net operating revenues for the three months ended September 30, 2013 compared to $11.2 million or 1.6% of net operating revenues for the three months ended September 31, 2012.

Adjusted EBITDA

Specialty Hospitals.  Adjusted EBITDA for our specialty hospitals decreased 10.0% to $75.3 million for the three months ended September 30, 2013 compared to $83.7 million for the three months ended September 30, 2012.  Our Adjusted EBITDA margin for the segment decreased to 14.1% for the three months ended September 30, 2013 from 15.7% for the three months ended September 30, 2012.  The decrease in Adjusted EBITDA for our specialty hospitals was primarily the result of the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 as discussed above under “Net Operating Revenues,” which reductions were accompanied by no relative offsetting reduction in costs.

Outpatient Rehabilitation.  Our Adjusted EBITDA for our outpatient rehabilitation segment increased 6.2% to $21.6 million for the three months ended September 30, 2013 compared to $20.4 million for the three months ended September 30, 2012.  The Adjusted EBITDA in our outpatient rehabilitation clinics increased by $1.3 million for the three months ended September 30, 2013 compared to the three months ended September 30, 2012, more than offsetting reductions in net operating revenues of $0.4 million due to the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the $1.9 million revenue reduction related to the MPPR Reduction.  Our Adjusted EBITDA margin for the outpatient rehabilitation segment increased to 11.4% for the three months ended September 30, 2013 from 11.2% for the three months ended September 30, 2012.  Our Adjusted EBITDA margins for our outpatient rehabilitation clinics were 13.0% for both the three months ended September 30, 2013 and 2012.

Other.  The Adjusted EBITDA loss was $16.5 million for the three months ended September 30, 2013 compared to an Adjusted EBITDA loss of $16.3 million for the three months ended September 30, 2012.

Income from Operations

For the three months ended September 30, 2013 we had income from operations of $62.4 million compared to $70.8 million for the three months ended September 30, 2012.  The decrease in our income from operations resulted principally from the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction, as discussed above under “Net Operating Revenues,” which reductions were accompanied by no relative offsetting reduction in costs.

43

Loss on Early Retirement of Debt

On September 12, 2012, we redeemed an aggregate of $275.0 million principal amount of Select’s 7 5/8% senior subordinated notes at a redemption price of 101.271% of the principal amount.  We recognized a loss on early retirement of debt of $6.1 million for the three months ended September 30, 2012 in connection with the redemption of Select’s 7 5/8% senior subordinated notes, which included the write-off of unamortized debt issuance costs and payment of call premiums.

Equity in Earnings (Losses) of Unconsolidated Subsidiaries

For the three months ended September 30, 2013, we had equity in losses of unconsolidated subsidiaries of $0.2 million compared to equity in earnings of unconsolidated subsidiaries of $1.2 million for the three months ended September 30, 2012.  The equity in losses of unconsolidated subsidiaries resulted from losses incurred by start-up companies where we own a minority interest.

Interest Expense

Select Medical Corporation.  Interest expense was $21.3 million for the three months ended September 30, 2013 compared to $21.7 million for the three months ended September 30, 2012.  The decrease in interest expense was principally due to lower interest rates on borrowings, offset in part by higher debt levels during the three months ended September 30, 2013.

Select Medical Holdings Corporation.  Interest expense was $21.3 million for the three months ended September 30, 2013 compared to $24.6 million for the three months ended September 30, 2012.  The decrease in interest expense was principally due to lower interest rates on borrowings.

Income Taxes

Select Medical Corporation. We recorded income tax expense of $15.8 million for the three months ended September 30, 2013. The expense represented an effective tax rate of 38.5%.  We recorded income tax expense of $17.2 million for the three months ended September 30, 2012. The expense represented an effective tax rate of 38.9%.  Select Medical Corporation is part of the consolidated federal tax return for Select Medical Holdings Corporation.  We allocate income taxes between Select and Holdings for purposes of financial statement presentation.  Because Holdings is a passive investment company incorporated in Delaware, it does not incur any state income tax expense or benefit on its specific income or loss and, as such, receives a tax allocation equal to the federal statutory rate of 35% on its specific income or loss.  Based upon the relative size of Holdings’ income or loss, this can cause the effective tax rate for Select to differ from the effective tax rate for the consolidated company.

Select Medical Holdings Corporation.  We recorded income tax expense of $15.8 million for the three months ended September 30, 2013, which represented an effective tax rate of 38.5%.  We recorded income tax expense of $16.2 million for the three months ended September 30, 2012, which represented an effective tax rate of 39.2%.  The decline in our effective tax rate has resulted from an increase in earnings of our consolidated subsidiaries where we have less than a 100% ownership interest that are taxed as pass-through entities in which we only record income taxes on our share of the income, offset in part by an increase in our state effective tax rates that has resulted from a higher proportion of our income being generated in states with higher tax rates.

44

Non-Controlling Interests

Non-controlling interests in consolidated earnings were $1.9 million for the three months ended September 30, 2013 and $1.0 million for the three months ended September 30, 2012. This increase is due to increased profitability in certain of our consolidated subsidiaries that are less than 100% owned.

Nine Months Ended September 30, 2013 Compared to Nine Months Ended September 30, 2012

In the following discussion, we discuss changes in the components of our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, income from operations, equity in earnings of unconsolidated subsidiaries and non-controlling interest which are the same for Holdings and Select.  In addition, we discuss separately for Holdings and Select, changes related to loss on early retirement of debt, interest expense and income taxes.

Net Operating Revenues

Our net operating revenues increased by 1.0% to $2,229.5 million for the nine months ended September 30, 2013 compared to $2,207.9 million for the nine months ended September 30, 2012.

Specialty Hospitals.  Our specialty hospital net operating revenues increased by 0.5% to $1,649.7 million for the nine months ended September 30, 2013 compared to $1,641.6 million for the nine months ended September 30, 2012.  The growth in net operating revenues primarily resulted from increases in our patient volume and increases in revenues that are generated from contracted labor services provided to certain of our non-consolidated joint ventures.  These increases were offset in part by a 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and reductions in our non-Medicare net revenue per patient day.  The reductions in our specialty hospital Medicare net operating revenue due to the Budget Control Act of 2011 were $15.9 million for the nine months ended September 30, 2013.  Our patient days increased 0.9% to 1,017,157 days for the nine months ended September 30, 2013 as compared to the nine months ended September 30, 2012.  Our occupancy percentage was 72% for the nine months ended September 30, 2013 compared to 71% for the nine months ended September 30, 2012.  Our average net revenue per patient day decreased to $1,516 for the nine months ended September 30, 2013 compared to $1,532 for the nine months ended September 30, 2012.  This decrease principally resulted from decreases in our average Medicare net revenue per patient day as a result of the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and reductions in our non-Medicare net revenue per patient day.

Outpatient Rehabilitation.  Our outpatient rehabilitation segment net operating revenues increased 2.3% to $579.4 million for the nine months ended September 30, 2013 compared to $566.2 million for the nine months ended September 30, 2012, more than offsetting reductions in net operating revenues of $0.7 million due to the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the $3.6 million revenue reduction related to the MPPR Reduction.  The net operating revenues generated by our outpatient rehabilitation clinics for the nine months ended September 30, 2013 increased 5.1% to $443.3 million compared to the nine months ended September 30, 2012.  The increase was related to growth in both our number of visits and net revenue per visit.  The number of visits in our owned outpatient rehabilitation clinics increased 3.8% for the nine months ended September 30, 2013 to 3,577,114 visits compared to 3,447,774 visits for the nine months ended September 30, 2012.  Net revenue per visit in our owned outpatient rehabilitation clinics increased 1.0% to $104 for the nine months ended September 30, 2013 compared to $103 for the nine months ended September 30, 2012.  Our contract services business experienced a 5.8% decrease to $136.1 million in net operating revenues compared to the nine months ended September 30, 2012, which principally resulted from both regulatory changes that affected the annual limit for therapy services and reductions in the number of contracts under which services are provided.

45

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense and bad debt expense.  Our operating expenses increased by $43.6 million to $1,948.4 million for the nine months ended September 30, 2013 compared to $1,904.8 million for the nine months ended September 30, 2012, principally due to expense increases in our specialty hospital segment.  As a percentage of our net operating revenues, our operating expenses were 87.4% for the nine months ended September 30, 2013 compared to 86.3% for the nine months ended September 30, 2012.  Our cost of services, a major component of which is labor expense, were $1,867.9 million or 83.8% of net operating revenues for the nine months ended September 30, 2013 compared to $1,823.3 million or 82.6% of net operating revenues for the nine months ended September 30, 2012.  The principal cause of the increase in cost of services as a percentage of net operating revenues resulted from inflationary increases in labor costs in our specialty hospitals and the loss of net operating revenues associated with the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction discussed above under “Net Operating Revenues,” with no relative offsetting reduction in costs.  Facility rent expense, which is a component of cost of services, was $92.5 million for the nine months ended September 30, 2013 compared to $93.3 million for the nine months ended September 30, 2012.  General and administrative expenses were 2.4% of net operating revenues or $53.1 million for the nine months ended September 30, 2013 compared to 2.3% of net operating revenues or $49.9 million for the nine months ended September 30, 2012.  Our general and administrative expenses for the nine months ended September 30, 2012 were favorably impacted by a gain on the sale of a building; excluding this gain, general and administrative expenses for the nine months ended September 30, 2012 would have been 2.4% of net operating revenues.  Our bad debt expense was $27.4 million or 1.2% of net operating revenues for the nine months ended September 30, 2013 compared to $31.6 million or 1.4% of net operating revenues for the nine months ended September 30, 2012.

Adjusted EBITDA

Specialty Hospitals.  Adjusted EBITDA for our specialty hospitals decreased 7.3% to $265.0 million for the nine months ended September 30, 2013 compared to $285.8 million for the nine months ended September 30, 2012.  Our Adjusted EBITDA margin for the segment decreased to 16.1% for the nine months ended September 30, 2013 from 17.4% for the nine months ended September 30, 2012.  The decrease in Adjusted EBITDA for our specialty hospitals was primarily the result of the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 as discussed above under “Net Operating Revenues,” which reductions were accompanied by no relative offsetting reduction in costs, and increases in our operating expenses discussed above under “Operating Expenses.”

Outpatient Rehabilitation.  Our Adjusted EBITDA for our outpatient rehabilitation segment increased 2.7% to $70.5 million for the nine months ended September 30, 2013 compared to $68.7 million for the nine months ended September 30, 2012.  The Adjusted EBITDA in our outpatient rehabilitation clinics increased by $3.0 million for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012, more than offsetting reductions in net operating revenues of $0.7 million due to the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the $3.6 million revenue reduction related to the MPPR Reduction.  The Adjusted EBITDA in our contract services business decreased by 11.3% for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012.  Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 12.2% for the nine months ended September 30, 2013 compared to 12.1% for the nine months ended September 30, 2012.  Our Adjusted EBITDA margin for our outpatient rehabilitation clinics was 13.8% for both the nine months ended September 30, 2013 and 2012.

Other.  The Adjusted EBITDA loss was $49.1 million for the nine months ended September 30, 2013 compared to an Adjusted EBITDA loss of $47.4 million for the nine months ended September 30, 2012.  The

46

lower Adjusted EBITDA loss for the nine months ended September 30, 2012 is primarily attributable to the gain on the sale of a building during the same period last year, as described under “Operating Expenses.”

Income from Operations

For the nine months ended September 30, 2013, we had income from operations of $233.2 million compared to $255.9 million for the nine months ended September 30, 2012.  The decrease in our income from operations resulted principally from the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction, as discussed above under “Net Operating Revenues,” and increases in labor costs in our specialty hospitals as discussed above under “Operating Expenses.”

Loss on Early Retirement of Debt

Select Medical Corporation.  On March 22, 2013, Select redeemed all of its outstanding 7 5/8% senior subordinated notes due 2015. Select recognized a loss on early retirement of debt of $0.5 million in the three months ended March 31, 2013 for the unamortized debt issuance costs associated with the redeemed debt.  On May 28, 2013, Select repaid a portion of its original term loan and series A term loan of its senior secured credit facility and on June 3, 2013 Select amended its existing senior secured credit facility.  Select recognized a loss on early retirement of debt of $17.3 million in the three months ended June 30, 2013, which included unamortized debt issuance costs, unamortized original issue discount, and certain debt issuance costs associated with refinancing activities.

On September 12, 2012, Select redeemed an aggregate of $275.0 million principal amount of its 7 5/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount.  Select recognized a loss on early retirement of debt of $6.1 million in the three months ended September 30, 2012 in connection with the redemption of the 7 5/8% senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

Select Medical Holdings Corporation.  On March 22, 2013, we redeemed all of Select’s outstanding 7 5/8% senior subordinated notes due 2015, and redeemed all of our senior floating rate notes due 2015. We recognized a loss on early retirement of debt of $1.5 million in the three months ended March 31, 2013 for the unamortized debt issuance costs associated with the redeemed debt.  On May 28, 2013, we repaid a portion of Select’s original term loan and series A term loan of its senior secured credit facility and on June 3, 2013 Select amended its existing senior secured credit facility.  We recognized a loss of $17.3 million in the three months ended June 30, 2013, which included unamortized debt issuance costs, unamortized original issue discount, and certain debt issuance costs associated with refinancing activities.

On September 12, 2012, we redeemed an aggregate of $275.0 million principal amount of Select’s 7 5/8% senior subordinated notes at a redemption price of 101.271% of the principal amount.  We recognized a loss on early retirement of debt of $6.1 million in the three months ended September 30, 2012 in connection with the redemption of the 7 5/8% senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

Equity in Earnings of Unconsolidated Subsidiaries

For the nine months ended September 30, 2013, we had equity in earnings of unconsolidated subsidiaries of $1.4 million compared to equity in earnings of unconsolidated subsidiaries of $6.4 million for the nine months ended September 30, 2012.  The decrease in our equity in earnings of unconsolidated subsidiaries resulted from

47

decreases in earnings contributed from the Baylor JV and losses incurred by start-up companies where we own a minority interest.

Interest Expense

Select Medical Corporation.  Interest expense was $64.2 million for the nine months ended September 30, 2013 compared to $63.9 million for the nine months ended September 30, 2012.  The increase in interest expense was principally due to increased borrowings that were used to refinance debt held by Holdings in both the third quarter of 2012 and the first quarter of 2013, offset in part by lower interest rates.

Select Medical Holdings Corporation.  Interest expense was $66.6 million for the nine months ended September 30, 2013 compared to $72.3 million for the nine months ended September 30, 2012.  The decrease in interest expense was principally due to lower interest rates on borrowings.

Income Taxes

Select Medical Corporation.  We recorded income tax expense of $58.6 million for the nine months ended September 30, 2013. The expense represented an effective tax rate of 38.4%.  We recorded income tax expense of $74.3 million for the nine months ended September 30, 2012. The expense represented an effective tax rate of 38.7%.  Select Medical Corporation is part of the consolidated federal tax return for Select Medical Holdings Corporation.  We allocate income taxes between Select and Holdings for purposes of financial statement presentation.  Because Holdings is a passive investment company incorporated in Delaware, it does not incur any state income tax expense or benefit on its specific income or loss and, as such, receives a tax allocation equal to the federal statutory rate of 35% on its specific income or loss.  Based upon the relative size of Holdings’ income or loss, this can cause the effective tax rate for Select to differ from the effective tax rate for the consolidated company.

Select Medical Holdings Corporation.  We recorded income tax expense of $57.4 million for the nine months ended September 30, 2013, which represented an effective tax rate of 38.4%.  We recorded income tax expense of $71.4 million for the nine months ended September 30, 2012, which represented an effective tax rate of 38.8%.  The decline in our effective tax rate has resulted from an increase in earnings of our consolidated subsidiaries where we have less than a 100% ownership interest that are taxed as pass-through entities in which we only record income taxes on our share of the income, offset in part by an increase in our state effective tax rates that has resulted from a higher proportion of our income being generated in states with higher tax rates.

Non-Controlling Interests

Non-controlling interests in consolidated earnings were $6.4 million for the nine months ended September 30, 2013 and $3.7 million for the nine months ended September 30, 2012, due to increased profitability in the nine months ended September 30, 2013 in certain of our consolidated subsidiaries that are less than 100% owned.

48

Liquidity and Capital Resources

Cash Flows for the Nine Months Ended September 30, 2013 and Nine Months Ended September 30, 2012

	Select Medical Holdings Corporation						Select Medical Corporation
	Nine Months Ended September 30,						Nine MonthsEnded September 30,
	2012			2013			2012			2013
	(in thousands)						(in thousands)
Cash flows provided by operating activities	$	194,076		$	115,105		$	204,753		$	120,684
Cash flows used in investing activities	(40,123		)	(78,091		)	(40,123		)	(78,091		)
Cash flows used in financing activities	(116,320		)	(67,865		)	(126,997		)	(73,444		)
Net increase (decrease) in cash and cash equivalents	37,633			(30,851		)	37,633			(30,851		)
Cash and cash equivalents at beginning of period	12,043			40,144			12,043			40,144
Cash and cash equivalents at end of period	$	49,676		$	9,293		$	49,676		$	9,293

Operating activities for Holdings provided $115.1 million and for Select provided $120.7 million of cash flows for the nine months ended September 30, 2013.  Operating activities for Holdings provided $194.1 million and for Select provided $204.8 million of cash flows for the nine months ended September 30, 2012.  The operating cash flows of Select exceeded the operating cash flows of Holdings by $5.6 million for the nine months ended September 30, 2013 and by $10.7 million for the nine months ended September 30, 2012.  The difference relates to interest payments on Holdings’ indebtedness.  The decline in operating cash flows for both Holdings and Select in the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012 is due to reductions in income from operations resulting from the 2% reduction in our Medicare payments mandated by the Budget Control Act of 2011 and the MPPR Reduction and the timing of the periodic interim payments we receive from Medicare for the services provided at our specialty hospitals.

Our days sales outstanding were 54 days at September 30, 2013 compared to 51 days at September 30, 2012 and 45 days at December 31, 2012.  The increase in days sales outstanding between December 31, 2012 and September 30, 2013 is primarily related to the timing of the periodic interim payments we receive from Medicare for the services provided at our specialty hospitals.

Investing activities used $78.1 million of cash flow for the nine months ended September 30, 2013.  The principal use of cash included $45.3 million related to the purchase of property and equipment and $32.4 million related principally to investments in unconsolidated businesses.  Investing activities used $40.1 million of cash flow for the nine months ended September 30, 2012.  The principal use of cash included $45.2 million related to the purchase of property and equipment, $9.9 million related primarily to an additional investment in the Baylor JV and $1.5 million used for acquisitions.  This use of cash was offset by $16.5 million in proceeds related to the sale of a building.

Financing activities for Select used $73.4 million of cash flow for the nine months ended September 30, 2013. The primary financing activities were associated with a $600.0 million 6.375% senior notes offering on May 28, 2013. The proceeds of this senior notes offering were used to repay $587.0 million of Select’s senior

49

secured credit facility term loans and fund certain transaction costs amounting to $14.6 million. In addition, $298.5 million was provided through the issuance of senior secured credit facility term loans which was used to pay dividends to Holdings to fund the redemption of $167.3 million principal amount of Holdings’ senior floating rate notes, repurchase $70.0 million of Select’s 7 5/8% senior subordinated notes and pay $4.2 million of transaction costs related to the financing transactions completed during the first quarter ended March 31, 2013. In addition, during the nine months ended September 30, 2013 Select paid dividends to Holdings to fund $27.9 million of dividends paid to common stockholders, $10.9 million to fund Holdings’ repurchase of common stock and $5.6 million to fund interest payments on Holdings’ debt. Select also made net repayments on the revolving portion of the credit facility of $65.0 million. Financing activities for Select used $127.0 million of cash flow for the nine months ended September 30, 2012. The primary financing activities were associated with the repurchases and redemptions of its 7 5/8% senior subordinated notes of $278.5 million which were funded through additional senior secured credit facility net term loan borrowings of $266.8 million.  In addition, during the nine months ended September 30, 2012 Select paid dividends to Holdings to fund $57.5 million of stock repurchases and interest payments. Select also made net repayments on the revolving portion of the credit facility of $40.0 million.

The difference in cash flows used in financing activities of Holdings compared to Select of $5.6 million for the nine months ended September 30, 2013 and $10.7 million for the nine months ended September 30, 2012 related to dividends paid by Select to Holdings to service Holdings’ interest obligations related to its indebtedness.

Capital Resources

Select Medical Corporation.  Select had net working capital of $106.7 million at September 30, 2013 compared to net working capital of $63.2 million at December 31, 2012.  The increase in net working capital is primarily due to increases in accounts receivable.

Select Medical Holdings Corporation.  Holdings had net working capital of $106.7 million at September 30, 2013 compared to net working capital of $65.2 million at December 31, 2012.  The increase in net working capital is primarily due to increases in accounts receivable.

On February 20, 2013, Select entered into a credit extension amendment to its senior secured credit facilities providing for a $300.0 million additional term loan tranche, (the “series B term loan”) to Select.  Select used the borrowings under the series B term loan to redeem all of its outstanding 7 5/8% senior subordinated notes due 2015 on March 22, 2013, to finance Holdings’ redemption of all of its senior floating rate notes due 2015 on March 22, 2013 and to repay a portion of the balance outstanding under Select’s revolving credit facility.  The Company recognized a loss on early retirement of debt of $1.5 million during the three months ended March 31, 2013 for unamortized debt issuance costs of which, approximately $0.5 million was associated with Select’s 7 5/8% senior subordinated notes due 2015 and approximately $1.0 million was associated with Holdings’ senior floating rate notes due 2015.

Borrowings under the series B term loan bear interest at a rate equal to Adjusted LIBO plus 3.25%, or Alternate Base Rate plus 2.25%.  The series B term loan amortizes in equal quarterly installments on the last day of each March, June, September and December in aggregate annual amounts equal to $3.0 million.  The balance of the series B term loan is payable on February 20, 2016.

At the time of issuing the series B term loan, Select had additional term loan tranches including an $850.0 million term loan tranche issued on June 1, 2011 (the “original term loan”) and a $275.0 million incremental term loan tranche issued August 13, 2012 (the “series A term loan”). Both the original term loan and series A

50

term loan tranches were issued at a discount and amortized in equal quarterly installments on the last day of each March, June, September and December. The balance of both the original term loan and series A term loan was payable on June 1, 2018.

On May 28, 2013, Select issued and sold $600.0 million aggregate principal amount of its 6.375% senior notes due 2021.  On May 28, 2013, Select used the proceeds of the senior notes to pay a portion of the amounts then outstanding on the original term loan and the series A term loan, and to pay related fees and expenses.  Select recognized a loss on early retirement of debt of $17.3 million in the three months ended June 30, 2013 in connection with the repayment of a portion of its term loans and amendment of the existing senior secured credit facility, which included the write-off of unamortized debt issuance costs.

Interest on the senior notes accrues at the rate of 6.375% per annum and is payable semi-annually in cash in arrears on June 1 and December 1 of each year, commencing on December 1, 2013.  The senior notes are Select’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.  The senior notes are fully and unconditionally guaranteed by all of Select’s wholly owned subsidiaries.  The senior notes are guaranteed, jointly and severally, by Select’s direct or indirect existing and future domestic restricted subsidiaries other than certain non-guarantor subsidiaries.

Select may redeem some or all of the senior notes prior to June 1, 2016 by paying a “make-whole” premium.  Select may redeem some or all of the senior notes on or after June 1, 2016 at specified redemption prices.  In addition, prior to June 1, 2016, Select may redeem up to 35% of the senior notes with the net proceeds of certain equity offerings at a price of 106.375% plus accrued and unpaid interest, if any. Select is obligated to offer to repurchase the senior notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events.  These restrictions and prohibitions are subject to certain qualifications and exceptions.

The Indenture relating to the senior notes contains covenants that, among other things, limit Select’s ability and the ability of certain of its subsidiaries to (i) grant liens on its assets, (ii) make dividend payments, other distributions or other restricted payments, (iii) incur restrictions on the ability of Select’s restricted subsidiaries to pay dividends or make other payments, (iv) enter into sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of substantially all of their assets, (vi) incur additional indebtedness, (vii) make investments, (viii) sell assets, including capital stock of subsidiaries, (ix) use the proceeds from sales of assets, including capital stock of restricted subsidiaries, and (x) enter into transactions with affiliates.  In addition, the Indenture requires, among other things, Select to provide financial and current reports to holders of the senior notes or file such reports electronically with the SEC.  These covenants are subject to a number of exceptions, limitations and qualifications set forth in the Indenture.

On June 3, 2013, Select amended its existing senior secured credit facilities in order to:

·extend the maturity date on $293.3 million of its $300.0 million revolving credit facility from June 1, 2016 to March 1, 2018;

·convert the remaining original term loan and series A term loan to a series C term loan and lower the interest rate payable on the series C term loan from Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%, to Adjusted LIBO plus 3.00%, or Alternate Base Rate plus 2.00%, and amend the provision of the series C term loan from providing that Adjusted LIBO will at no time be less than 1.75% to providing that Adjusted LIBO will at no time be less than 1.00%; and

·amend the restrictive covenants governing the senior secured credit facilities in order to allow for unlimited restricted payments so long as there is no event of default under the senior secured credit

51

facilities and the total pro forma ratio of total indebtedness to Consolidated EBITDA (as defined in our senior secured credit facilities) is less than or equal to 2.75 to 1.00.

At September 30, 2013, we had outstanding borrowings of $809.4 million (net of unamortized original issue discounts of $6.8 million) under the term loans and borrowings of $65.0 million (excluding letters of credit) under the revolving loan portion of our senior secured credit facilities. We had $192.7 million of availability under our revolving loan facility (after giving effect to $42.3 million of outstanding letters of credit) at September 30, 2013.

The applicable margin percentage for borrowings under our revolving loan is subject to change based upon the ratio of Select’s leverage ratio (as defined in our senior secured credit facility). The applicable interest rate for revolving loans as of September 30, 2013 was (1) Alternate Base plus 2.75% for alternate base rate loans and (2) LIBO plus 3.75% for adjusted LIBO rate loans.

Our senior secured credit facility requires Select to maintain certain leverage ratios (as defined in our senior secured credit facility). For the four consecutive fiscal quarters ended September 30, 2013, Select was required to maintain its leverage ratio (its ratio of total indebtedness to consolidated EBITDA) at less than 4.50 to 1.00. Select’s leverage ratio was 3.90 to 1.00 as of September 30, 2013.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise.  Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.  The amounts involved may be material.

Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $350.0 million worth of shares of its common stock.  The program will remain in effect until March 31, 2014, unless extended by the board of directors.  Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings is funding this program with cash on hand and borrowings under its revolving credit facility.  During the nine months ended September 30, 2013, Holdings repurchased 1,115,691 shares at a cost of approximately $10.0 million, an average cost per share of $8.95, which includes transaction costs.  Since the inception of the program through September 30, 2013, Holdings has repurchased 23,606,080 shares at a cost of approximately $173.6 million, or $7.36 per share, which includes transaction costs.

We believe our internally generated cash flows and borrowing capacity under our senior secured credit facility will be sufficient to finance operations over the next twelve months.

We may from time to time pursue opportunities to develop new joint venture relationships with significant health systems, and from time to time we may also develop new inpatient rehabilitation hospitals.  With the expiration on December 28, 2012 of the moratorium on new LTCHs and new LTCH beds, we are adding new LTCH beds at certain of our hospitals.  We also intend to open new outpatient rehabilitation clinics in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth.  In addition to our development activities, we may grow our network of specialty hospitals through opportunistic acquisitions.

52

Dividend

On October 30, 2013, Holdings’ board of directors declared a quarterly cash dividend of $0.10 per share. The dividend will be payable on or about November 22, 2013 to stockholders of record as of the close of business on November 12, 2013.

Effects of inflation and changing prices

We derive a substantial portion of our revenues from the Medicare program. We have been, and could be in the future, affected by the continuing efforts of governmental and private third party payors to contain healthcare costs by limiting or reducing reimbursement payments.

Additionally, reimbursement payments under governmental and private third party payor programs may not increase to sufficiently cover increasing costs. Medicare reimbursement in long term acute care hospitals and inpatient rehabilitation facilities are subject to fixed payments under the Medicare prospective payment systems. In accordance with Medicare laws, CMS makes annual adjustments to Medicare payments under what is commonly known as a “market basket update.” Generally, these rates are adjusted for inflation. However, these adjustments may not reflect the actual increase in the costs of providing healthcare services and may be reduced by CMS for other adjustments.

The healthcare industry is labor intensive and the Company’s largest expenses are labor related costs. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. While we believe the current economic climate may help to moderate wage increases in the near term, there can be no guarantee we will not experience increases in the cost of labor, as the need for clinical healthcare professionals is expected to grow. In addition, suppliers pass along rising costs to us in the form of higher prices.  We have little or no ability to pass on these increased costs associated with providing services due to federal laws that establish fixed reimbursement rates.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Quantitative and Qualitative Disclosures About Market Risk

We are subject to interest rate risk in connection with our long-term indebtedness.  Our principal interest rate exposure relates to the loans outstanding under our senior secured credit facility.  As of September 30, 2013, we had $816.2 million (excluding unamortized original issue discount) in term loans outstanding under our senior secured credit facility and $65.0 million in revolving loans outstanding under our senior secured credit facility, which bear interest at variable rates. Each eighth point change in interest rates on the variable rate portion of our long-term indebtedness would result in a $1.1 million annual change in interest expense.  However, because the variable interest rate for an aggregate $518.5 million in series C term loan is subject to an Adjusted LIBO Rate floor of 1.00% until the Adjusted LIBO Rate exceeds 1.00%, because the adjusted LIBO Rate is currently less than 1.00% our interest rate on this indebtedness is currently effectively fixed at 4.00%.

53

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective as of September 30, 2013 to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the third quarter ended September 30, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met.  In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.  Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

PART IIOTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

Litigation

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”) or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company’s specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability

54

insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

On January 8, 2013, a federal magistrate judge unsealed an Amended Complaint in United States of America and the State of Indiana, ex rel. Doe I, Doe II and Doe III v. Select Medical Corporation, Select Specialty Hospital-Evansville, Evansville Physician Investment Corporation, Dr. Richard Sloan and Dr. Jeffrey Selby. The Amended Complaint, which was served on the Company on February 15, 2013, is a civil action filed under seal on September 28, 2012 in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States and the state of Indiana under the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act. Although the Amended Complaint identifies the relators by fictitious pseudonyms, on March 28, 2013, the relators filed a Notice identifying themselves as the former CEO at the Company’s long term acute care hospital in Evansville, Indiana (“SSH-Evansville”) and two former case managers at SSH-Evansville. The named defendants include the Company, SSH-Evansville, and two physicians who have practiced at SSH-Evansville. On March 26, 2013, the defendants, relators and the United States filed a joint motion seeking a stay of the proceedings, in which the United States notified the court that its investigation has not been completed and therefore it is not yet able to decide whether or not to intervene, and on March 29, 2013, the magistrate judge granted the motion and stayed all deadlines in the case for 90 days. On June 26, 2013, the United States filed a motion seeking to extend such stay of the proceedings for an additional 90 days, and, on August 12, 2013, the court granted the motion and stayed all deadlines in the case until October 1, 2013. On September 25, 2013, the United States filed a motion seeking to extend such stay for an additional 90 days.

The Amended Complaint alleges that the defendants manipulated the length of stay of patients at SSH-Evansville in order to maximize reimbursement under the Medicare prospective payment system applicable to long term acute care hospitals. It also alleges that the defendants manipulated the discharge of patients to other facilities and the timing of readmissions from those facilities in order to enable SSH-Evansville to receive two separate Medicare payments and causing the other facility to submit claims for unnecessary services. The Amended Complaint discusses the federal Stark Law and Anti-Kickback Statute and implies that the behavior of physicians referring to or providing services at SSH-Evansville was based on their financial interests. The Amended Complaint further alleges that Dr. Selby, a pulmonologist formerly on the medical staff of SSH-Evansville, performed unnecessary bronchoscopies at the hospital with the knowledge of the Company, and that Dr. Sloan, the Chief Medical Officer and an attending physician at SSH-Evansville, falsely coded the diagnoses of Medicare patients in order to increase SSH-Evansville’s reimbursement. Moreover, the Amended Complaint alleges that the practices at SSH-Evansville involved corporate policies of the Company used to maximize profit at all Select long term acute care hospitals. The Amended Complaint alleges that, through these acts, the defendants have violated the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act and are liable for unspecified treble damages and penalties.

55

As previously disclosed, beginning in April 2012, the Company and SSH-Evansville have received various subpoenas and demands for documents relating to SSH-Evansville, including a request for information and subpoenas from the Office of Inspector General of the U.S. Department of Health and Human Services and subpoenas from the Office of Attorney General for the State of Indiana, and the Evansville (Indiana) Police Department has executed a search warrant at SSH-Evansville. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

ITEM 1A.RISK FACTORS

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2012 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2013.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.OTHER INFORMATION

None.

ITEM 6.EXHIBITS

The exhibits to this report are listed in the Exhibit Index appearing on page 58 hereof.

56

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrants have duly caused this Report to be signed on their behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL CORPORATION
By:	/s/        Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer
	(Duly Authorized Officer)
By:	/s/        Scott A. Romberger
	Scott A. Romberger
	Senior Vice President, Chief Accounting Officer and Controller
	(Principal Accounting Officer)

Dated:  October 31, 2013
	SELECT MEDICAL HOLDINGS CORPORATION
	By:	/s/        Martin F. Jackson
		Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)
	By:	/s/        Scott A. Romberger
		Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated: October 31, 2013

57

EXHIBIT INDEX

Exhibit	Description
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012, (ii) Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012, (iii) Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012, (iv) Consolidated Statements of Changes in Equity and Income for the nine months ended September 30, 2013 and (v) Notes to Consolidated Financial Statements.*

*  XBRL information is furnished and not filed herewith, is not part of a registration statement or prospectus for purposes of section 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

58

EX-31.1

EXHIBIT 31.1

SELECT MEDICAL HOLDINGS CORPORATION AND

SELECT MEDICAL CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Robert A. Ortenzio, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2013	/s/ Robert A. Ortenzio
	Robert A. Ortenzio
	Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SELECT MEDICAL HOLDINGS CORPORATION AND

SELECT MEDICAL CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Martin F. Jackson, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2013	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation (the “Company”) for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Robert A. Ortenzio and Martin F. Jackson, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

October 31, 2013

/s/ Robert A. Ortenzio

Robert A. Ortenzio

Chief Executive Officer

/s/ Martin F. Jackson

Martin F. Jackson

Executive Vice President and Chief Financial Officer

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes

9 Months Ended

Sep. 30, 2013

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes

10. Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select’s 6.375% Senior Notes

Select’s 6.375% senior notes are fully and unconditionally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly-owned subsidiaries (the “Subsidiary Guarantors”) which is defined as a subsidiary where Select or a subsidiary of Select holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the “Non-Guarantor Subsidiaries”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2012 and September 30, 2013 and for the three and nine months ended September 30, 2012 and 2013.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2013

(unaudited)

	Select Medical  Corporation (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	5,052		$	2,996	$	1,245	$	—		$	9,293
Accounts receivable, net	—			360,805		62,529		—			423,334
Current deferred tax asset	8,038			2,945		4,389		—			15,372
Prepaid income taxes	4,044			—		—		—			4,044
Intercompany receivables	—			1,034,542		100,930		(1,135,472		)(a)	—
Other current assets	8,325			26,783		4,860		—			39,968
Total Current Assets	25,459			1,428,071		173,953		(1,135,472		)	492,011
Property and equipment, net	14,911			426,915		57,705		—			499,531
Investment in affiliates	3,024,968			80,282		—		(3,105,250		)(b) (c)	—
Goodwill	—			1,641,836		—		—			1,641,836
Other identifiable intangibles	—			71,831		—		—			71,831
Non-current deferred tax asset	8,097			—		—		(8,097		)(d)	—
Other assets	36,509			100,113		593		—			137,215
Total Assets	$	3,109,944		$	3,749,048	$	232,251	$	(4,248,819	)	$	2,842,424
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	7,435		$	—	$	—	$	—		$	7,435
Current portion of long-term debt and notes payable	9,467			1,918		2,581		—			13,966
Accounts payable	7,554			75,452		13,354		—			96,360
Intercompany payables	1,135,472			—		—		(1,135,472		)(a)	—
Accrued payroll	516			80,527		260		—			81,303
Accrued vacation	4,502			45,567		7,259		—			57,328
Accrued interest	20,783			1,222		—		—			22,005
Accrued other	52,028			41,525		9,372		—			102,925
Due to third party payors	—			733		3,235		—			3,968
Total Current Liabilities	1,237,757			246,944		36,061		(1,135,472		)	385,290
Long-term debt, net of current portion	1,048,053			367,232		59,630		—			1,474,915
Non-current deferred tax liability	—			89,222		9,734		(8,097		)(d)	90,859
Other non-current liabilities	55,718			23,028		1,331		—			80,077
Total Liabilities	2,341,528			726,426		106,756		(1,143,569		)	2,031,141
Redeemable non-controlling interest	—			—		11,623		—			11,623
Stockholder’s Equity:
Common stock	0			—		—		—			0
Capital in excess of par	866,423			—		—		—			866,423
Retained earnings (accumulated deficit)	(98,007		)	886,099		18,438		(904,537		)(c)	(98,007		)
Subsidiary investment	—			2,136,523		64,190		(2,200,713		)(b)	—
Total Select Medical Corporation Stockholder’s Equity	768,416			3,022,622		82,628		(3,105,250		)	768,416
Non-controlling interest	—			—		31,244		—			31,244
Total Equity	768,416			3,022,622		113,872		(3,105,250		)	799,660
Total Liabilities and Equity	$	3,109,944		$	3,749,048	$	232,251	$	(4,248,819	)	$	2,842,424

(a)  Elimination of intercompany.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	12		$	617,415		$	105,418		$	—		$	722,845
Costs and expenses:
Cost of services	608			526,198			90,475			—			617,281
General and administrative	17,696			44			—			—			17,740
Bad debt expense	—			7,563			1,699			—			9,262
Depreciation and amortization	917			12,831			2,415			—			16,163
Total costs and expenses	19,221			546,636			94,589			—			660,446
Income (loss) from operations	(19,209		)	70,779			10,829			—			62,399
Other income and expense:
Intercompany interest and royalty fees	(278		)	310			(32		)	—			—
Intercompany management fees	32,621			(27,386		)	(5,235		)	—			—
Equity in earnings (losses) of unconsolidated subsidiaries	—			(196		)	17			—			(179		)
Interest expense	(14,192		)	(6,031		)	(1,029		)	—			(21,252		)
Income (loss) from operations before income taxes	(1,058		)	37,476			4,550			—			40,968
Income tax expense	44			15,218			499			—			15,761
Equity in earnings of subsidiaries	24,374			1,952			—			(26,326		)(a)	—
Net income	23,272			24,210			4,051			(26,326		)	25,207
Less: Net income attributable to non-controlling interests	—			—			1,935			—			1,935
Net income attributable to Select Medical Corporation	$	23,272		$	24,210		$	2,116		$	(26,326	)	$	23,272

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	322		$	1,913,597		$	315,554		$	—		$	2,229,473
Costs and expenses:
Cost of services	1,718			1,599,493			266,704			—			1,867,915
General and administrative	52,915			150			—			—			53,065
Bad debt expense	—			22,485			4,944			—			27,429
Depreciation and amortization	2,862			37,856			7,154			—			47,872
Total costs and expenses	57,495			1,659,984			278,802			—			1,996,281
Income (loss) from operations	(57,173		)	253,613			36,752			—			233,192
Other income and expense:
Intercompany interest and royalty fees	(1,033		)	1,051			(18		)	—			—
Intercompany management fees	114,597			(100,005		)	(14,592		)	—			—
Loss on early retirement of debt	(17,788		)	—			—			—			(17,788		)
Equity in earnings of unconsolidated subsidiaries	—			1,375			72			—			1,447
Interest expense	(44,345		)	(16,800		)	(3,059		)	—			(64,204		)
Income (loss) from operations before income taxes	(5,742		)	139,234			19,155			—			152,647
Income tax expense	1,956			55,900			714						58,570
Equity in earnings of subsidiaries	95,358			12,073			—			(107,431		)(a)	—
Net income	87,660			95,407			18,441			(107,431		)	94,077
Less: Net income attributable to non-controlling interests	—			—			6,417			—			6,417
Net income attributable to Select Medical Corporation	$	87,660		$	95,407		$	12,024		$	(107,431	)	$	87,660

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	87,660		$	95,407		$	18,441		$	(107,431	)(a)	$	94,077
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,862			37,856			7,154			—			47,872
Provision for bad debts	—			22,485			4,944			—			27,429
Equity in earnings of unconsolidated subsidiaries	—			(1,375		)	(72		)	—			(1,447		)
Loss on early retirement of debt	17,788			—			—			—			17,788
Loss (gain) from disposal of assets	—			25			(118		)	—			(93		)
Non-cash stock compensation expense	5,403			—			—			—			5,403
Amortization of debt discount and issuance costs	6,418			—			—			—			6,418
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(95,358		)	(12,073		)	—			107,431		(a)	—
Accounts receivable	—			(75,295		)	(13,942		)	—			(89,237		)
Other current assets	(2,725		)	(6,620		)	1,703			—			(7,642		)
Other assets	(7,829		)	4,519			99			—			(3,211		)
Accounts payable	2,880			3,224			694			—			6,798
Due to third-party payors	—			2,378			512			—			2,890
Accrued expenses	(3,211		)	10,381			876			—			8,046
Income and deferred taxes	5,593			—			—			—			5,593
Net cash provided by operating activities	19,481			80,912			20,291			—			120,684
Investing activities
Purchases of property and equipment	(1,428		)	(39,101		)	(4,802		)	—			(45,331		)
Proceeds from sale of assets	—			62			456			—			518
Investment in businesses, net of distributions	—			(32,430		)	—			—			(32,430		)
Acquisition of businesses, net of cash acquired	—			(848		)	—			—			(848		)
Net cash used in investing activities	(1,428		)	(72,317		)	(4,346		)	—			(78,091		)
Financing activities
Borrowings on revolving credit facility	580,000			—			—			—			580,000
Payments on revolving credit facility	(645,000		)	—			—			—			(645,000		)
Borrowings on credit facility term loans, net of discount	298,500			—			—			—			298,500
Payments on credit facility term loans	(594,668		)	—			—			—			(594,668		)
Issuance of 6.375% senior notes	600,000			—			—			—			600,000
Repurchase of 7 5/8% senior subordinated notes	(70,000		)	—			—			—			(70,000		)
Borrowings of other debt	8,154			—			1,084			—			9,238
Principal payments on other debt	(5,971		)	(521		)	(975		)	—			(7,467		)
Debt issuance costs	(18,820		)	—			—			—			(18,820		)
Dividends paid to Holdings	(211,754		)	—			—			—			(211,754		)
Repayments of bank overdrafts	(10,401		)	—			—			—			(10,401		)
Intercompany	21,889			(8,812		)	(13,077		)	—			—
Distributions to non-controlling interests	—			—			(3,072		)	—			(3,072		)
Net cash used in financing activities	(48,071		)	(9,333		)	(16,040		)	—			(73,444		)
Net decrease in cash and cash equivalents	(30,018		)	(738		)	(95		)	—			(30,851		)
Cash and cash equivalents at beginning of period	35,070			3,734			1,340			—			40,144
Cash and cash equivalents at end of period	$	5,052		$	2,996		$	1,245		$	—		$	9,293

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Consolidating Balance Sheet

December 31, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)		Subsidiary Guarantors		Non-Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	35,070	$	3,734	$	1,340	$	—		$	40,144
Accounts receivable, net	—		308,043		53,531		(1,645		)(a)	359,929
Current deferred tax asset	12,383		1,060		4,434		—			17,877
Prepaid income taxes	3,895		—		—		—			3,895
Intercompany receivables	—		1,021,479		102,694		(1,124,173		)(b)	—
Other current assets	5,600		19,655		6,563		—			31,818
Total Current Assets	56,948		1,353,971		168,562		(1,125,818		)	453,663
Property and equipment, net	16,344		425,677		59,531		—			501,552
Investment in affiliates	2,930,022		82,475		—		(3,012,497		)(c) (d)	—
Goodwill	—		1,640,534		—		—			1,640,534
Other identifiable intangibles	—		71,745		—		—			71,745
Non-current deferred tax asset	5,107		—		—		(5,107		)(e)	—
Other assets	28,680		63,447		692		—			92,819
Total Assets	$	3,037,101	$	3,637,849	$	228,785	$	(4,143,422	)	$	2,760,313
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	17,836	$	—	$	—	$	—		$	17,836
Current portion of long-term debt and notes payable	8,916		1,059		1,671		—			11,646
Accounts payable	4,674		72,213		12,660		—			89,547
Intercompany payables	1,124,173		—		—		(1,124,173		)(b)	—
Accrued payroll	186		88,096		304		—			88,586
Accrued vacation	4,249		44,508		6,957		—			55,714
Accrued interest	17,955		804		—		—			18,759
Accrued other	58,650		39,876		8,754		—			107,280
Due to third party payors	—		—		2,723		(1,645		)(a)	1,078
Total Current Liabilities	1,236,639		246,556		33,069		(1,125,818		)	390,446
Long-term debt, net of current portion	872,671		358,104		60,522		—			1,291,297
Non-current deferred tax liability	—		85,287		9,330		(5,107		)(e)	89,510
Other non-current liabilities	46,474		20,275		1,753		—			68,502
Total Liabilities	2,155,784		710,222		104,674		(1,130,925		)	1,839,755
Redeemable non-controlling interests	—		—		10,811		—			10,811
Stockholder’s Equity:
Common stock	0		—		—		—			0
Capital in excess of par	859,839		—		—		—			859,839
Retained earnings	21,478		790,692		21,197		(811,889		)(d)	21,478
Subsidiary investment	—		2,136,935		63,673		(2,200,608		)(c)	—
Total Select Medical Corporation Stockholder’s Equity	881,317		2,927,627		84,870		(3,012,497		)	881,317
Non-controlling interests	—		—		28,430		—			28,430
Total Equity	881,317		2,927,627		113,300		(3,012,497		)	909,747
Total Liabilities and Equity	$	3,037,101	$	3,637,849	$	228,785	$	(4,143,422	)	$	2,760,313

(a)  Reclass portion of due to third party payor to accounts receivable net in consolidation.

(b)  Elimination of intercompany.

(c)  Elimination of investments in consolidated subsidiaries.

(d)  Elimination of investments in consolidated subsidiaries’ earnings.

(e)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	14		$	616,610		$	97,045		$	—		$	713,669
Costs and expenses:
Cost of services	544			514,136			84,304			—			598,984
General and administrative	17,742			(612		)	—			—			17,130
Bad debt expense	—			9,525			1,674			—			11,199
Depreciation and amortization	832			12,372			2,333			—			15,537
Total costs and expenses	19,118			535,421			88,311			—			642,850
Income (loss) from operations	(19,104		)	81,189			8,734			—			70,819
Other income and expense:
Intercompany interest and royalty fees	(469		)	459			10			—			—
Intercompany management fees	34,811			(29,960		)	(4,851		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			1,146			21			—			1,167
Interest expense	(14,676		)	(6,010		)	(1,054		)	—			(21,740		)
Income (loss) from operations before income taxes	(5,502		)	46,824			2,860			—			44,182
Income tax expense (benefit)	(3,589		)	21,020			(250		)	—			17,181
Equity in earnings of subsidiaries	27,866			2,123			—			(29,989		)(a)	—
Net income	25,953			27,927			3,110			(29,989		)	27,001
Less: Net income attributable to non-controlling interests	—			—			1,048			—			1,048
Net income attributable to Select Medical Corporation	$	25,953		$	27,927		$	2,062		$	(29,989	)	$	25,953

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	111		$	1,910,563		$	297,209		$	—		$	2,207,883
Costs and expenses:
Cost of services	1,554			1,567,080			254,638			—			1,823,272
General and administrative	51,197			(1,289		)	—			—			49,908
Bad debt expense	—			27,199			4,404			—			31,603
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Total costs and expenses	55,006			1,630,942			265,999			—			1,951,947
Income (loss) from operations	(54,895		)	279,621			31,210			—			255,936
Other income and expense:
Intercompany interest and royalty fees	(2,025		)	1,998			27			—			—
Intercompany management fees	91,940			(78,202		)	(13,738		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			6,340			44			—			6,384
Interest expense	(40,823		)	(19,920		)	(3,204		)	—			(63,947		)
Income (loss) from operations before income taxes	(11,867		)	189,837			14,339			—			192,309
Income tax expense (benefit)	(1,613		)	75,924			26			—			74,337
Equity in earnings of subsidiaries	124,504			11,234			—			(135,738		)(a)	—
Net income	114,250			125,147			14,313			(135,738		)	117,972
Less: Net income attributable to non-controlling interests	—			—			3,722			—			3,722
Net income attributable to Select Medical Corporation	$	114,250		$	125,147		$	10,591		$	(135,738	)	$	114,250

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	114,250		$	125,147		$	14,313		$	(135,738	)(a)	$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Provision for bad debts	—			27,199			4,404			—			31,603
Equity in earnings of unconsolidated subsidiaries	—			(6,340		)	(44		)	—			(6,384		)
Loss on early retirement of debt	6,064			—			—			—			6,064
Loss (gain) from disposal of assets	—			(3,501		)	17			—			(3,484		)
Non-cash stock compensation expense	3,990			—			—			—			3,990
Amortization of debt discount and issuance costs	5,215			—			—			—			5,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(124,504		)	(11,234		)	—			135,738		(a)	—
Accounts receivable	—			7,296			(17,803		)	—			(10,507		)
Other current assets	1,182			(2,141		)	(890		)	—			(1,849		)
Other assets	(604		)	1,688			186			—			1,270
Accounts payable	418			(5,842		)	1,326			—			(4,098		)
Due to third-party payors	—			(10,928		)	11,288			—			360
Accrued expenses	3,870			(1,912		)	998			—			2,956
Income and deferred taxes	14,481			—			—			—			14,481
Net cash provided by operating activities	26,617			157,384			20,752			—			204,753
Investing activities
Purchases of property and equipment	(3,617		)	(31,978		)	(9,593		)	—			(45,188		)
Proceeds from sale of assets	—			16,511			—			—			16,511
Investment in business, net of distributions	—			(9,899		)	—			—			(9,899		)
Acquisition of businesses, net of cash acquired	—			(1,547		)	—			—			(1,547		)
Net cash used in investing activities	(3,617		)	(26,913		)	(9,593		)	—			(40,123		)
Financing activities
Borrowings on revolving credit facility	365,000			—			—			—			365,000
Payments on revolving credit facility	(405,000		)	—			—			—			(405,000		)
Borrowings on credit facility term loans, net of discount	266,750			—			—			—			266,750
Payments on credit facility term loans	(7,063		)	—			—			—			(7,063		)
Repurchase of 7 5/8% senior subordinated notes	(278,495		)	—			—			—			(278,495		)
Borrowings of other debt	5,557			—			278			—			5,835
Principal payments on other debt	(6,667		)	(322		)	(428		)	—			(7,417		)
Debt issuance costs	(4,236		)	—			—			—			(4,236		)
Dividends paid to Holdings	(57,467		)	—			—			—			(57,467		)
Equity investment by Holdings	1,104			—			—			—			1,104
Repayment of bank overdrafts	(3,011		)	—			—			—			(3,011		)
Intercompany	134,170			(126,614		)	(7,556		)	—			—
Distributions to non-controlling interests	—			—			(2,997		)	—			(2,997		)
Net cash provided by (used in) financing activities	10,642			(126,936		)	(10,703		)	—			(126,997		)
Net increase in cash and cash equivalents	33,642			3,535			456			—			37,633
Cash and cash equivalents at beginning of period	11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	45,069		$	3,535		$	1,072		$	—		$	49,676

(a)  Elimination of equity in earnings of consolidated subsidiaries.

XML

Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net operating revenues	$ 722,845		$ 713,669	$ 2,229,473	$ 2,207,883
Costs and expenses:
Cost of services	617,281		598,984	1,867,915	1,823,272
General and administrative	17,740		17,130	53,065	49,908
Bad debt expense	9,262		11,199	27,429	31,603
Depreciation and amortization	16,163		15,537	47,872	47,164
Total costs and expenses	660,446		642,850	1,996,281	1,951,947
Income from operations	62,399		70,819	233,192	255,936
Other income and expense:
Loss on early retirement of debt		(1,500)	(6,064)	(18,747)	(6,064)
Equity in earnings (losses) of unconsolidated subsidiaries	(179)		1,167	1,447	6,384
Interest expense	(21,252)		(24,575)	(66,614)	(72,295)
Income before income taxes	40,968		41,347	149,278	183,961
Income tax expense	15,761		16,189	57,391	71,415
Net income	25,207		25,158	91,887	112,546
Less: Net income attributable to non-controlling interests	1,935		1,048	6,417	3,722
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	23,272		24,110	85,470	108,824
Income per common share:
Basic (in dollars per share)	$ 0.17		$ 0.17	$ 0.61	$ 0.77
Diluted (in dollars per share)	$ 0.17		$ 0.17	$ 0.61	$ 0.77
Select
Net operating revenues	722,845		713,669	2,229,473	2,207,883
Costs and expenses:
Cost of services	617,281		598,984	1,867,915	1,823,272
General and administrative	17,740		17,130	53,065	49,908
Bad debt expense	9,262		11,199	27,429	31,603
Depreciation and amortization	16,163		15,537	47,872	47,164
Total costs and expenses	660,446		642,850	1,996,281	1,951,947
Income from operations	62,399		70,819	233,192	255,936
Other income and expense:
Loss on early retirement of debt			(6,064)	(17,788)	(6,064)
Equity in earnings (losses) of unconsolidated subsidiaries	(179)		1,167	1,447	6,384
Interest expense	(21,252)		(21,740)	(64,204)	(63,947)
Income before income taxes	40,968		44,182	152,647	192,309
Income tax expense	15,761		17,181	58,570	74,337
Net income	25,207		27,001	94,077	117,972
Less: Net income attributable to non-controlling interests	1,935		1,048	6,417	3,722
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 23,272		$ 25,953	$ 87,660	$ 114,250

XML

Intangible Assets

9 Months Ended

Sep. 30, 2013

Intangible Assets

Intangible Assets

3.  Intangible Assets

The gross carrying amounts of the Company’s indefinite-lived intangible assets consist of the following:

	December 31, 2012		September 30, 2013
	(in thousands)
Goodwill	$	1,640,534	$	1,641,836
Trademarks	57,709		57,709
Certificates of need	11,914		12,039
Accreditations	2,122		2,083
Total	$	1,712,279	$	1,713,667

The Company’s accreditations and trademarks have renewal terms. The costs to renew these intangibles are expensed as incurred. At September 30, 2013, the accreditations and trademarks have a weighted average time until next renewal of approximately 1.5 years and 6.7 years, respectively.

The changes in the carrying amount of goodwill for the Company’s reportable segments for the nine months ended September 30, 2013 are as follows:

	Specialty Hospitals		Outpatient Rehabilitation			Total
	(in thousands)
Balance as of December 31, 2012	$	1,333,220	$	307,314		$	1,640,534
Goodwill acquired during the period	1,395		40			1,435
Purchase price adjustment	—		(133		)	(133		)
Balance as of September 30, 2013	$	1,334,615	$	307,221		$	1,641,836

XML

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Indefinite-lived intangible assets:
Gross Carrying Amount of Goodwill	$ 1,641,836	$ 1,640,534
Gross Carrying Amount	1,713,667	1,712,279
Trademarks
Indefinite-lived intangible assets:
Gross Carrying Amount	57,709	57,709
Weighted average time until next renewal	6 years 8 months 12 days
Certificates of need
Indefinite-lived intangible assets:
Gross Carrying Amount	12,039	11,914
Accreditations
Indefinite-lived intangible assets:
Gross Carrying Amount	$ 2,083	$ 2,122
Weighted average time until next renewal	1 year 6 months

XML

Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Accounting Policies

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

XML

Fair Value (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value
Carrying value	$ 1,488,881,000	$ 1,470,243,000
Select
Fair Value
Carrying value	1,488,881,000	1,302,943,000
Senior secured credit facility | Select
Fair Value
Carrying value	874,400,000	1,226,600,000
Fair value	867,900,000	1,216,200,000
6.375% senior notes
Fair Value
Carrying value	600,000,000
Interest rate of debt (as a percent)	6.375%
6.375% senior notes | Select
Fair Value
Carrying value	600,000,000
Fair value	$ 570,000,000
Interest rate of debt (as a percent)	6.375%

XML

Indebtedness (Details) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended			0 Months Ended					3 Months Ended					9 Months Ended		9 Months Ended				0 Months Ended				0 Months Ended						3 Months Ended								3 Months Ended			9 Months Ended		9 Months Ended
	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2012 Select Medical Corporation	Sep. 30, 2013 Select Medical Corporation	Sep. 30, 2012 Select Medical Corporation	Dec. 31, 2012 Select Medical Corporation	Jun. 04, 2013 Amended senior secured facilities Select Medical Corporation Maximum	Sep. 30, 2013 2011 - senior secured credit facilities: Revolving loan	Dec. 31, 2012 2011 - senior secured credit facilities: Revolving loan	Sep. 30, 2013 2011 - senior secured credit facilities: Revolving loan Select Medical Corporation	Dec. 31, 2012 2011 - senior secured credit facilities: Revolving loan Select Medical Corporation	Jun. 30, 2013 Senior secured credit facility Select Medical Corporation	Sep. 30, 2013 2011 - senior secured credit facilities: Term loans	Dec. 31, 2012 2011 - senior secured credit facilities: Term loans	Sep. 30, 2013 2011 - senior secured credit facilities: Term loans Select Medical Corporation	Dec. 31, 2012 2011 - senior secured credit facilities: Term loans Select Medical Corporation	Sep. 30, 2013 Series B Term Loan Select Medical Corporation	Feb. 20, 2013 Series B Term Loan Select Medical Corporation	Sep. 30, 2013 Series B Term Loan Select Medical Corporation Adjusted LIBO	Sep. 30, 2013 Series B Term Loan Select Medical Corporation Alternate base rate	Jun. 04, 2013 Series B Term Loan Amended senior secured facilities Select Medical Corporation	Jun. 01, 2011 Original term loan Select Medical Corporation	Jun. 02, 2013 Original term loan Select Medical Corporation Adjusted LIBO	Jun. 02, 2013 Original term loan Select Medical Corporation Alternate base rate	Jun. 02, 2013 Original term loan Select Medical Corporation Minimum Adjusted LIBO	Aug. 13, 2012 Incremental term loan tranche Select Medical Corporation	Jun. 02, 2013 Incremental term loan tranche Select Medical Corporation Adjusted LIBO	Jun. 02, 2013 Incremental term loan tranche Select Medical Corporation Alternate base rate	Jun. 02, 2013 Incremental term loan tranche Select Medical Corporation Minimum Adjusted LIBO	Jun. 04, 2013 Series C Term Loan Amended senior secured facilities Select Medical Corporation Adjusted LIBO	Jun. 04, 2013 Series C Term Loan Amended senior secured facilities Select Medical Corporation Alternate base rate	Jun. 04, 2013 Series C Term Loan Amended senior secured facilities Select Medical Corporation Minimum Adjusted LIBO	Mar. 31, 2013 Senior floating rate notes	Dec. 31, 2012 Senior floating rate notes	Sep. 30, 2013 Other	Dec. 31, 2012 Other	Sep. 30, 2013 Other Select Medical Corporation	Dec. 31, 2012 Other Select Medical Corporation	Sep. 30, 2013 7 5/8% senior subordinated notes	Dec. 31, 2012 7 5/8% senior subordinated notes	Mar. 31, 2013 7 5/8% senior subordinated notes Select Medical Corporation	Dec. 31, 2012 7 5/8% senior subordinated notes Select Medical Corporation	Sep. 30, 2013 6.375% senior notes	Sep. 30, 2013 6.375% senior notes Select Medical Corporation	May 28, 2013 6.375% senior notes Select Medical Corporation	Sep. 30, 2013 6.375% senior notes Select Medical Corporation Prior to June 1, 2016	Sep. 30, 2013 6.375% senior notes Select Medical Corporation Maximum Prior to June 1, 2016
Long-Term Debt and Notes Payable
Interest rate of debt (as a percent)																																										7.625%	7.625%		7.625%	6.375%	6.375%
Total debt			$ 1,488,881,000		$ 1,470,243,000		$ 1,488,881,000		$ 1,302,943,000		$ 65,000,000	$ 130,000,000	$ 65,000,000	$ 130,000,000		$ 809,438,000	$ 1,096,641,000	$ 809,438,000	$ 1,096,641,000																		$ 167,300,000	$ 14,443,000	$ 6,302,000	$ 14,443,000	$ 6,302,000		$ 70,000,000		$ 70,000,000	$ 600,000,000	$ 600,000,000
Less: current maturities			13,966,000		11,646,000		13,966,000		11,646,000
Total long-term debt			1,474,915,000		1,458,597,000		1,474,915,000		1,291,297,000
Unamortized discounts																6,800,000	14,200,000	6,800,000	14,200,000
Maximum borrowing capacity																					300,000,000
Extended maturity amount of revolving credit facility																								293,300,000
Variable rate basis																						Adjusted LIBO	Alternate base rate			Adjusted LIBO	Alternate Base Rate			Adjusted LIBO	Alternate Base Rate		Adjusted LIBO	Alternate Base Rate
Interest rate margin (as a percent)																						3.25%	2.25%			3.75%	2.75%			3.75%	2.75%		3.00%	2.00%
Reference rate (as a percent)																												1.75%				1.75%			1.00%
Pro forma ratio of total indebtedness to Consolidated EBITDA										2.75
Aggregate principal amount drawn																									850,000,000				275,000,000																			600,000,000
Loss on early retirement of debt	1,500,000	6,064,000	18,747,000	6,064,000		6,064,000	17,788,000	6,064,000							17,300,000																					1,000,000								500,000
Periodic payment in equal quarterly installments																				3,000,000
Percentage of principal amount at which notes may be required to be repurchased in event of change of control by the entity																																															101.00%
Percentage of the principal amount of the debt instrument which the entity may redeem with the proceeds from certain equity offerings																																																		35.00%
Percentage of the principal amount representing the redemption price of notes which may be redeemed with proceeds from certain equity offerings																																																	106.375%
Maturities of Long-Term Debt and Notes Payable
October 1, 2013 - December 31, 2013			4,869,000
2014			11,497,000
2015			10,086,000
2016			296,134,000
2017			4,075,000
2018 and beyond			$ 1,162,220,000

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details 2) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Current Assets:
Cash and cash equivalents	$ 9,293	$ 40,144	$ 49,676	$ 12,043
Accounts receivable, net	423,334	359,929
Current deferred tax asset	15,372	17,877
Prepaid income taxes	4,044	3,895
Other current assets	39,968	31,818
Total Current Assets	492,011	453,663
Property and equipment, net	499,531	501,552
Goodwill	1,641,836	1,640,534
Other identifiable intangibles	71,831	71,745
Other assets	137,215	93,867
Total Assets	2,842,424	2,761,361	2,781,808
Current Liabilities:
Bank overdrafts	7,435	17,836
Current portion of long-term debt and notes payable	13,966	11,646
Accounts payable	96,360	89,547
Accrued payroll	81,303	88,586
Accrued vacation	57,328	55,714
Accrued interest	22,005	22,016
Accrued other	102,925	102,040
Due to third party payors	3,968	1,078
Total Current Liabilities	385,290	388,463
Long-term debt, net of current portion	1,474,915	1,458,597
Non-current deferred tax liability	90,859	89,510
Other non-current liabilities	80,077	68,502
Total Liabilities	2,031,141	2,005,072
Redeemable non-controlling interests	11,623	10,811
Stockholder's Equity:
Common stock	140	141
Capital in excess of par	472,080	473,697
Retained earnings (accumulated deficit)	296,196	243,210
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	768,416	717,048
Non-controlling interests	31,244	28,430
Total Equity	799,660	745,478
Total Liabilities and Equity	2,842,424	2,761,361
Select Medical Corporation
Current Assets:
Cash and cash equivalents	9,293	40,144	49,676	12,043
Accounts receivable, net	423,334	359,929
Current deferred tax asset	15,372	17,877
Prepaid income taxes	4,044	3,895
Other current assets	39,968	31,818
Total Current Assets	492,011	453,663
Property and equipment, net	499,531	501,552
Goodwill	1,641,836	1,640,534
Other identifiable intangibles	71,831	71,745
Other assets	137,215	92,819
Total Assets	2,842,424	2,760,313	2,780,678
Current Liabilities:
Bank overdrafts	7,435	17,836
Current portion of long-term debt and notes payable	13,966	11,646
Accounts payable	96,360	89,547
Accrued payroll	81,303	88,586
Accrued vacation	57,328	55,714
Accrued interest	22,005	18,759
Accrued other	102,925	107,280
Due to third party payors	3,968	1,078
Total Current Liabilities	385,290	390,446
Long-term debt, net of current portion	1,474,915	1,291,297
Non-current deferred tax liability	90,859	89,510
Other non-current liabilities	80,077	68,502
Total Liabilities	2,031,141	1,839,755
Redeemable non-controlling interests	11,623	10,811
Stockholder's Equity:
Common stock	0	0
Capital in excess of par	866,423	859,839
Retained earnings (accumulated deficit)	(98,007)	21,478
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	768,416	881,317
Non-controlling interests	31,244	28,430
Total Equity	799,660	909,747
Total Liabilities and Equity	2,842,424	2,760,313
Select Medical Corporation | Reportable legal entities | Select Medical Corporation (Parent Company Only)
Current Assets:
Cash and cash equivalents	5,052	35,070	45,069	11,427
Current deferred tax asset	8,038	12,383
Prepaid income taxes	4,044	3,895
Other current assets	8,325	5,600
Total Current Assets	25,459	56,948
Property and equipment, net	14,911	16,344
Investment in affiliates	3,024,968	2,930,022
Non-current deferred tax asset	8,097	5,107
Other assets	36,509	28,680
Total Assets	3,109,944	3,037,101
Current Liabilities:
Bank overdrafts	7,435	17,836
Current portion of long-term debt and notes payable	9,467	8,916
Accounts payable	7,554	4,674
Intercompany accounts	1,135,472	1,124,173
Accrued payroll	516	186
Accrued vacation	4,502	4,249
Accrued interest	20,783	17,955
Accrued other	52,028	58,650
Total Current Liabilities	1,237,757	1,236,639
Long-term debt, net of current portion	1,048,053	872,671
Other non-current liabilities	55,718	46,474
Total Liabilities	2,341,528	2,155,784
Stockholder's Equity:
Common stock	0	0
Capital in excess of par	866,423	859,839
Retained earnings (accumulated deficit)	(98,007)	21,478
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	768,416	881,317
Total Equity	768,416	881,317
Total Liabilities and Equity	3,109,944	3,037,101
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors
Current Assets:
Cash and cash equivalents	2,996	3,734	3,535
Accounts receivable, net	360,805	308,043
Current deferred tax asset	2,945	1,060
Intercompany receivables	1,034,542	1,021,479
Other current assets	26,783	19,655
Total Current Assets	1,428,071	1,353,971
Property and equipment, net	426,915	425,677
Investment in affiliates	80,282	82,475
Goodwill	1,641,836	1,640,534
Other identifiable intangibles	71,831	71,745
Other assets	100,113	63,447
Total Assets	3,749,048	3,637,849
Current Liabilities:
Current portion of long-term debt and notes payable	1,918	1,059
Accounts payable	75,452	72,213
Accrued payroll	80,527	88,096
Accrued vacation	45,567	44,508
Accrued interest	1,222	804
Accrued other	41,525	39,876
Due to third party payors	733
Total Current Liabilities	246,944	246,556
Long-term debt, net of current portion	367,232	358,104
Non-current deferred tax liability	89,222	85,287
Other non-current liabilities	23,028	20,275
Total Liabilities	726,426	710,222
Stockholder's Equity:
Retained earnings (accumulated deficit)	886,099	790,692
Subsidiary investment	2,136,523	2,136,935
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	3,022,622	2,927,627
Total Equity	3,022,622	2,927,627
Total Liabilities and Equity	3,749,048	3,637,849
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries
Current Assets:
Cash and cash equivalents	1,245	1,340	1,072	616
Accounts receivable, net	62,529	53,531
Current deferred tax asset	4,389	4,434
Intercompany receivables	100,930	102,694
Other current assets	4,860	6,563
Total Current Assets	173,953	168,562
Property and equipment, net	57,705	59,531
Other assets	593	692
Total Assets	232,251	228,785
Current Liabilities:
Current portion of long-term debt and notes payable	2,581	1,671
Accounts payable	13,354	12,660
Accrued payroll	260	304
Accrued vacation	7,259	6,957
Accrued other	9,372	8,754
Due to third party payors	3,235	2,723
Total Current Liabilities	36,061	33,069
Long-term debt, net of current portion	59,630	60,522
Non-current deferred tax liability	9,734	9,330
Other non-current liabilities	1,331	1,753
Total Liabilities	106,756	104,674
Redeemable non-controlling interests	11,623	10,811
Stockholder's Equity:
Retained earnings (accumulated deficit)	18,438	21,197
Subsidiary investment	64,190	63,673
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	82,628	84,870
Non-controlling interests	31,244	28,430
Total Equity	113,872	113,300
Total Liabilities and Equity	232,251	228,785
Select Medical Corporation | Eliminations
Current Assets:
Accounts receivable, net		(1,645)
Intercompany receivables	(1,135,472)	(1,124,173)
Total Current Assets	(1,135,472)	(1,125,818)
Investment in affiliates	(3,105,250)	(3,012,497)
Non-current deferred tax asset	(8,097)	(5,107)
Total Assets	(4,248,819)	(4,143,422)
Current Liabilities:
Intercompany accounts	(1,135,472)	(1,124,173)
Due to third party payors		(1,645)
Total Current Liabilities	(1,135,472)	(1,125,818)
Non-current deferred tax liability	(8,097)	(5,107)
Total Liabilities	(1,143,569)	(1,130,925)
Stockholder's Equity:
Retained earnings (accumulated deficit)	(904,537)	(811,889)
Subsidiary investment	(2,200,713)	(2,200,608)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	(3,105,250)	(3,012,497)
Total Equity	(3,105,250)	(3,012,497)
Total Liabilities and Equity	$ (4,248,819)	$ (4,143,422)

XML

Commitments and Contingencies (Details) (USD $) In Millions, unless otherwise specified		0 Months Ended				9 Months Ended
	Sep. 30, 2013	Sep. 25, 2013 SSH-Evansville Amended complaint	Jun. 26, 2013 SSH-Evansville Amended complaint	Mar. 29, 2013 SSH-Evansville Amended complaint	Jan. 08, 2013 SSH-Evansville Amended complaint item	Sep. 30, 2013 Professional liability claims	Sep. 30, 2013 General liability claims
Commitments and Contingencies
Self insurance retention per occurrence						$ 2.0	$ 2.0
Number of case managers identified as plaintiff					2
Number of physicians named as defendants					2
Number of alleged receipts of separate Medicare payments					2
Number of days the deadlines have been stayed from the Magistrate judge				90 days
Number of additional days the deadlines had been requested to be stayed		90 days	90 days
Construction Commitments
Outstanding commitments under construction contracts	$ 15.3

XML

Intangible Assets (Details 2) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013
Goodwill.
Balance at the beginning of the period	$ 1,640,534
Goodwill acquired during the period	1,435
Purchase price adjustment	(133)
Balance at the end of the period	1,641,836
Specialty Hospitals
Goodwill.
Balance at the beginning of the period	1,333,220
Goodwill acquired during the period	1,395
Balance at the end of the period	1,334,615
Outpatient Rehabilitation
Goodwill.
Balance at the beginning of the period	307,314
Goodwill acquired during the period	40
Purchase price adjustment	(133)
Balance at the end of the period	$ 307,221

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities
Net income	$ 91,887	$ 112,546
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	47,872	47,164
Provision for bad debts	27,429	31,603
Equity in earnings of unconsolidated subsidiaries	(1,447)	(6,384)
Loss on early retirement of debt	18,747	6,064
Gain from disposal or sale of assets	(93)	(3,484)
Non-cash stock compensation expense	5,403	3,990
Amortization of debt discount and issuance costs	6,507	5,494
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable	(89,237)	(10,507)
Other current assets	(7,642)	(1,849)
Other assets	(3,211)	1,270
Accounts payable	6,798	(4,098)
Due to third-party payors	2,890	360
Accrued expenses	4,788	348
Income and deferred taxes	4,414	11,559
Net cash provided by operating activities	115,105	194,076
Investing activities
Purchases of property and equipment	(45,331)	(45,188)
Proceeds from sale of assets	518	16,511
Investment in businesses, net of distributions	(32,430)	(9,899)
Acquisition of businesses, net of cash acquired	(848)	(1,547)
Net cash used in investing activities	(78,091)	(40,123)
Financing activities
Borrowings on revolving credit facility	580,000	365,000
Payments on revolving credit facility	(645,000)	(405,000)
Borrowings on credit facility term loans, net of discount	298,500	266,750
Payments on credit facility term loans	(594,668)	(7,063)
Issuance of 6.375% senior notes	600,000
Repurchase of senior floating rate notes	(167,300)
Repurchase of 7 5/8% senior subordinated notes	(70,000)	(278,495)
Borrowings of other debt	9,238	5,835
Principal payments on other debt	(7,467)	(7,417)
Debt issuance costs	(18,820)	(4,236)
Dividends paid	(27,929)
Repurchase of common stock	(10,946)	(46,790)
Proceeds from issuance of common stock		1,104
Repayment of bank overdrafts	(10,401)	(3,011)
Distributions to non-controlling interests	(3,072)	(2,997)
Net cash used in financing activities	(67,865)	(116,320)
Net increase (decrease) in cash and cash equivalents	(30,851)	37,633
Cash and cash equivalents at beginning of period	40,144	12,043
Cash and cash equivalents at end of period	9,293	49,676
Supplemental Cash Flow Information
Cash paid for interest	60,439	68,122
Cash paid for taxes	52,977	59,850
Select
Operating activities
Net income	94,077	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	47,872	47,164
Provision for bad debts	27,429	31,603
Equity in earnings of unconsolidated subsidiaries	(1,447)	(6,384)
Loss on early retirement of debt	17,788	6,064
Gain from disposal or sale of assets	(93)	(3,484)
Non-cash stock compensation expense	5,403	3,990
Amortization of debt discount and issuance costs	6,418	5,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable	(89,237)	(10,507)
Other current assets	(7,642)	(1,849)
Other assets	(3,211)	1,270
Accounts payable	6,798	(4,098)
Due to third-party payors	2,890	360
Accrued expenses	8,046	2,956
Income and deferred taxes	5,593	14,481
Net cash provided by operating activities	120,684	204,753
Investing activities
Purchases of property and equipment	(45,331)	(45,188)
Proceeds from sale of assets	518	16,511
Investment in businesses, net of distributions	(32,430)	(9,899)
Acquisition of businesses, net of cash acquired	(848)	(1,547)
Net cash used in investing activities	(78,091)	(40,123)
Financing activities
Borrowings on revolving credit facility	580,000	365,000
Payments on revolving credit facility	(645,000)	(405,000)
Borrowings on credit facility term loans, net of discount	298,500	266,750
Payments on credit facility term loans	(594,668)	(7,063)
Issuance of 6.375% senior notes	600,000
Repurchase of 7 5/8% senior subordinated notes	(70,000)	(278,495)
Borrowings of other debt	9,238	5,835
Principal payments on other debt	(7,467)	(7,417)
Debt issuance costs	(18,820)	(4,236)
Dividends paid	(211,754)	(57,467)
Equity investment by Holdings		1,104
Repayment of bank overdrafts	(10,401)	(3,011)
Distributions to non-controlling interests	(3,072)	(2,997)
Net cash used in financing activities	(73,444)	(126,997)
Net increase (decrease) in cash and cash equivalents	(30,851)	37,633
Cash and cash equivalents at beginning of period	40,144	12,043
Cash and cash equivalents at end of period	9,293	49,676
Supplemental Cash Flow Information
Cash paid for interest	54,860	57,448
Cash paid for taxes	$ 52,977	$ 59,850

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2013

Basis of Presentation

Basis of Presentation

1. Basis of Presentation

The unaudited consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) and Select Medical Corporation (“Select”) as of September 30, 2013 and for the three and nine month periods ended September 30, 2012 and 2013 have been prepared in accordance with generally accepted accounting principles (“GAAP”).  In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.  All significant intercompany transactions and balances have been eliminated.  The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2013.  Holdings and Select and their subsidiaries are collectively referred to as the “Company.” The consolidated financial statements of Holdings include the accounts of its wholly-owned subsidiary Select. Holdings conducts substantially all of its business through Select and its subsidiaries.

Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted consistent with the rules and regulations of the Securities and Exchange Commission (the “SEC”), although the Company believes the disclosure is adequate to make the information presented not misleading.   The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2012 contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2013.

XML

Indebtedness

9 Months Ended

Sep. 30, 2013

Indebtedness

Indebtedness

4.  Indebtedness

The components of long-term debt and notes payable are as follows:

	Select Medical Holdings Corporation
	December 31, 2012		September 30, 2013
	(in thousands)
7 5/8% senior subordinated notes	$	70,000	$	—
6.375% senior notes	—		600,000
Senior secured credit facilities:
Revolving loan	130,000		65,000
Term loans (1)	1,096,641		809,438
Senior floating rate notes	167,300		—
Other	6,302		14,443
Total debt	1,470,243		1,488,881
Less: current maturities	11,646		13,966
Total long-term debt	$	1,458,597	$	1,474,915

	Select Medical Corporation
	December 31, 2012		September 30, 2013
	(in thousands)
7 5/8% senior subordinated notes	$	70,000	$	—
6.375% senior notes	—		600,000
Senior secured credit facilities:
Revolving loan	130,000		65,000
Term loans (1)	1,096,641		809,438
Other	6,302		14,443
Total debt	1,302,943		1,488,881
Less: current maturities	11,646		13,966
Total long-term debt	$	1,291,297	$	1,474,915

(1) Presented net of unamortized discounts of $14.2 million and $6.8 million at December 31, 2012 and September 30, 2013, respectively.

On February 20, 2013, Select entered into a credit extension amendment to its senior secured credit facilities providing for a $300.0 million additional term loan tranche, (the “series B term loan”) to Select.  Select used the borrowings under the series B term loan to redeem all of its outstanding 7 5/8% senior subordinated notes due 2015 on March 22, 2013, to finance Holdings’ redemption of all of its senior floating rate notes due 2015 on March 22, 2013 and to repay a portion of the balance outstanding under Select’s revolving credit facility.  The Company recognized a loss on early retirement of debt of $1.5 million during the three months ended March 31, 2013 for unamortized debt issuance costs, of which approximately $0.5 million was associated with Select’s 7 5/8% senior subordinated notes due 2015 and approximately $1.0 million was associated with Holdings’ senior floating rate notes due 2015.

Borrowings under the series B term loan bear interest at a rate equal to Adjusted LIBO plus 3.25%, or Alternate Base Rate plus 2.25%.  The series B term loan amortizes in equal quarterly installments on the last day of each March, June, September and December in aggregate annual amounts equal to $3.0 million.  The balance of the series B term loan is payable on February 20, 2016.

At the time of issuing the series B term loan, Select had additional term loan tranches outstanding including an $850.0 million term loan tranche issued on June 1, 2011 (the “original term loan”) and a $275.0 million incremental term loan tranche issued August 13, 2012 (the “series A term loan”). Both the original term loan and series A term loan tranches were issued at a discount and amortized in equal quarterly installments on the last day of each March, June, September and December. The balance of both the original term loan and series A term loan was payable on June 1, 2018.

On May 28, 2013, Select issued and sold $600.0 million aggregate principal amount of its 6.375% senior notes due 2021.  On May 28, 2013, Select used the proceeds of the senior notes to pay a portion of the amounts then outstanding on the original term loan and the series A term loan, and to pay related fees and expenses.  Select recognized a loss on early retirement of debt of $17.3 million in the three months ended June 30, 2013 in connection with the repayment of a portion of its term loans and amendment of the existing senior secured credit facility, which included the write-off of unamortized debt issuance costs.

Interest on the senior notes accrues at the rate of 6.375% per annum and is payable semi-annually in cash in arrears on June 1 and December 1 of each year, commencing on December 1, 2013.  The senior notes are Select’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.  The senior notes are unconditionally guaranteed by all of Select’s wholly-owned subsidiaries.  The senior notes are guaranteed, jointly and severally, by Select’s direct or indirect existing and future domestic restricted subsidiaries other than certain non-guarantor subsidiaries.

Select may redeem some or all of the senior notes prior to June 1, 2016 by paying a “make-whole” premium.  Select may redeem some or all of the senior notes on or after June 1, 2016 at specified redemption prices.  In addition, prior to June 1, 2016, Select may redeem up to 35% of the senior notes with the net proceeds of certain equity offerings at a price of 106.375% plus accrued and unpaid interest, if any. Select is obligated to offer to repurchase the senior notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events.  These restrictions and prohibitions are subject to certain qualifications and exceptions.

The Indenture relating to the senior notes contains covenants that, among other things, limit Select’s ability and the ability of certain of its subsidiaries to (i) grant liens on its assets, (ii) make dividend payments, other distributions or other restricted payments, (iii) incur restrictions on the ability of Select’s restricted subsidiaries to pay dividends or make other payments, (iv) enter into sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of substantially all of their assets, (vi) incur additional indebtedness, (vii) make investments, (viii) sell assets, including capital stock of subsidiaries, (ix) use the proceeds from sales of assets, including capital stock of restricted subsidiaries, and (x) enter into transactions with affiliates.  In addition, the Indenture requires, among other things, Select to provide financial and current reports to holders of the senior notes or file such reports electronically with the U.S. Securities and Exchange Commission (the “SEC”).  These covenants are subject to a number of exceptions, limitations and qualifications set forth in the Indenture.

On June 3, 2013, Select amended its existing senior secured credit facilities in order to:

· extend the maturity date on $293.3 million of its $300.0 million revolving credit facility from June 1, 2016 to March 1, 2018;

· convert the remaining original term loan and series A term loan to a series C term loan and lower the interest rate payable on the series C term loan from Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%, to Adjusted LIBO plus 3.00%, or Alternate Base Rate plus 2.00%, and amend the provision of the series C term loan from providing that Adjusted LIBO will at no time be less than 1.75% to providing that Adjusted LIBO will at no time be less than 1.00%; and

· amend the restrictive covenants governing the senior secured credit facilities in order to allow for unlimited restricted payments so long as there is no event of default under the senior secured credit facilities and the total pro forma ratio of total indebtedness to Consolidated EBITDA (as defined in our senior secured credit facilities) is less than or equal to 2.75 to 1.00.

Maturities of Long-Term Debt and Notes Payable

Maturities of the Company’s long-term debt for the period from October 1, 2013 through December 31, 2013 and the years after 2013 are approximately as follows and are presented net of the discounts on the senior secured credit facility term loans (in thousands):

October 1, 2013 – December 31, 2013	$	4,869
2014	11,497
2015	10,086
2016	296,134
2017	4,075
2018 and beyond	1,162,220

XML

Accounting Policies

9 Months Ended

Sep. 30, 2013

Accounting Policies

Accounting Policies

2. Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

XML

Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Summary of selected financial data
Net operating revenues	$ 722,845	$ 713,669	$ 2,229,473	$ 2,207,883
Adjusted EBITDA	80,428	87,747	286,467	307,090
Total assets:	2,842,424	2,781,808	2,842,424	2,781,808	2,761,361
Capital expenditures	17,369	17,254	45,331	45,188
Select Medical Corporation
Summary of selected financial data
Net operating revenues	722,845	713,669	2,229,473	2,207,883
Total assets:	2,842,424	2,780,678	2,842,424	2,780,678	2,760,313
Capital expenditures			45,331	45,188
Operating Segments | Specialty Hospitals
Summary of selected financial data
Net operating revenues	532,610	531,409	1,649,747	1,641,577
Adjusted EBITDA	75,280	83,659	265,020	285,779
Total assets:	2,232,756	2,165,248	2,232,756	2,165,248
Capital expenditures	14,157	12,281	35,257	31,963
Operating Segments | Specialty Hospitals | Select Medical Corporation
Summary of selected financial data
Total assets:	2,232,756	2,165,248	2,232,756	2,165,248
Operating Segments | Outpatient Rehabilitation
Segment Information
Number of operating segments			2
Summary of selected financial data
Net operating revenues	190,223	182,246	579,404	566,195
Adjusted EBITDA	21,619	20,354	70,506	68,669
Total assets:	445,729	431,310	445,729	431,310
Capital expenditures	2,802	3,073	8,646	9,786
Operating Segments | Outpatient Rehabilitation | Select Medical Corporation
Summary of selected financial data
Total assets:	445,729	431,310	445,729	431,310
Other
Summary of selected financial data
Net operating revenues	12	14	322	111
Adjusted EBITDA	(16,471)	(16,266)	(49,059)	(47,358)
Total assets:	163,939	185,250	163,939	185,250
Capital expenditures	410	1,900	1,428	3,439
Other | Select Medical Corporation
Summary of selected financial data
Total assets:	$ 163,939	$ 184,120	$ 163,939	$ 184,120

XML

Subsequent Event (Details) (Subsequent Event, USD $)	0 Months Ended
	Oct. 30, 2013
Subsequent Event
Subsequent Event
Cash dividend declared (in dollars per share)	$ 0.10

XML

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 41,255	$ 41,854
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	700,000,000	700,000,000
Common stock, shares issued	139,546,090	140,589,256
Common stock, shares outstanding	139,546,090	140,589,256
Select
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 41,255	$ 41,854
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued	100	100
Common stock, shares outstanding	100	100

XML

Income per Common Share

9 Months Ended

Sep. 30, 2013

Income per Common Share

Income per Common Share

7.  Income per Common Share

The Company applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings. The following table sets forth for the periods indicated the calculation of income per common share in the Company’s consolidated statement of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted income per common share, respectively:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2012		2013		2012		2013
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	24,110	$	23,272	$	108,824	$	85,470
Less: Earnings allocated to unvested restricted stockholders	407		497		1,759		1,802
Net income available to common stockholders	$	23,703	$	22,775	$	107,065	$	83,668
Denominator:
Weighted average shares — basic	137,551		136,646		139,138		136,879
Effect of dilutive securities:
Stock options	337		147		266		161
Weighted average shares — diluted	137,888		136,793		139,404		137,040
Basic income per common share	$	0.17	$	0.17	$	0.77	$	0.61
Diluted income per common share	$	0.17	$	0.17	$	0.77	$	0.61

The following share amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2012	2013	2012	2013
	(in thousands)
Stock options	78	1,477	1,683	1,528

XML

Consolidated Statements of Changes in Equity and Income (USD $) In Thousands, unless otherwise specified	Total	Select	Comprehensive Income	Comprehensive Income Select	Common Stock	Common Stock Select	Capital in Excess of Par	Capital in Excess of Par Select	Retained Earnings (accumulated deficit)	Retained Earnings (accumulated deficit) Select	Non-controlling Interests	Non-controlling Interests Select
Balance at Dec. 31, 2012	$ 745,478	$ 909,747			$ 141	$ 0	$ 473,697	$ 859,839	$ 243,210	$ 21,478	$ 28,430	$ 28,430
Balance (in shares) at Dec. 31, 2012					140,589	0
Increase (Decrease) in Stockholders' Equity
Net income	89,588	91,778	89,588	91,778					85,470	87,660	4,118	4,118
Net income - attributable to redeemable non-controlling interests			2,299	2,299
Total comprehensive income			91,887	94,077
Issuance and vesting of restricted stock	4,695				0		4,695
Issuance and vesting of restricted stock (in shares)					72
Stock option expense	708						708
Repurchase of common shares	(10,946)				(1)		(7,020)		(3,925)
Repurchase of common shares (in shares)					(1,115)
Federal tax benefit of losses contributed by Holdings		1,181						1,181
Net change in dividends payable to Holdings		5,239								5,239
Dividends declared and paid	(27,929)	(211,754)							(27,929)	(211,754)
Contribution related to restricted stock awards and stock option issuances by Holdings		5,403						5,403
Acquisitions of non-controlling interests	261	261									261	261
Distributions to non-controlling interests	(1,565)	(1,565)									(1,565)	(1,565)
Redeemable non-controlling interests redemption value adjustment	(630)	(630)							(630)	(630)
Balance at Sep. 30, 2013	$ 799,660	$ 799,660			$ 140	$ 0	$ 472,080	$ 866,423	$ 296,196	$ (98,007)	$ 31,244	$ 31,244
Balance (in shares) at Sep. 30, 2013					139,546	0

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Current Assets:
Cash and cash equivalents	$ 9,293	$ 40,144	$ 49,676	$ 12,043
Accounts receivable, net of allowance for doubtful accounts of $41,854 and $41,255 at 2012 and 2013, respectively	423,334	359,929
Current deferred tax asset	15,372	17,877
Prepaid income taxes	4,044	3,895
Other current assets	39,968	31,818
Total Current Assets	492,011	453,663
Property and equipment, net	499,531	501,552
Goodwill	1,641,836	1,640,534
Other identifiable intangibles	71,831	71,745
Other assets	137,215	93,867
Total Assets	2,842,424	2,761,361	2,781,808
Current Liabilities:
Bank overdrafts	7,435	17,836
Current portion of long-term debt and notes payable	13,966	11,646
Accounts payable	96,360	89,547
Accrued payroll	81,303	88,586
Accrued vacation	57,328	55,714
Accrued interest	22,005	22,016
Accrued other	102,925	102,040
Due to third party payors	3,968	1,078
Total Current Liabilities	385,290	388,463
Long-term debt, net of current portion	1,474,915	1,458,597
Non-current deferred tax liability	90,859	89,510
Other non-current liabilities	80,077	68,502
Total Liabilities	2,031,141	2,005,072
Redeemable non-controlling interests	11,623	10,811
Stockholders' Equity:
Common stock	140	141
Capital in excess of par	472,080	473,697
Retained earnings (accumulated deficit)	296,196	243,210
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	768,416	717,048
Non-controlling interest	31,244	28,430
Total Equity	799,660	745,478
Total Liabilities and Equity	2,842,424	2,761,361
Select
Current Assets:
Cash and cash equivalents	9,293	40,144	49,676	12,043
Accounts receivable, net of allowance for doubtful accounts of $41,854 and $41,255 at 2012 and 2013, respectively	423,334	359,929
Current deferred tax asset	15,372	17,877
Prepaid income taxes	4,044	3,895
Other current assets	39,968	31,818
Total Current Assets	492,011	453,663
Property and equipment, net	499,531	501,552
Goodwill	1,641,836	1,640,534
Other identifiable intangibles	71,831	71,745
Other assets	137,215	92,819
Total Assets	2,842,424	2,760,313	2,780,678
Current Liabilities:
Bank overdrafts	7,435	17,836
Current portion of long-term debt and notes payable	13,966	11,646
Accounts payable	96,360	89,547
Accrued payroll	81,303	88,586
Accrued vacation	57,328	55,714
Accrued interest	22,005	18,759
Accrued other	102,925	107,280
Due to third party payors	3,968	1,078
Total Current Liabilities	385,290	390,446
Long-term debt, net of current portion	1,474,915	1,291,297
Non-current deferred tax liability	90,859	89,510
Other non-current liabilities	80,077	68,502
Total Liabilities	2,031,141	1,839,755
Redeemable non-controlling interests	11,623	10,811
Stockholders' Equity:
Common stock	0	0
Capital in excess of par	866,423	859,839
Retained earnings (accumulated deficit)	(98,007)	21,478
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	768,416	881,317
Non-controlling interest	31,244	28,430
Total Equity	799,660	909,747
Total Liabilities and Equity	$ 2,842,424	$ 2,760,313

XML

Segment Information (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Information
Adjusted EBITDA	$ 80,428		$ 87,747	$ 286,467	$ 307,090
Depreciation and amortization	(16,163)		(15,537)	(47,872)	(47,164)
Income from operations	62,399		70,819	233,192	255,936
Equity in earnings (losses) of unconsolidated subsidiaries	(179)		1,167	1,447	6,384
Loss on early retirement of debt		(1,500)	(6,064)	(18,747)	(6,064)
Interest expense	(21,252)		(24,575)	(66,614)	(72,295)
Income before income taxes	40,968		41,347	149,278	183,961
Select Medical Corporation
Segment Information
Depreciation and amortization	(16,163)		(15,537)	(47,872)	(47,164)
Income from operations	62,399		70,819	233,192	255,936
Equity in earnings (losses) of unconsolidated subsidiaries	(179)		1,167	1,447	6,384
Loss on early retirement of debt			(6,064)	(17,788)	(6,064)
Interest expense	(21,252)		(21,740)	(64,204)	(63,947)
Income before income taxes	40,968		44,182	152,647	192,309
Operating Segments | Specialty Hospitals
Segment Information
Adjusted EBITDA	75,280		83,659	265,020	285,779
Depreciation and amortization	(12,267)		(11,553)	(36,061)	(34,875)
Income from operations	63,013		72,106	228,959	250,904
Operating Segments | Outpatient Rehabilitation
Segment Information
Adjusted EBITDA	21,619		20,354	70,506	68,669
Depreciation and amortization	(2,979)		(3,152)	(8,949)	(10,034)
Income from operations	18,640		17,202	61,557	58,635
Other
Segment Information
Adjusted EBITDA	(16,471)		(16,266)	(49,059)	(47,358)
Depreciation and amortization	(917)		(832)	(2,862)	(2,255)
Stock compensation expense	(1,866)		(1,391)	(5,403)	(3,990)
Income from operations	$ (19,254)		$ (18,489)	$ (57,324)	$ (53,603)

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Tables)

9 Months Ended

Sep. 30, 2013

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes

Schedule of Consolidating Balance Sheet

Condensed Consolidating Balance Sheet

September 30, 2013

(unaudited)

	Select Medical  Corporation (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	5,052		$	2,996	$	1,245	$	—		$	9,293
Accounts receivable, net	—			360,805		62,529		—			423,334
Current deferred tax asset	8,038			2,945		4,389		—			15,372
Prepaid income taxes	4,044			—		—		—			4,044
Intercompany receivables	—			1,034,542		100,930		(1,135,472		)(a)	—
Other current assets	8,325			26,783		4,860		—			39,968
Total Current Assets	25,459			1,428,071		173,953		(1,135,472		)	492,011
Property and equipment, net	14,911			426,915		57,705		—			499,531
Investment in affiliates	3,024,968			80,282		—		(3,105,250		)(b) (c)	—
Goodwill	—			1,641,836		—		—			1,641,836
Other identifiable intangibles	—			71,831		—		—			71,831
Non-current deferred tax asset	8,097			—		—		(8,097		)(d)	—
Other assets	36,509			100,113		593		—			137,215
Total Assets	$	3,109,944		$	3,749,048	$	232,251	$	(4,248,819	)	$	2,842,424
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	7,435		$	—	$	—	$	—		$	7,435
Current portion of long-term debt and notes payable	9,467			1,918		2,581		—			13,966
Accounts payable	7,554			75,452		13,354		—			96,360
Intercompany payables	1,135,472			—		—		(1,135,472		)(a)	—
Accrued payroll	516			80,527		260		—			81,303
Accrued vacation	4,502			45,567		7,259		—			57,328
Accrued interest	20,783			1,222		—		—			22,005
Accrued other	52,028			41,525		9,372		—			102,925
Due to third party payors	—			733		3,235		—			3,968
Total Current Liabilities	1,237,757			246,944		36,061		(1,135,472		)	385,290
Long-term debt, net of current portion	1,048,053			367,232		59,630		—			1,474,915
Non-current deferred tax liability	—			89,222		9,734		(8,097		)(d)	90,859
Other non-current liabilities	55,718			23,028		1,331		—			80,077
Total Liabilities	2,341,528			726,426		106,756		(1,143,569		)	2,031,141
Redeemable non-controlling interest	—			—		11,623		—			11,623
Stockholder’s Equity:
Common stock	0			—		—		—			0
Capital in excess of par	866,423			—		—		—			866,423
Retained earnings (accumulated deficit)	(98,007		)	886,099		18,438		(904,537		)(c)	(98,007		)
Subsidiary investment	—			2,136,523		64,190		(2,200,713		)(b)	—
Total Select Medical Corporation Stockholder’s Equity	768,416			3,022,622		82,628		(3,105,250		)	768,416
Non-controlling interest	—			—		31,244		—			31,244
Total Equity	768,416			3,022,622		113,872		(3,105,250		)	799,660
Total Liabilities and Equity	$	3,109,944		$	3,749,048	$	232,251	$	(4,248,819	)	$	2,842,424

(a)  Elimination of intercompany.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Consolidating Balance Sheet

December 31, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)		Subsidiary Guarantors		Non-Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	35,070	$	3,734	$	1,340	$	—		$	40,144
Accounts receivable, net	—		308,043		53,531		(1,645		)(a)	359,929
Current deferred tax asset	12,383		1,060		4,434		—			17,877
Prepaid income taxes	3,895		—		—		—			3,895
Intercompany receivables	—		1,021,479		102,694		(1,124,173		)(b)	—
Other current assets	5,600		19,655		6,563		—			31,818
Total Current Assets	56,948		1,353,971		168,562		(1,125,818		)	453,663
Property and equipment, net	16,344		425,677		59,531		—			501,552
Investment in affiliates	2,930,022		82,475		—		(3,012,497		)(c) (d)	—
Goodwill	—		1,640,534		—		—			1,640,534
Other identifiable intangibles	—		71,745		—		—			71,745
Non-current deferred tax asset	5,107		—		—		(5,107		)(e)	—
Other assets	28,680		63,447		692		—			92,819
Total Assets	$	3,037,101	$	3,637,849	$	228,785	$	(4,143,422	)	$	2,760,313
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	17,836	$	—	$	—	$	—		$	17,836
Current portion of long-term debt and notes payable	8,916		1,059		1,671		—			11,646
Accounts payable	4,674		72,213		12,660		—			89,547
Intercompany payables	1,124,173		—		—		(1,124,173		)(b)	—
Accrued payroll	186		88,096		304		—			88,586
Accrued vacation	4,249		44,508		6,957		—			55,714
Accrued interest	17,955		804		—		—			18,759
Accrued other	58,650		39,876		8,754		—			107,280
Due to third party payors	—		—		2,723		(1,645		)(a)	1,078
Total Current Liabilities	1,236,639		246,556		33,069		(1,125,818		)	390,446
Long-term debt, net of current portion	872,671		358,104		60,522		—			1,291,297
Non-current deferred tax liability	—		85,287		9,330		(5,107		)(e)	89,510
Other non-current liabilities	46,474		20,275		1,753		—			68,502
Total Liabilities	2,155,784		710,222		104,674		(1,130,925		)	1,839,755
Redeemable non-controlling interests	—		—		10,811		—			10,811
Stockholder’s Equity:
Common stock	0		—		—		—			0
Capital in excess of par	859,839		—		—		—			859,839
Retained earnings	21,478		790,692		21,197		(811,889		)(d)	21,478
Subsidiary investment	—		2,136,935		63,673		(2,200,608		)(c)	—
Total Select Medical Corporation Stockholder’s Equity	881,317		2,927,627		84,870		(3,012,497		)	881,317
Non-controlling interests	—		—		28,430		—			28,430
Total Equity	881,317		2,927,627		113,300		(3,012,497		)	909,747
Total Liabilities and Equity	$	3,037,101	$	3,637,849	$	228,785	$	(4,143,422	)	$	2,760,313

(a)  Reclass portion of due to third party payor to accounts receivable net in consolidation.

(b)  Elimination of intercompany.

(c)  Elimination of investments in consolidated subsidiaries.

(d)  Elimination of investments in consolidated subsidiaries’ earnings.

(e)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Schedule of Consolidating Statement of Operations

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	12		$	617,415		$	105,418		$	—		$	722,845
Costs and expenses:
Cost of services	608			526,198			90,475			—			617,281
General and administrative	17,696			44			—			—			17,740
Bad debt expense	—			7,563			1,699			—			9,262
Depreciation and amortization	917			12,831			2,415			—			16,163
Total costs and expenses	19,221			546,636			94,589			—			660,446
Income (loss) from operations	(19,209		)	70,779			10,829			—			62,399
Other income and expense:
Intercompany interest and royalty fees	(278		)	310			(32		)	—			—
Intercompany management fees	32,621			(27,386		)	(5,235		)	—			—
Equity in earnings (losses) of unconsolidated subsidiaries	—			(196		)	17			—			(179		)
Interest expense	(14,192		)	(6,031		)	(1,029		)	—			(21,252		)
Income (loss) from operations before income taxes	(1,058		)	37,476			4,550			—			40,968
Income tax expense	44			15,218			499			—			15,761
Equity in earnings of subsidiaries	24,374			1,952			—			(26,326		)(a)	—
Net income	23,272			24,210			4,051			(26,326		)	25,207
Less: Net income attributable to non-controlling interests	—			—			1,935			—			1,935
Net income attributable to Select Medical Corporation	$	23,272		$	24,210		$	2,116		$	(26,326	)	$	23,272

(a) Elimination of equity in earnings of subsidiaries.

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	322		$	1,913,597		$	315,554		$	—		$	2,229,473
Costs and expenses:
Cost of services	1,718			1,599,493			266,704			—			1,867,915
General and administrative	52,915			150			—			—			53,065
Bad debt expense	—			22,485			4,944			—			27,429
Depreciation and amortization	2,862			37,856			7,154			—			47,872
Total costs and expenses	57,495			1,659,984			278,802			—			1,996,281
Income (loss) from operations	(57,173		)	253,613			36,752			—			233,192
Other income and expense:
Intercompany interest and royalty fees	(1,033		)	1,051			(18		)	—			—
Intercompany management fees	114,597			(100,005		)	(14,592		)	—			—
Loss on early retirement of debt	(17,788		)	—			—			—			(17,788		)
Equity in earnings of unconsolidated subsidiaries	—			1,375			72			—			1,447
Interest expense	(44,345		)	(16,800		)	(3,059		)	—			(64,204		)
Income (loss) from operations before income taxes	(5,742		)	139,234			19,155			—			152,647
Income tax expense	1,956			55,900			714						58,570
Equity in earnings of subsidiaries	95,358			12,073			—			(107,431		)(a)	—
Net income	87,660			95,407			18,441			(107,431		)	94,077
Less: Net income attributable to non-controlling interests	—			—			6,417			—			6,417
Net income attributable to Select Medical Corporation	$	87,660		$	95,407		$	12,024		$	(107,431	)	$	87,660

(a) Elimination of equity in earnings of subsidiaries.

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	14		$	616,610		$	97,045		$	—		$	713,669
Costs and expenses:
Cost of services	544			514,136			84,304			—			598,984
General and administrative	17,742			(612		)	—			—			17,130
Bad debt expense	—			9,525			1,674			—			11,199
Depreciation and amortization	832			12,372			2,333			—			15,537
Total costs and expenses	19,118			535,421			88,311			—			642,850
Income (loss) from operations	(19,104		)	81,189			8,734			—			70,819
Other income and expense:
Intercompany interest and royalty fees	(469		)	459			10			—			—
Intercompany management fees	34,811			(29,960		)	(4,851		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			1,146			21			—			1,167
Interest expense	(14,676		)	(6,010		)	(1,054		)	—			(21,740		)
Income (loss) from operations before income taxes	(5,502		)	46,824			2,860			—			44,182
Income tax expense (benefit)	(3,589		)	21,020			(250		)	—			17,181
Equity in earnings of subsidiaries	27,866			2,123			—			(29,989		)(a)	—
Net income	25,953			27,927			3,110			(29,989		)	27,001
Less: Net income attributable to non-controlling interests	—			—			1,048			—			1,048
Net income attributable to Select Medical Corporation	$	25,953		$	27,927		$	2,062		$	(29,989	)	$	25,953

(a) Elimination of equity in earnings of subsidiaries.

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	111		$	1,910,563		$	297,209		$	—		$	2,207,883
Costs and expenses:
Cost of services	1,554			1,567,080			254,638			—			1,823,272
General and administrative	51,197			(1,289		)	—			—			49,908
Bad debt expense	—			27,199			4,404			—			31,603
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Total costs and expenses	55,006			1,630,942			265,999			—			1,951,947
Income (loss) from operations	(54,895		)	279,621			31,210			—			255,936
Other income and expense:
Intercompany interest and royalty fees	(2,025		)	1,998			27			—			—
Intercompany management fees	91,940			(78,202		)	(13,738		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			6,340			44			—			6,384
Interest expense	(40,823		)	(19,920		)	(3,204		)	—			(63,947		)
Income (loss) from operations before income taxes	(11,867		)	189,837			14,339			—			192,309
Income tax expense (benefit)	(1,613		)	75,924			26			—			74,337
Equity in earnings of subsidiaries	124,504			11,234			—			(135,738		)(a)	—
Net income	114,250			125,147			14,313			(135,738		)	117,972
Less: Net income attributable to non-controlling interests	—			—			3,722			—			3,722
Net income attributable to Select Medical Corporation	$	114,250		$	125,147		$	10,591		$	(135,738	)	$	114,250

(a) Elimination of equity in earnings of subsidiaries.

Schedule of Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2013

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	87,660		$	95,407		$	18,441		$	(107,431	)(a)	$	94,077
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,862			37,856			7,154			—			47,872
Provision for bad debts	—			22,485			4,944			—			27,429
Equity in earnings of unconsolidated subsidiaries	—			(1,375		)	(72		)	—			(1,447		)
Loss on early retirement of debt	17,788			—			—			—			17,788
Loss (gain) from disposal of assets	—			25			(118		)	—			(93		)
Non-cash stock compensation expense	5,403			—			—			—			5,403
Amortization of debt discount and issuance costs	6,418			—			—			—			6,418
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(95,358		)	(12,073		)	—			107,431		(a)	—
Accounts receivable	—			(75,295		)	(13,942		)	—			(89,237		)
Other current assets	(2,725		)	(6,620		)	1,703			—			(7,642		)
Other assets	(7,829		)	4,519			99			—			(3,211		)
Accounts payable	2,880			3,224			694			—			6,798
Due to third-party payors	—			2,378			512			—			2,890
Accrued expenses	(3,211		)	10,381			876			—			8,046
Income and deferred taxes	5,593			—			—			—			5,593
Net cash provided by operating activities	19,481			80,912			20,291			—			120,684
Investing activities
Purchases of property and equipment	(1,428		)	(39,101		)	(4,802		)	—			(45,331		)
Proceeds from sale of assets	—			62			456			—			518
Investment in businesses, net of distributions	—			(32,430		)	—			—			(32,430		)
Acquisition of businesses, net of cash acquired	—			(848		)	—			—			(848		)
Net cash used in investing activities	(1,428		)	(72,317		)	(4,346		)	—			(78,091		)
Financing activities
Borrowings on revolving credit facility	580,000			—			—			—			580,000
Payments on revolving credit facility	(645,000		)	—			—			—			(645,000		)
Borrowings on credit facility term loans, net of discount	298,500			—			—			—			298,500
Payments on credit facility term loans	(594,668		)	—			—			—			(594,668		)
Issuance of 6.375% senior notes	600,000			—			—			—			600,000
Repurchase of 7 5/8% senior subordinated notes	(70,000		)	—			—			—			(70,000		)
Borrowings of other debt	8,154			—			1,084			—			9,238
Principal payments on other debt	(5,971		)	(521		)	(975		)	—			(7,467		)
Debt issuance costs	(18,820		)	—			—			—			(18,820		)
Dividends paid to Holdings	(211,754		)	—			—			—			(211,754		)
Repayments of bank overdrafts	(10,401		)	—			—			—			(10,401		)
Intercompany	21,889			(8,812		)	(13,077		)	—			—
Distributions to non-controlling interests	—			—			(3,072		)	—			(3,072		)
Net cash used in financing activities	(48,071		)	(9,333		)	(16,040		)	—			(73,444		)
Net decrease in cash and cash equivalents	(30,018		)	(738		)	(95		)	—			(30,851		)
Cash and cash equivalents at beginning of period	35,070			3,734			1,340			—			40,144
Cash and cash equivalents at end of period	$	5,052		$	2,996		$	1,245		$	—		$	9,293

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	114,250		$	125,147		$	14,313		$	(135,738	)(a)	$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Provision for bad debts	—			27,199			4,404			—			31,603
Equity in earnings of unconsolidated subsidiaries	—			(6,340		)	(44		)	—			(6,384		)
Loss on early retirement of debt	6,064			—			—			—			6,064
Loss (gain) from disposal of assets	—			(3,501		)	17			—			(3,484		)
Non-cash stock compensation expense	3,990			—			—			—			3,990
Amortization of debt discount and issuance costs	5,215			—			—			—			5,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(124,504		)	(11,234		)	—			135,738		(a)	—
Accounts receivable	—			7,296			(17,803		)	—			(10,507		)
Other current assets	1,182			(2,141		)	(890		)	—			(1,849		)
Other assets	(604		)	1,688			186			—			1,270
Accounts payable	418			(5,842		)	1,326			—			(4,098		)
Due to third-party payors	—			(10,928		)	11,288			—			360
Accrued expenses	3,870			(1,912		)	998			—			2,956
Income and deferred taxes	14,481			—			—			—			14,481
Net cash provided by operating activities	26,617			157,384			20,752			—			204,753
Investing activities
Purchases of property and equipment	(3,617		)	(31,978		)	(9,593		)	—			(45,188		)
Proceeds from sale of assets	—			16,511			—			—			16,511
Investment in business, net of distributions	—			(9,899		)	—			—			(9,899		)
Acquisition of businesses, net of cash acquired	—			(1,547		)	—			—			(1,547		)
Net cash used in investing activities	(3,617		)	(26,913		)	(9,593		)	—			(40,123		)
Financing activities
Borrowings on revolving credit facility	365,000			—			—			—			365,000
Payments on revolving credit facility	(405,000		)	—			—			—			(405,000		)
Borrowings on credit facility term loans, net of discount	266,750			—			—			—			266,750
Payments on credit facility term loans	(7,063		)	—			—			—			(7,063		)
Repurchase of 7 5/8% senior subordinated notes	(278,495		)	—			—			—			(278,495		)
Borrowings of other debt	5,557			—			278			—			5,835
Principal payments on other debt	(6,667		)	(322		)	(428		)	—			(7,417		)
Debt issuance costs	(4,236		)	—			—			—			(4,236		)
Dividends paid to Holdings	(57,467		)	—			—			—			(57,467		)
Equity investment by Holdings	1,104			—			—			—			1,104
Repayment of bank overdrafts	(3,011		)	—			—			—			(3,011		)
Intercompany	134,170			(126,614		)	(7,556		)	—			—
Distributions to non-controlling interests	—			—			(2,997		)	—			(2,997		)
Net cash provided by (used in) financing activities	10,642			(126,936		)	(10,703		)	—			(126,997		)
Net increase in cash and cash equivalents	33,642			3,535			456			—			37,633
Cash and cash equivalents at beginning of period	11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	45,069		$	3,535		$	1,072		$	—		$	49,676

(a)  Elimination of equity in earnings of consolidated subsidiaries.

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details 3) (USD $) In Thousands, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidating Statement of Operations
Net operating revenues	$ 722,845		$ 713,669	$ 2,229,473	$ 2,207,883
Costs and expenses:
Cost of services	617,281		598,984	1,867,915	1,823,272
General and administrative	17,740		17,130	53,065	49,908
Bad debt expense	9,262		11,199	27,429	31,603
Depreciation and amortization	16,163		15,537	47,872	47,164
Total costs and expenses	660,446		642,850	1,996,281	1,951,947
Income from operations	62,399		70,819	233,192	255,936
Other income and expense:
Loss on early retirement of debt		(1,500)	(6,064)	(18,747)	(6,064)
Equity in earnings (losses) of unconsolidated subsidiaries	(179)		1,167	1,447	6,384
Interest expense	(21,252)		(24,575)	(66,614)	(72,295)
Income before income taxes	40,968		41,347	149,278	183,961
Income tax expense (benefit)	15,761		16,189	57,391	71,415
Net income	25,207		25,158	91,887	112,546
Less: Net income attributable to non-controlling interests	1,935		1,048	6,417	3,722
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	23,272		24,110	85,470	108,824
Select Medical Corporation
Consolidating Statement of Operations
Net operating revenues	722,845		713,669	2,229,473	2,207,883
Costs and expenses:
Cost of services	617,281		598,984	1,867,915	1,823,272
General and administrative	17,740		17,130	53,065	49,908
Bad debt expense	9,262		11,199	27,429	31,603
Depreciation and amortization	16,163		15,537	47,872	47,164
Total costs and expenses	660,446		642,850	1,996,281	1,951,947
Income from operations	62,399		70,819	233,192	255,936
Other income and expense:
Loss on early retirement of debt			(6,064)	(17,788)	(6,064)
Equity in earnings (losses) of unconsolidated subsidiaries	(179)		1,167	1,447	6,384
Interest expense	(21,252)		(21,740)	(64,204)	(63,947)
Income before income taxes	40,968		44,182	152,647	192,309
Income tax expense (benefit)	15,761		17,181	58,570	74,337
Net income	25,207		27,001	94,077	117,972
Less: Net income attributable to non-controlling interests	1,935		1,048	6,417	3,722
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	23,272		25,953	87,660	114,250
Select Medical Corporation | Reportable legal entities | Select Medical Corporation (Parent Company Only)
Consolidating Statement of Operations
Net operating revenues	12		14	322	111
Costs and expenses:
Cost of services	608		544	1,718	1,554
General and administrative	17,696		17,742	52,915	51,197
Depreciation and amortization	917		832	2,862	2,255
Total costs and expenses	19,221		19,118	57,495	55,006
Income from operations	(19,209)		(19,104)	(57,173)	(54,895)
Other income and expense:
Intercompany interest and royalty fees	(278)		(469)	(1,033)	(2,025)
Intercompany management fees	32,621		34,811	114,597	91,940
Loss on early retirement of debt			(6,064)	(17,788)	(6,064)
Interest expense	(14,192)		(14,676)	(44,345)	(40,823)
Income before income taxes	(1,058)		(5,502)	(5,742)	(11,867)
Income tax expense (benefit)	44		(3,589)	1,956	(1,613)
Equity in earnings of subsidiaries	24,374		27,866	95,358	124,504
Net income	23,272		25,953	87,660	114,250
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	23,272		25,953	87,660	114,250
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors
Consolidating Statement of Operations
Net operating revenues	617,415		616,610	1,913,597	1,910,563
Costs and expenses:
Cost of services	526,198		514,136	1,599,493	1,567,080
General and administrative	44		(612)	150	(1,289)
Bad debt expense	7,563		9,525	22,485	27,199
Depreciation and amortization	12,831		12,372	37,856	37,952
Total costs and expenses	546,636		535,421	1,659,984	1,630,942
Income from operations	70,779		81,189	253,613	279,621
Other income and expense:
Intercompany interest and royalty fees	310		459	1,051	1,998
Intercompany management fees	(27,386)		(29,960)	(100,005)	(78,202)
Equity in earnings (losses) of unconsolidated subsidiaries	(196)		1,146	1,375	6,340
Interest expense	(6,031)		(6,010)	(16,800)	(19,920)
Income before income taxes	37,476		46,824	139,234	189,837
Income tax expense (benefit)	15,218		21,020	55,900	75,924
Equity in earnings of subsidiaries	1,952		2,123	12,073	11,234
Net income	24,210		27,927	95,407	125,147
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	24,210		27,927	95,407	125,147
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries
Consolidating Statement of Operations
Net operating revenues	105,418		97,045	315,554	297,209
Costs and expenses:
Cost of services	90,475		84,304	266,704	254,638
Bad debt expense	1,699		1,674	4,944	4,404
Depreciation and amortization	2,415		2,333	7,154	6,957
Total costs and expenses	94,589		88,311	278,802	265,999
Income from operations	10,829		8,734	36,752	31,210
Other income and expense:
Intercompany interest and royalty fees	(32)		10	(18)	27
Intercompany management fees	(5,235)		(4,851)	(14,592)	(13,738)
Equity in earnings (losses) of unconsolidated subsidiaries	17		21	72	44
Interest expense	(1,029)		(1,054)	(3,059)	(3,204)
Income before income taxes	4,550		2,860	19,155	14,339
Income tax expense (benefit)	499		(250)	714	26
Net income	4,051		3,110	18,441	14,313
Less: Net income attributable to non-controlling interests	1,935		1,048	6,417	3,722
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	2,116		2,062	12,024	10,591
Select Medical Corporation | Eliminations
Other income and expense:
Equity in earnings of subsidiaries	(26,326)		(29,989)	(107,431)	(135,738)
Net income	(26,326)		(29,989)	(107,431)	(135,738)
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ (26,326)		$ (29,989)	$ (107,431)	$ (135,738)

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details 4) (USD $) In Thousands, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Operating activities
Net income	$ 25,207		$ 25,158	$ 91,887	$ 112,546
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	16,163		15,537	47,872	47,164
Provision for bad debts	9,262		11,199	27,429	31,603
Equity in earnings of unconsolidated subsidiaries	179		(1,167)	(1,447)	(6,384)
Loss on early retirement of debt		1,500	6,064	18,747	6,064
Loss (gain) from disposal of assets				(93)	(3,484)
Non-cash stock compensation expense				5,403	3,990
Amortization of debt discount and issuance costs				6,507	5,494
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable				(89,237)	(10,507)
Other current assets				(7,642)	(1,849)
Other assets				(3,211)	1,270
Accounts payable				6,798	(4,098)
Due to third-party payors				2,890	360
Accrued expenses				4,788	348
Income and deferred taxes				4,414	11,559
Net cash provided by operating activities				115,105	194,076
Investing activities
Purchases of property and equipment	(17,369)		(17,254)	(45,331)	(45,188)
Proceeds from sale of assets				518	16,511
Investment in business, net of distributions				(32,430)	(9,899)
Acquisition of businesses, net of cash acquired				(848)	(1,547)
Net cash used in investing activities				(78,091)	(40,123)
Financing activities
Borrowings on revolving credit facility				580,000	365,000
Payments on revolving credit facility				(645,000)	(405,000)
Borrowings on credit facility term loans, net of discount				298,500	266,750
Payments on credit facility term loans				(594,668)	(7,063)
Repurchase of 7 5/8% senior subordinated notes				(70,000)	(278,495)
Borrowings of other debt				9,238	5,835
Principal payments on other debt				(7,467)	(7,417)
Debt issuance costs				(18,820)	(4,236)
Dividends paid to Holdings				(27,929)
Repayments of bank overdrafts				(10,401)	(3,011)
Distributions to non-controlling interests				(3,072)	(2,997)
Net cash used in financing activities				(67,865)	(116,320)
Net increase (decrease) in cash and cash equivalents				(30,851)	37,633
Cash and cash equivalents at beginning of period		40,144		40,144	12,043
Cash and cash equivalents at end of period	9,293		49,676	9,293	49,676
Select Medical Corporation
Operating activities
Net income	25,207		27,001	94,077	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	16,163		15,537	47,872	47,164
Provision for bad debts	9,262		11,199	27,429	31,603
Equity in earnings of unconsolidated subsidiaries	179		(1,167)	(1,447)	(6,384)
Loss on early retirement of debt			6,064	17,788	6,064
Loss (gain) from disposal of assets				(93)	(3,484)
Non-cash stock compensation expense				5,403	3,990
Amortization of debt discount and issuance costs				6,418	5,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable				(89,237)	(10,507)
Other current assets				(7,642)	(1,849)
Other assets				(3,211)	1,270
Accounts payable				6,798	(4,098)
Due to third-party payors				2,890	360
Accrued expenses				8,046	2,956
Income and deferred taxes				5,593	14,481
Net cash provided by operating activities				120,684	204,753
Investing activities
Purchases of property and equipment				(45,331)	(45,188)
Proceeds from sale of assets				518	16,511
Investment in business, net of distributions				(32,430)	(9,899)
Acquisition of businesses, net of cash acquired				(848)	(1,547)
Net cash used in investing activities				(78,091)	(40,123)
Financing activities
Borrowings on revolving credit facility				580,000	365,000
Payments on revolving credit facility				(645,000)	(405,000)
Borrowings on credit facility term loans, net of discount				298,500	266,750
Payments on credit facility term loans				(594,668)	(7,063)
Issuance of 6.375% senior notes				600,000
Repurchase of 7 5/8% senior subordinated notes				(70,000)	(278,495)
Borrowings of other debt				9,238	5,835
Principal payments on other debt				(7,467)	(7,417)
Debt issuance costs				(18,820)	(4,236)
Dividends paid to Holdings				(211,754)	(57,467)
Equity investment by Holdings					1,104
Repayments of bank overdrafts				(10,401)	(3,011)
Distributions to non-controlling interests				(3,072)	(2,997)
Net cash used in financing activities				(73,444)	(126,997)
Net increase (decrease) in cash and cash equivalents				(30,851)	37,633
Cash and cash equivalents at beginning of period		40,144		40,144	12,043
Cash and cash equivalents at end of period	9,293		49,676	9,293	49,676
Select Medical Corporation | Reportable legal entities | Select Medical Corporation (Parent Company Only)
Operating activities
Net income	23,272		25,953	87,660	114,250
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	917		832	2,862	2,255
Loss on early retirement of debt			6,064	17,788	6,064
Non-cash stock compensation expense				5,403	3,990
Amortization of debt discount and issuance costs				6,418	5,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(24,374)		(27,866)	(95,358)	(124,504)
Other current assets				(2,725)	1,182
Other assets				(7,829)	(604)
Accounts payable				2,880	418
Accrued expenses				(3,211)	3,870
Income and deferred taxes				5,593	14,481
Net cash provided by operating activities				19,481	26,617
Investing activities
Purchases of property and equipment				(1,428)	(3,617)
Net cash used in investing activities				(1,428)	(3,617)
Financing activities
Borrowings on revolving credit facility				580,000	365,000
Payments on revolving credit facility				(645,000)	(405,000)
Borrowings on credit facility term loans, net of discount				298,500	266,750
Payments on credit facility term loans				(594,668)	(7,063)
Issuance of 6.375% senior notes				600,000
Repurchase of 7 5/8% senior subordinated notes				(70,000)	(278,495)
Borrowings of other debt				8,154	5,557
Principal payments on other debt				(5,971)	(6,667)
Debt issuance costs				(18,820)	(4,236)
Dividends paid to Holdings				(211,754)	(57,467)
Equity investment by Holdings					1,104
Repayments of bank overdrafts				(10,401)	(3,011)
Intercompany				21,889	134,170
Net cash used in financing activities				(48,071)	10,642
Net increase (decrease) in cash and cash equivalents				(30,018)	33,642
Cash and cash equivalents at beginning of period		35,070		35,070	11,427
Cash and cash equivalents at end of period	5,052		45,069	5,052	45,069
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors
Operating activities
Net income	24,210		27,927	95,407	125,147
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	12,831		12,372	37,856	37,952
Provision for bad debts	7,563		9,525	22,485	27,199
Equity in earnings of unconsolidated subsidiaries	196		(1,146)	(1,375)	(6,340)
Loss (gain) from disposal of assets				25	(3,501)
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(1,952)		(2,123)	(12,073)	(11,234)
Accounts receivable				(75,295)	7,296
Other current assets				(6,620)	(2,141)
Other assets				4,519	1,688
Accounts payable				3,224	(5,842)
Due to third-party payors				2,378	(10,928)
Accrued expenses				10,381	(1,912)
Net cash provided by operating activities				80,912	157,384
Investing activities
Purchases of property and equipment				(39,101)	(31,978)
Proceeds from sale of assets				62	16,511
Investment in business, net of distributions				(32,430)	(9,899)
Acquisition of businesses, net of cash acquired				(848)	(1,547)
Net cash used in investing activities				(72,317)	(26,913)
Financing activities
Principal payments on other debt				(521)	(322)
Intercompany				(8,812)	(126,614)
Net cash used in financing activities				(9,333)	(126,936)
Net increase (decrease) in cash and cash equivalents				(738)	3,535
Cash and cash equivalents at beginning of period		3,734		3,734
Cash and cash equivalents at end of period	2,996		3,535	2,996	3,535
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries
Operating activities
Net income	4,051		3,110	18,441	14,313
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,415		2,333	7,154	6,957
Provision for bad debts	1,699		1,674	4,944	4,404
Equity in earnings of unconsolidated subsidiaries	(17)		(21)	(72)	(44)
Loss (gain) from disposal of assets				(118)	17
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable				(13,942)	(17,803)
Other current assets				1,703	(890)
Other assets				99	186
Accounts payable				694	1,326
Due to third-party payors				512	11,288
Accrued expenses				876	998
Net cash provided by operating activities				20,291	20,752
Investing activities
Purchases of property and equipment				(4,802)	(9,593)
Proceeds from sale of assets				456
Net cash used in investing activities				(4,346)	(9,593)
Financing activities
Borrowings of other debt				1,084	278
Principal payments on other debt				(975)	(428)
Intercompany				(13,077)	(7,556)
Distributions to non-controlling interests				(3,072)	(2,997)
Net cash used in financing activities				(16,040)	(10,703)
Net increase (decrease) in cash and cash equivalents				(95)	456
Cash and cash equivalents at beginning of period		1,340		1,340	616
Cash and cash equivalents at end of period	1,245		1,072	1,245	1,072
Select Medical Corporation | Eliminations
Operating activities
Net income	(26,326)		(29,989)	(107,431)	(135,738)
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	$ 26,326		$ 29,989	$ 107,431	$ 135,738

XML

Segment Information

9 Months Ended

Sep. 30, 2013

Segment Information

Segment Information

6.  Segment Information

The Company’s reportable segments consist of (i) specialty hospitals and (ii) outpatient rehabilitation. Other activities include the Company’s corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The outpatient rehabilitation reportable segment has two operating segments: outpatient rehabilitation clinics and contract therapy. These operating segments are aggregated for reporting purposes as they have common economic characteristics and provide a similar service to a similar patient base. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries and other income (expense).

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select with the exception of total assets:

	Three Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	531,409	$	182,246	$	14		$	713,669
Adjusted EBITDA	83,659		20,354		(16,266		)	87,747
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	12,281		3,073		1,900			17,254

	Three Months Ended September 30, 2013
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	532,610	$	190,223	$	12		$	722,845
Adjusted EBITDA	75,280		21,619		(16,471		)	80,428
Total assets:
Select Medical Corporation	2,232,756		445,729		163,939			2,842,424
Select Medical Holdings Corporation	2,232,756		445,729		163,939			2,842,424
Capital expenditures	14,157		2,802		410			17,369

	Nine Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	1,641,577	$	566,195	$	111		$	2,207,883
Adjusted EBITDA	285,779		68,669		(47,358		)	307,090
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	31,963		9,786		3,439			45,188

	Nine Months Ended September 30, 2013
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	1,649,747	$	579,404	$	322		$	2,229,473
Adjusted EBITDA	265,020		70,506		(49,059		)	286,467
Total assets:
Select Medical Corporation	2,232,756		445,729		163,939			2,842,424
Select Medical Holdings Corporation	2,232,756		445,729		163,939			2,842,424
Capital expenditures	35,257		8,646		1,428			45,331

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2012
	Specialty Hospitals				Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$		83,659		$	20,354		$	(16,266	)
Depreciation and amortization	(11,553			)	(3,152		)	(832		)
Stock compensation expense	—				—			(1,391		)
Income (loss) from operations	$	72,106			$	17,202		$	(18,489	)	$	70,819		$	70,819
Loss on early retirement of debt											(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries											1,167			1,167
Interest expense											(24,575		)	(21,740		)
Income before income taxes											$	41,347		$	44,182

	Three Months Ended September 30, 2013
	Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$	75,280		$	21,619		$	(16,471	)
Depreciation and amortization	(12,267		)	(2,979		)	(917		)
Stock compensation expense	—			—			(1,866		)
Income (loss) from operations	$	63,013		$	18,640		$	(19,254	)	$	62,399		$	62,399
Equity in losses of unconsolidated subsidiaries										(179		)	(179		)
Interest expense										(21,252		)	(21,252		)
Income before income taxes										$	40,968		$	40,968

		Nine Months Ended September 30, 2012
		Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
		(in thousands)
Adjusted EBITDA		$	285,779		$	68,669		$	(47,358	)
Depreciation and amortization			(34,875	)		(10,034	)		(2,255	)
Stock compensation expense		—			—			(3,990		)
Income (loss) from operations	$		250,904		$	58,635		$	(53,603	)	$	255,936		$	255,936
Loss on early retirement of debt											(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries											6,384			6,384
Interest expense											(72,295		)	(63,947		)
Income before income taxes											$	183,961		$	192,309

	Nine Months Ended September 30, 2013
	Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$	265,020		$	70,506		$	(49,059	)
Depreciation and amortization	(36,061		)	(8,949		)	(2,862		)
Stock compensation expense	—			—			(5,403		)
Income (loss) from operations	$	228,959		$	61,557		$	(57,324	)	$	233,192		$	233,192
Equity in earnings of unconsolidated subsidiaries										1,447			1,447
Loss on early retirement of debt										(18,747		)	(17,788		)
Interest expense										(66,614		)	(64,204		)
Income before income taxes										$	149,278		$	152,647

XML

Income per Common Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:
Net income attributable to Select Medical Holdings Corporation	$ 23,272	$ 24,110	$ 85,470	$ 108,824
Less: Earnings allocated to unvested restricted stockholders	497	407	1,802	1,759
Net income available to common stockholders	$ 22,775	$ 23,703	$ 83,668	$ 107,065
Denominator:
Weighted average shares - basic	136,646	137,551	136,879	139,138
Effect of dilutive securities: Stock options (in shares)	147	337	161	266
Weighted average shares - diluted	136,793	137,888	137,040	139,404
Income per common share
Basic income per common share (in dollars per share)	$ 0.17	$ 0.17	$ 0.61	$ 0.77
Diluted income per common share (in dollars per share)	$ 0.17	$ 0.17	$ 0.61	$ 0.77
Anti-dilutive securities excluded from computation of earnings per share
Stock options (in shares)	1,477	78	1,528	1,683

XML

Subsequent Event

9 Months Ended

Sep. 30, 2013

Subsequent Event

Subsequent Event

9. Subsequent Event

On October 30, 2013, Holdings’ board of directors declared a quarterly cash dividend of $0.10 per share. The dividend will be payable on or about November 22, 2013 to stockholders of record as of the close of business on November 12, 2013.

XML

Fair Value

9 Months Ended

Sep. 30, 2013

Fair Value

Fair Value

5.  Fair Value

Financial instruments include cash and cash equivalents, notes payable and long-term debt.  The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

The carrying value of Select’s senior secured credit facility was $1,226.6 million and $874.4 million at December 31, 2012 and September 30, 2013, respectively.  The fair value of Select’s senior secured credit facility was $1,216.2 million and $867.9 million at December 31, 2012 and September 30, 2013, respectively.  The fair value of Select’s senior secured credit facility was based on quoted market prices for this debt in the syndicated loan market.

The carrying value of Select’s 6.375% senior notes was $600.0 million at September 30, 2013.  The fair value of Select’s 6.375% senior notes was $570.0 million at September 30, 2013.  The fair value of this debt was based on quoted market prices.

The Company considers the inputs in the valuation process of its senior secured credit facility and 6.375% senior notes to be Level 2 in the fair value hierarchy.  Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly which includes quoted prices for identical assets or liabilities in markets that are not active.

XML

Consolidated Statements of Cash Flows (Parenthetical)	Sep. 30, 2013	Dec. 31, 2012
7 5/8% senior subordinated notes
Long-Term Debt and Notes Payable
Interest rate of debt (as a percent)	7.625%	7.625%
6.375% senior notes
Long-Term Debt and Notes Payable
Interest rate of debt (as a percent)	6.375%

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details) (6.375% senior notes)	Sep. 30, 2013
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes
Interest rate of debt (as a percent)	6.375%
Select
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes
Interest rate of debt (as a percent)	6.375%

XML

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2013

Intangible Assets

Schedule of gross carrying amounts of the Company's indefinite-lived intangible assets

	December 31, 2012		September 30, 2013
	(in thousands)
Goodwill	$	1,640,534	$	1,641,836
Trademarks	57,709		57,709
Certificates of need	11,914		12,039
Accreditations	2,122		2,083
Total	$	1,712,279	$	1,713,667

Schedule of changes in the carrying amount of goodwill for the Company's reportable segments

	Specialty Hospitals		Outpatient Rehabilitation			Total
	(in thousands)
Balance as of December 31, 2012	$	1,333,220	$	307,314		$	1,640,534
Goodwill acquired during the period	1,395		40			1,435
Purchase price adjustment	—		(133		)	(133		)
Balance as of September 30, 2013	$	1,334,615	$	307,221		$	1,641,836

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies

Commitments and Contingencies

8. Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”) or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company’s specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

On January 8, 2013, a federal magistrate judge unsealed an Amended Complaint in United States of America and the State of Indiana, ex rel. Doe I, Doe II and Doe III v. Select Medical Corporation, Select Specialty Hospital-Evansville, Evansville Physician Investment Corporation, Dr. Richard Sloan and Dr. Jeffrey Selby. The Amended Complaint, which was served on the Company on February 15, 2013, is a civil action filed under seal on September 28, 2012 in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States and the state of Indiana under the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act. Although the Amended Complaint identifies the relators by fictitious pseudonyms, on March 28, 2013, the relators filed a Notice identifying themselves as the former CEO at the Company’s long term acute care hospital in Evansville, Indiana (“SSH-Evansville”) and two former case managers at SSH-Evansville. The named defendants include the Company, SSH-Evansville, and two physicians who have practiced at SSH-Evansville. On March 26, 2013, the defendants, relators and the United States filed a joint motion seeking a stay of the proceedings, in which the United States notified the court that its investigation has not been completed and therefore it is not yet able to decide whether or not to intervene, and on March 29, 2013, the magistrate judge granted the motion and stayed all deadlines in the case for 90 days. On June 26, 2013, the United States filed a motion seeking to extend such stay of the proceedings for an additional 90 days, and, on August 12, 2013, the court granted the motion and stayed all deadlines in the case until October 1, 2013. On September 25, 2013, the United States filed a motion seeking to extend such stay for an additional 90 days.

The Amended Complaint alleges that the defendants manipulated the length of stay of patients at SSH-Evansville in order to maximize reimbursement under the Medicare prospective payment system applicable to long term acute care hospitals. It also alleges that the defendants manipulated the discharge of patients to other facilities and the timing of readmissions from those facilities in order to enable SSH-Evansville to receive two separate Medicare payments and causing the other facility to submit claims for unnecessary services. The Amended Complaint discusses the federal Stark Law and Anti-Kickback Statute and implies that the behavior of physicians referring to or providing services at SSH-Evansville was based on their financial interests. The Amended Complaint further alleges that Dr. Selby, a pulmonologist formerly on the medical staff of SSH-Evansville, performed unnecessary bronchoscopies at the hospital with the knowledge of the Company, and that Dr. Sloan, the Chief Medical Officer and an attending physician at SSH-Evansville, falsely coded the diagnoses of Medicare patients in order to increase SSH-Evansville’s reimbursement. Moreover, the Amended Complaint alleges that the practices at SSH-Evansville involved corporate policies of the Company used to maximize profit at all Select long term acute care hospitals. The Amended Complaint alleges that, through these acts, the defendants have violated the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act and are liable for unspecified treble damages and penalties.

As previously disclosed, beginning in April 2012, the Company and SSH-Evansville have received various subpoenas and demands for documents relating to SSH-Evansville, including a request for information and subpoenas from the Office of Inspector General of the U.S. Department of Health and Human Services and subpoenas from the Office of Attorney General for the State of Indiana, and the Evansville (Indiana) Police Department has executed a search warrant at SSH-Evansville. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

Construction Commitments

At September 30, 2013, the Company had outstanding commitments under construction contracts related to new construction, improvements and renovations at the Company’s long term acute care properties and inpatient rehabilitation facilities totaling approximately $15.3 million.

XML

Income per Common Share (Tables)

9 Months Ended

Sep. 30, 2013

Income per Common Share

Schedule of computation of basic and diluted income per common share

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2012		2013		2012		2013
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	24,110	$	23,272	$	108,824	$	85,470
Less: Earnings allocated to unvested restricted stockholders	407		497		1,759		1,802
Net income available to common stockholders	$	23,703	$	22,775	$	107,065	$	83,668
Denominator:
Weighted average shares — basic	137,551		136,646		139,138		136,879
Effect of dilutive securities:
Stock options	337		147		266		161
Weighted average shares — diluted	137,888		136,793		139,404		137,040
Basic income per common share	$	0.17	$	0.17	$	0.77	$	0.61
Diluted income per common share	$	0.17	$	0.17	$	0.77	$	0.61

Schedule of anti-dilutive shares excluded from computation

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2012	2013	2012	2013
	(in thousands)
Stock options	78	1,477	1,683	1,528

XML

Indebtedness (Tables)

9 Months Ended

Sep. 30, 2013

Indebtedness

Schedule of components of long-term debt and notes payable

	Select Medical Holdings Corporation
	December 31, 2012		September 30, 2013
	(in thousands)
7 5/8% senior subordinated notes	$	70,000	$	—
6.375% senior notes	—		600,000
Senior secured credit facilities:
Revolving loan	130,000		65,000
Term loans (1)	1,096,641		809,438
Senior floating rate notes	167,300		—
Other	6,302		14,443
Total debt	1,470,243		1,488,881
Less: current maturities	11,646		13,966
Total long-term debt	$	1,458,597	$	1,474,915

	Select Medical Corporation
	December 31, 2012		September 30, 2013
	(in thousands)
7 5/8% senior subordinated notes	$	70,000	$	—
6.375% senior notes	—		600,000
Senior secured credit facilities:
Revolving loan	130,000		65,000
Term loans (1)	1,096,641		809,438
Other	6,302		14,443
Total debt	1,302,943		1,488,881
Less: current maturities	11,646		13,966
Total long-term debt	$	1,291,297	$	1,474,915

(1) Presented net of unamortized discounts of $14.2 million and $6.8 million at December 31, 2012 and September 30, 2013, respectively.

Schedule of maturities of the Company's long-term debt

Maturities of the Company’s long-term debt for the period from October 1, 2013 through December 31, 2013 and the years after 2013 are approximately as follows and are presented net of the discounts on the senior secured credit facility term loans (in thousands):

October 1, 2013 – December 31, 2013	$	4,869
2014	11,497
2015	10,086
2016	296,134
2017	4,075
2018 and beyond	1,162,220

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 15, 2013
Document and Entity Information
Entity Registrant Name	SELECT MEDICAL HOLDINGS CORP
Entity Central Index Key	0001320414
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		139,546,090
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2013

Segment Information

Schedule of selected financial data for the Company's reportable segments

	Three Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	531,409	$	182,246	$	14		$	713,669
Adjusted EBITDA	83,659		20,354		(16,266		)	87,747
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	12,281		3,073		1,900			17,254

	Three Months Ended September 30, 2013
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	532,610	$	190,223	$	12		$	722,845
Adjusted EBITDA	75,280		21,619		(16,471		)	80,428
Total assets:
Select Medical Corporation	2,232,756		445,729		163,939			2,842,424
Select Medical Holdings Corporation	2,232,756		445,729		163,939			2,842,424
Capital expenditures	14,157		2,802		410			17,369

	Nine Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	1,641,577	$	566,195	$	111		$	2,207,883
Adjusted EBITDA	285,779		68,669		(47,358		)	307,090
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	31,963		9,786		3,439			45,188

	Nine Months Ended September 30, 2013
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(in thousands)
Net operating revenues	$	1,649,747	$	579,404	$	322		$	2,229,473
Adjusted EBITDA	265,020		70,506		(49,059		)	286,467
Total assets:
Select Medical Corporation	2,232,756		445,729		163,939			2,842,424
Select Medical Holdings Corporation	2,232,756		445,729		163,939			2,842,424
Capital expenditures	35,257		8,646		1,428			45,331

Schedule of reconciliation of Adjusted EBITDA to income before income taxes

	Three Months Ended September 30, 2012
	Specialty Hospitals				Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$		83,659		$	20,354		$	(16,266	)
Depreciation and amortization	(11,553			)	(3,152		)	(832		)
Stock compensation expense	—				—			(1,391		)
Income (loss) from operations	$	72,106			$	17,202		$	(18,489	)	$	70,819		$	70,819
Loss on early retirement of debt											(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries											1,167			1,167
Interest expense											(24,575		)	(21,740		)
Income before income taxes											$	41,347		$	44,182

	Three Months Ended September 30, 2013
	Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$	75,280		$	21,619		$	(16,471	)
Depreciation and amortization	(12,267		)	(2,979		)	(917		)
Stock compensation expense	—			—			(1,866		)
Income (loss) from operations	$	63,013		$	18,640		$	(19,254	)	$	62,399		$	62,399
Equity in losses of unconsolidated subsidiaries										(179		)	(179		)
Interest expense										(21,252		)	(21,252		)
Income before income taxes										$	40,968		$	40,968

		Nine Months Ended September 30, 2012
		Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
		(in thousands)
Adjusted EBITDA		$	285,779		$	68,669		$	(47,358	)
Depreciation and amortization			(34,875	)		(10,034	)		(2,255	)
Stock compensation expense		—			—			(3,990		)
Income (loss) from operations	$		250,904		$	58,635		$	(53,603	)	$	255,936		$	255,936
Loss on early retirement of debt											(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries											6,384			6,384
Interest expense											(72,295		)	(63,947		)
Income before income taxes											$	183,961		$	192,309

	Nine Months Ended September 30, 2013
	Specialty Hospitals			Outpatient Rehabilitation			Other			Select Medical Holdings Corporation			Select Medical Corporation
	(in thousands)
Adjusted EBITDA	$	265,020		$	70,506		$	(49,059	)
Depreciation and amortization	(36,061		)	(8,949		)	(2,862		)
Stock compensation expense	—			—			(5,403		)
Income (loss) from operations	$	228,959		$	61,557		$	(57,324	)	$	233,192		$	233,192
Equity in earnings of unconsolidated subsidiaries										1,447			1,447
Loss on early retirement of debt										(18,747		)	(17,788		)
Interest expense										(66,614		)	(64,204		)
Income before income taxes										$	149,278		$	152,647